Catamaran 10-K 2 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Billions, except Share data, unless otherwise specified	Dec. 31, 2014	Jan. 31, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	CTRX
Entity Registrant Name	Catamaran Corp
Entity Central Index Key	1363851
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		207,493,541
Entity Current Reporting Status	Yes
Entity Voluntary Filer	No
Entity Well-known Seasoned Issuer	Yes
Entity Public Float			$9.20

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets
Cash and cash equivalents	$1,011,952	$387,241
Accounts receivable, net of allowance for doubtful accounts of $4,867 (2013 - $5,860)	1,254,336	959,586
Rebates receivable	863,824	305,955
Other current assets	219,435	184,893
Total current assets	3,349,547	1,837,675
Property and equipment, net of accumulated depreciation of $144,220 (2013 - $103,858)	210,027	197,007
Goodwill	4,724,639	4,720,275
Other intangible assets, net of accumulated amortization of $574,503 (2013 - $363,546)	968,199	1,181,419
Other long-term assets	71,773	59,387
Total assets	9,324,185	7,995,763
Current liabilities
Accounts payable	967,791	817,805
Accrued expenses and other current liabilities	327,190	254,100
Rebates payable	967,733	356,265
Current portion - long-term debt	81,250	50,000
Total current liabilities	2,343,964	1,478,170
Deferred income taxes	257,325	301,341
Long-term debt	1,344,973	1,215,363
Other long-term liabilities	98,816	89,391
Total liabilities	4,045,078	3,084,265
Commitments and contingencies (Note 16)
Shareholders’ equity
Common shares: no par value, unlimited shares authorized; 207,493,541 shares issued and outstanding at December 31, 2014 (2013 - 206,305,070)	4,264,764	4,215,291
Additional paid-in capital	74,071	77,790
Retained earnings	934,454	617,161
Accumulated other comprehensive loss	-1,310	-1,752
Total shareholders' equity	5,271,979	4,908,490
Non-controlling interest	7,128	3,008
Total equity	5,279,107	4,911,498
Total liabilities and equity	$9,324,185	$7,995,763

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Assets
Accounts receivable, allowance for doubtful accounts	$4,867	$5,860
Property and equipment, accumulated depreciation	144,220	103,858
Other intangible assets, accumulated amortization	$574,503	$363,546
Shareholders’ equity
Common Stock, shares issued	207,493,541	206,305,070
Common Stock, shares outstanding	207,493,541	206,305,070

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Revenue	$21,581,890	$14,780,094	$9,940,120
Cost of revenue	20,221,837	13,654,449	9,206,744
Gross profit	1,360,053	1,125,645	733,376
Expenses:
Selling, general and administrative	518,351	440,759	369,492
Depreciation of property and equipment	59,486	37,926	16,749
Amortization of intangible assets	213,220	203,192	130,116
Total expenses	791,057	681,877	516,357
Operating income	568,996	443,768	217,019
Interest and other expense, net	61,088	41,626	26,682
Income before income taxes	507,908	402,142	190,337
Income tax expense	134,186	103,403	69,316
Net income	373,722	298,739	121,021
Less net income attributable to non-controlling interest	56,429	36,569	4,363
Net income attributable to the Company	$317,293	$262,170	$116,658
Earnings per share attributable to the Company:
Basic (in dollars per share)	$1.53	$1.27	$0.70
Diluted (in dollars per share)	$1.53	$1.27	$0.70

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement of Comprehensive Income [Abstract]
Net income	$373,722	$298,739	$121,021
Other comprehensive income, net of tax
Unrealized income (loss) on cash flow hedge, net of income tax expense of $158, $156, and $0 in 2014, 2013, and 2012, respectively	442	439	-2,191
Comprehensive income	374,164	299,178	118,830
Less comprehensive income attributable to non-controlling interest	56,429	36,569	4,363
Comprehensive income attributable to the Company	$317,735	$262,609	$114,467

Consolidated_Statements_of_Com1

Consolidated Statements of Comprehensive Income (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement of Comprehensive Income [Abstract]
Income tax expense on unrealized income (loss) cash flow hedges	$158	$156	$0

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net income	$373,722	$298,739	$121,021
Items not involving cash:
Stock-based compensation	33,554	25,562	17,667
Depreciation of property and equipment	63,468	42,232	20,234
Amortization of intangible assets	213,220	203,192	130,116
Deferred lease inducements and rent	5,523	28,119	3,136
Deferred income taxes	-58,047	-44,336	-37,925
Tax benefit on option exercises	-3,492	-9,732	-19,397
Deferred financing cost amortization	9,595	9,127	4,985
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	-294,728	-217,468	-134,282
Rebates receivable	-558,123	2,993	-40,988
Other current assets	-44,628	-25,346	82,797
Accounts payable	149,990	149,429	70,620
Accrued expenses and other current liabilities	72,601	-43,657	1,720
Rebates payable	611,468	39,616	60,929
Other long-term assets and liabilities	16,058	16,951	-30,900
Net cash provided by operating activities	590,181	475,421	249,733
Cash flows from investing activities:
Acquisitions, net of cash acquired	-2,026	-388,866	-1,565,705
Purchases of property and equipment	-78,078	-128,842	-40,236
Proceeds from restricted cash	20,006	20,004	0
Net cash used in investing activities	-60,098	-497,704	-1,605,941
Cash flows from financing activities:
Proceeds from issuance of debt	492,500	450,000	1,475,448
Repayment of long-term debt	-337,500	-362,500	-616,993
Proceeds from public offering, net of issuance costs	0	0	519,075
Payment of financing costs	-1,963	-2,347	-18,806
Proceeds from exercise of options	5,639	2,992	7,763
Tax benefit on option exercises	3,492	9,732	19,397
Proceeds from warrants exercised	3,452	487	0
Payments of contingent consideration	-18,338	-23,203	0
Distribution to non-controlling interest	-52,309	-36,314	0
Other	-383	0	-268
Net cash provided by financing activities	94,590	38,847	1,385,616
Effect of foreign exchange on cash balances	38	-99	-14
Increase in cash and cash equivalents	624,711	16,465	29,394
Cash and cash equivalents, beginning of period	387,241	370,776	341,382
Cash and cash equivalents, end of period	$1,011,952	$387,241	$370,776

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Total	Common Shares	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Non-Controlling Interest
In Thousands, except Share data, unless otherwise specified
Total shareholders’ equity, beginning at Dec. 31, 2011	$671,038	$394,769	$37,936	$238,333	$0	$0
Common stock, shares, beginning at Dec. 31, 2011		124,767,322
Activities during the period [Roll Forward]
Net income	121,021			116,658		4,363
Issuance of common shares for public offering, shares		11,960,000
Issuance of common shares for public offering, value	519,075	519,075
Issuance of common shares for acquisitions, shares		66,780,040
Issuance of common shares for acquisitions, value	3,237,877	3,237,877
Issuance of warrants and common stock for acquisitions	19,824		19,824
Acquisition of non-controlling interest in conjunction with Catalyst Merger	-1,610					-1,610
Exercise of stock options, shares		1,419,744
Exercise of stock options, amount	7,763	11,036	-3,273
Vesting of restricted stock units, shares		471,996
Vesting of restricted stock units, amount	0	18,021	-18,021
Tax benefit on options exercised	19,397		19,397
Stock-based compensation	17,667		17,667
Other comprehensive income, net of tax	-2,191				-2,191
Total shareholders’ equity, ending at Dec. 31, 2012	4,609,861	4,180,778	73,530	354,991	-2,191	2,753
Common stock, shares, ending at Dec. 31, 2012		205,399,102
Activities during the period [Roll Forward]
Net income	298,739			262,170		36,569
Exercise of stock options, shares		348,068
Exercise of stock options, amount	2,992	4,262	-1,270
Exercise of warrants during period, shares		60,000
Exercise of warrants during period, value	487	2,910	-2,423
Vesting of restricted stock units, shares		497,900
Vesting of restricted stock units, amount	0	27,341	-27,341
Tax benefit on options exercised	9,732		9,732
Stock-based compensation	25,562		25,562
Distribution to non-controlling interest	-36,314					-36,314
Other comprehensive income, net of tax	439				439
Total shareholders’ equity, ending at Dec. 31, 2013	4,911,498	4,215,291	77,790	617,161	-1,752	3,008
Common stock, shares, ending at Dec. 31, 2013	206,305,070	206,305,070
Activities during the period [Roll Forward]
Net income	373,722			317,293		56,429
Exercise of stock options, shares		298,108
Exercise of stock options, amount	5,639	8,011	-2,372
Exercise of warrants during period, shares		425,160
Exercise of warrants during period, value	3,452	20,624	-17,172
Vesting of restricted stock units, shares		465,203
Vesting of restricted stock units, amount	0	20,838	-20,838
Tax benefit on options exercised	3,492		3,492
Stock-based compensation	33,554		33,554
Distribution to non-controlling interest	-52,309					-52,309
Other comprehensive income, net of tax	442				442
Other	-383		-383
Total shareholders’ equity, ending at Dec. 31, 2014	$5,279,107	$4,264,764	$74,071	$934,454	($1,310)	$7,128
Common stock, shares, ending at Dec. 31, 2014	207,493,541	207,493,541

Description_of_Business

Description of Business	12 Months Ended
	Dec. 31, 2014
Description of Business [Abstract]
Description of Business	Description of Business
	Catamaran Corporation (“Catamaran” or the “Company”) is a leading provider of pharmacy benefits management (“PBM”) services and healthcare information technology (“HCIT”) solutions to the healthcare benefits management industry. The Company’s product offerings and solutions combine a wide range of PBM services, software applications, application service provider (“ASP”) processing services and professional services designed for many of the largest organizations in the pharmaceutical supply chain, such as federal, provincial, state and local governments, unions, corporations, pharmacy benefit managers, managed care organizations, retail pharmacy chains and other healthcare intermediaries. The Company is headquartered in Schaumburg, Illinois with several locations in the U.S. and Canada.
	In July 2012, SXC Health Solutions Corp. changed the name and brand for the company to Catamaran Corporation. The Company's common shares trade on the Nasdaq Stock Market under the ticker symbol "CTRX" and on the Toronto Stock Exchange under ticker symbol “CCT.”

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies
	(a) Significant accounting policies are summarized below:
	Basis of presentation:
	The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and include its wholly-owned subsidiaries as well as non-controlled entities. Amounts in the consolidated financial statements are expressed in U.S. dollars, except where otherwise indicated. Within the financial statements and tables presented, the totals of certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages presented are calculated from the underlying whole-dollar amounts. Certain reclassifications have been made to conform the prior years’ consolidated financial statements to the current year’s presentation.
	Principles of Consolidation:
	The consolidated financial statements include the accounts of the Company and its controlled subsidiaries, which are generally wholly owned. All significant inter-company transactions and balances have been eliminated in consolidation. Any non-controlling interest in the equity of a subsidiary is reported in equity in the Consolidated Statements of Shareholders' Equity. Net income attributable to the non-controlling interest is subtracted from Net Income to arrive at Net Income Attributable to the Company in the Consolidated Statements of Operations.
	Use of estimates:
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant items subject to such estimates and assumptions include revenue recognition, purchase price allocation and contingent consideration in connection with acquisitions, valuation of property and equipment, valuation of intangible assets acquired and related amortization periods, impairment of goodwill, contingencies, valuation allowances for receivables and income taxes. Actual results could differ from those estimates.
	Revenue recognition:
	The Company's revenue is primarily derived from prescription drug sales. The Company has a small portion of its revenue that is derived from transaction processing and other services related to its HCIT products.
	The Company recognizes revenue when all of the following conditions are satisfied: (i) there is persuasive evidence of an arrangement; (ii) the service or product has been provided to the customer and no uncertainties exist surrounding product acceptance; (iii) the amount of fees to be paid by the customer is fixed or determinable; and (iv) the collection of fees is reasonably assured.
	When the Company enters into arrangements with multiple deliverables, exclusive of arrangements with software deliverables, it applies the Financial Accounting Standards Board's guidance for revenue arrangements with multiple deliverables and evaluates each deliverable to determine whether it represents a separate unit of accounting based on the following criteria: (i) whether the delivered item has value to the customer on a stand-alone basis, and (ii) if the contract includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Revenue is allocated to each unit of accounting or element based on relative selling prices. The Company determines relative selling prices by using either (i) vendor specific objective evidence (“VSOE”) if it exists; or (ii) third-party evidence of selling price ("TPE"). When neither VSOE nor TPE of selling price exists for a deliverable, the Company uses its best estimate of the selling price for that deliverable.
	After determining which deliverables represent a separate unit of accounting, each unit is then accounted for under the applicable revenue recognition guidance. In cases where elements cannot be treated as separate units of accounting, the elements are combined into a single unit of accounting for revenue recognition purposes.
	When the Company enters into arrangements with multiple deliverables involving software, the Company applies the accounting guidance for software. The entire arrangement fee is allocated to each element in the arrangement based on the respective VSOE of fair value of each element.
	When an arrangement includes software and non-software deliverables, the Company allocates the arrangement consideration to the non-software deliverables, and to the software deliverables as a group, based on the relative selling prices of all deliverables in the arrangement. When a tangible product contains software that is not essential to the product’s functionality, that nonessential software and any other deliverables within the arrangement that relate to that nonessential software are accounted for under accounting guidance for software. The non-software deliverables sold by the Company typically do not include software deliverables that are considered essential to the functionality of a tangible product.
	Revenue is recognized for specific types of transactions as follows:
	PBM revenue:  The Company’s PBM revenue is primarily derived from sales of prescription drugs, together with any associated administrative fees, to customers and participants through the Company’s nationwide network of pharmacies. Revenue related to the sales of prescription drugs by the Company’s nationwide network of pharmacies is recognized when the claims are adjudicated. Claims are adjudicated at the point-of-sale using the Company’s on-line processing system. The Company records an offsetting reduction to revenue for any rebates earned from pharmaceutical manufacturers and third-party administrators that are payable to the Company’s customers.
	For transactions at the Company's participating pharmacies, under the terms of the customer contracts, the pharmacy is solely obligated to collect the co-payments from the participants. The Company does not assume liability for participant co-payments in non-Company owned pharmacy transactions, and therefore does not include participant co-payments in revenue or cost of revenue. If these amounts were included in the Company’s operating results, its operating income and net income would not have been affected.
	The Company evaluates customer contracts to determine whether the Company acts as a principal or as an agent in the fulfillment of prescriptions through its participating pharmacy network. The Company acts as a principal in certain of its transactions with customers and, in these cases, revenues are recognized at the prescription price (ingredient cost plus dispensing fee) negotiated with customers, plus the Company’s administrative fees (“gross reporting”). Gross reporting is appropriate when the Company (i) has separate contractual relationships with customers and with pharmacies, (ii) is responsible to validate and manage a claim through its claims adjudication process, (iii) commits to set prescription prices for the pharmacy, (iv) manages the overall prescription drug plan relationship with the patients, who are members of customers’ plans, and (v) has credit risk for the amount due from the customer.
	Revenue for the sale of prescription drugs dispensed at the Company's mail and specialty pharmacies, including amounts due from third-party payors and member co-payments, is recorded when the prescription drugs are shipped.
	HCIT revenue: HCIT revenues are generated primarily from transaction processing and related services. The Company recognizes revenue for its HCIT products and services at the time the transaction is processed, or at the time the service is provided. If multiple elements are required to be delivered under a customer contract, the Company follows the guidance described above in relation to multiple elements.
	Cost of revenue:
	The Company’s cost of revenue includes the cost of pharmaceuticals dispensed, either directly dispensed at its mail and specialty pharmacy locations, or indirectly through its nationwide network of participating pharmacies. Cost of revenue is reduced for rebates earned from pharmaceutical manufacturers and third-party administrators. Cost of revenue also includes the cost of personnel to support the Company’s transaction processing services, system sales, maintenance, and professional services. In addition, the Company includes in cost of revenue an amount of depreciation expense that is related to property and equipment used to provide services to customers.
	Cash and cash equivalents:
	The Company considers cash on hand, deposits in banks, money market funds, and bank term deposits with original maturities of ninety days or less as cash and cash equivalents. The amounts presented in the consolidated balance sheets approximate fair value of cash and cash equivalents. These assets are deemed Level 1 securities in the fair value hierarchy.
	Fair value measurements:
	The Company applies the fair value accounting guidance for measuring its financial and non-financial assets and liabilities. Currently, none of the Company’s non-financial assets are required to be carried at fair value. The Company would apply the fair value accounting guidance to non-financial assets and liabilities in the event that a non-financial asset or liability was impaired, or, if non-financial assets and liabilities were purchased in a business acquisition.
	The fair value of contingent consideration is based upon probability-weighted discounted cash flow models, utilizing the Company's expectation of the amounts to be paid in the future to settle the contingent purchase price. The inputs utilized in calculating the fair value of the contingent purchase price liabilities are not observable in the marketplace. The fair value of the Company’s interest rate contracts is based upon observable market-based inputs that reflect the current value of the difference between the fixed rate payments the Company will make to the counter party, and the future variable rate receipts from the counterparty.
	Other assets and liabilities held by the Company deemed as financial instruments and required to be carried at fair value include cash and cash equivalents, accounts receivable, rebates receivable, accounts payable, accrued liabilities (current portion), pharmacy benefit management rebates payable and pharmacy benefit claim payments payable. The estimated fair values of these financial instruments approximate their carrying amounts due to the short-term nature of their maturities.
	Inventory:
	Inventory consists primarily of prescription drugs held for resale and is carried at the lower of cost or net realizable value. Inventory costs are calculated using the first-in, first-out method and the weighted-average method.
	Property and equipment:
	Property and equipment (“P&E”) are stated at cost less accumulated depreciation. Depreciation is generally calculated over the expected estimated useful lives of the assets. Assets are depreciated in the following manner: 1) Furniture and equipment is depreciated using the straight- line method based on a useful life of five years, 2) Computer equipment and software assets are depreciated using a straight-line method and a useful life of three to five years, and 3) Leasehold improvements are depreciated on a straight-line basis over the shorter of the asset’s life or the lease term.
	Accounts receivable and allowance for doubtful accounts:
	Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Amounts collected on trade accounts receivable are included in net cash provided by operating activities in the consolidated statements of cash flows. In assessing the valuation of the allowance for doubtful accounts, management reviews the collectability of accounts receivable in aggregate and on an individual account-basis. Individual customer events such as subsequent collections, discussions with management of the debtor companies, or other activities are used by management as factors in concluding whether to increase or decrease the calculated allowance. Any increase or decrease to the allowance is recognized in the statements of operations as bad debt expense within selling, general and administrative expense.
	Impairment of long-lived assets:
	Long-lived assets or asset groups held and used, including P&E and purchased intangibles subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances that could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; the accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and a current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its previously estimated useful life. Recoverability is assessed based on the carrying amount of the asset and the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset or asset group. An impairment loss is recognized when the carrying amount is not recoverable and exceeds the fair value of the asset or asset group. The impairment loss is measured as the amount by which the carrying amount of undiscounted cash flows exceeds fair value. During each of the years ended December 31, 2014, 2013 and 2012, no events or circumstances occurred that indicated that the carrying amounts of the long-lived assets may not be recoverable.
	While no asset was deemed impaired during 2012, the Company assessed whether one of its assets was recoverable due to a triggering event. In October 2012, the Company launched its new specialty brand BriovaRx. The Company previously acquired MedfusionRx, a specialty pharmacy, and recorded a trade name intangible asset related to the acquisition. As a result of the re-branding of the specialty business, the Company concluded that a triggering event had occurred that could impair the value of the trade name. While the asset was not deemed impaired, the Company concluded that the useful life of the trade name intangible asset should be reduced since the name would no longer be used by the Company, which was the asset's highest and best use. Before adjusting the useful life of the asset, the Company considered whether the asset had any value as a defensible asset which would extend its useful life. The Company determined that the MedfusionRx trade name had an insignificant value as a defensible asset, and the asset's useful life should be shortened due to the name change of the business. As a result, the Company recorded an additional $8.0 million in amortization expense in 2012.
	Goodwill:
	Goodwill is the residual amount that results when the purchase price of an acquired business exceeds the sum of the amounts allocated to the identifiable assets acquired, less liabilities assumed, based on their fair values. Goodwill is allocated to the Company’s reporting unit that is expected to benefit from the business combination as of the date of the business combination. As of December 31, 2014, the amount of goodwill carried at the PBM and HCIT segments was $4.7 billion and $19.7 million, respectively.
	Goodwill is not amortized, but rather, is tested for impairment annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired. The Company completes its goodwill impairment test annually as of October 31. Circumstances that could trigger an interim impairment test include: a significant adverse change in the business climate or legal factors; an adverse action or assessment by a regulator; unanticipated competition; the loss of key personnel; a change in reporting units; the likelihood that a reporting unit or significant portion of a reporting unit will be sold or otherwise disposed of; the results of testing for recoverability of a significant asset group within a reporting unit; and the recognition of a goodwill impairment loss in the financial statements of a subsidiary that is a component of a reporting unit.
	The Company performed its goodwill impairment assessment in 2014 and there was no indication of an impairment to the Company's goodwill balances. In addition, an impairment in the near future is not considered reasonably likely. The Company previously completed impairment tests in 2013 and 2012 and concluded no impairments existed.
	The qualitative assessment performed by the Company considered the current operating results of the Company's reporting units, future expectations of each reporting unit, industry and competitor performance and other recent events that may impact each reporting unit. The Company then assessed whether, in light of the evidence gathered, it was more likely than not that a reporting unit's fair value was less than its carrying amount. As noted above, the Company concluded that it was not more likely than not that a reporting unit's fair value was less than its carrying value. If in the future the Company's qualitative assessment indicates that a reporting unit's fair value may be below its carrying value, the Company would prepare a quantitative test to determine whether an impairment existed, and the amount of such impairment.
	The quantitative impairment test is carried out in two steps for each of the Company's reporting units. In the first step, the carrying amount of the reporting unit is compared with its fair value. When the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not to be impaired and the second step of the impairment test is unnecessary. The second step is carried out when the carrying amount of a reporting unit exceeds its fair value, in which case the implied fair value of the reporting unit’s goodwill is compared with its carrying amount to measure the amount of the impairment loss, if any. The implied fair value of goodwill is determined in the same manner as the value of goodwill is determined in a business combination using the fair value of the reporting unit as if it was the purchase price. When the carrying amount of reporting unit goodwill exceeds the implied fair value of the goodwill, an impairment loss is recognized in an amount equal to the excess and is presented as a separate line item in the consolidated statements of operations.
	Intangible assets:
	The cost of a group of intangible assets acquired in a transaction, including those acquired in a business combination that meet the specified criteria for recognition apart from goodwill, is recorded to the individual assets acquired based on their fair values. Intangible assets acquired individually or as part of a group of other assets are initially recognized and measured at cost.
	Intangible assets with finite useful lives are amortized over their estimated useful lives on either a straight-line basis or in proportion to the economic benefits expected to be consumed. Customer relationships acquired with the acquisitions are amortized based on projected cash flows associated with existing customers at the acquisition date and typically have a life of three to ten years. The Company's remaining intangible assets are amortized on a straight-line basis over one to fifteen years.
	Rebates:
	The Company administers a rebate program through which it receives rebates and administrative fees from pharmaceutical manufacturers and third-party administrators that are shared with a majority of the Company’s customers. The rebates earned for the administration of the program are recorded as a reduction of cost of revenue and the portion of the rebate payable to customers, if applicable, is treated as a reduction of revenue. Rebates receivable include billed and unbilled PBM receivables from pharmaceutical manufacturers and third-party administrators. The Company records the gross rebate receivable and the related payable to the customers based on estimates, which are subject to final settlement due to the required validation of claims data submitted to the pharmaceutical manufacturers and third-party administrators, as well as contingent items contained in the total calculation for rebates earned. The estimates are based upon claims submitted and the Company’s rebate contracts, and are adjusted as additional information becomes available. Upon billing the pharmaceutical manufacturer or third-party administrator, any difference between the Company’s estimate and the actual amount of the rebate receivable is recorded to cost of revenue, net of the estimated impact to the Company’s customers. The Company generally pays rebates to its customers on a quarterly basis, or as agreed upon with its customers. There are certain instances where the Company pays rebates to its customers on a more accelerated basis. As of December 31, 2014 and 2013, total unbilled pharmaceutical manufacturer rebates receivable amounted to $366.7 million and $54.6 million, respectively.
	Stock-based compensation:
	For stock-based awards issued to employees and directors, compensation cost related to those awards is measured based on the fair value of the awards on the date of the grant. For stock options, the fair value is determined by using the Black-Scholes-Merton option-pricing model. The compensation cost of the awards expected to vest is recognized on a straight-line basis over the service period as compensation expense and additional paid-in capital. In addition, the Company estimates forfeitures as part of the initial measure of the grant date fair value of the award.
	The cumulative compensation cost is treated as a temporary difference for stock-based awards that are deductible for tax purposes. If a deduction reported on a tax return exceeds the cumulative compensation cost for those awards, any resulting realized tax benefit that exceeds the previously recognized deferred tax asset for those awards (the excess tax benefit) is recognized as additional paid-in capital. If the amount deductible is less than the cumulative compensation cost recognized for financial reporting purposes, the write-off of a deferred tax asset related to that deficiency, net of the related valuation allowance, if any, is first offset to the extent of any remaining additional paid-in capital from excess tax benefits from previous awards with the remainder recognized in the statement of operations.
	Derivatives:
	The Company accounts for derivative instruments pursuant to derivative and hedge accounting guidance. The guidance requires that all derivative instruments are recorded on the balance sheet at their respective fair values. The Company records the change in the fair value of its derivative instruments deemed as cash flow hedges through other comprehensive income in each reporting period.
	Foreign currency:
	The Company’s functional currency and reporting currency is the U.S. dollar. Monetary items denominated in foreign currency are translated to U.S. dollars at exchange rates in effect at the balance sheet date and non-monetary items are translated at rates in effect when the assets were acquired or obligations incurred. Revenue and expenses are translated at rates in effect at the time of the transactions. Foreign exchange gains and losses are included in the consolidated statements of operations as "Interest and other expense, net."
	Earnings per share:
	Basic earnings per share (“EPS”) is computed by dividing net income by the weighted-average number of common shares outstanding for the period. Diluted EPS is computed by dividing net income by the weighted-average number of common shares adjusted for the dilutive effect of outstanding stock-based awards. The dilutive effect is calculated by assuming that the proceeds from the exercise of in-the-money stock options were used to acquire shares of common stock at the average market price for the period.
	Income taxes:
	The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the deferred tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment.
	Future tax benefits resulting from historical net operating losses (“NOLs”) and deductible temporary differences are recognized in accordance with tax accounting guidance. In assessing the realizability of the related deferred income tax assets (“DTAs”), management considers whether it is more likely than not that some portion or all of the DTAs will be realized. The ultimate realization of DTAs is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible, in addition to management’s tax planning strategies. Management considers projected future taxable income, uncertainties related to the industry in which the Company operates, tax planning strategies, historical taxable income, and a comparison of actual levels of taxable income with pre-tax book income in making this assessment. Valuation allowances are established for DTAs that are not considered more likely than not to be realized. The amount of this valuation allowance is subject to adjustment by the Company in future periods based upon its assessment of evidence supporting the degree of probability that DTAs will be realized.
	The Company recognizes liabilities for uncertain tax positions, although the Company believes its tax position is supportable, when the Company believes that the tax positions may not be fully sustained upon review by tax authorities. Benefits from uncertain tax positions are recognized in the consolidated financial statements only when it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority having full knowledge of all relevant information. A tax position that meets the more-likely-than-not recognition threshold is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon settlement. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense.
	Non-refundable investment tax credits for Scientific Research and Experimental Development (“SRED”) activities are recorded when the Company has reasonable assurance that the credit will be realized. Management has made a number of estimates and assumptions in determining the expenditures eligible for the investment tax credit claim. It is possible that the allowable amount of the investment tax credit claim could be materially different from the recorded amount upon assessment by the Canada Revenue Agency. Non-refundable investment tax credits are recorded as a reduction of income tax expense on the consolidated statements of operations.
	(b) Recent accounting standards implemented are summarized below:
In July 2013, the FASB issued authoritative guidance containing changes to the presentation of an unrecognized tax benefit when a loss or credit carryforward exists. The new standard requires the netting of unrecognized tax benefits against a deferred tax asset for a loss or other carryforward that would apply in the settlement of the uncertain tax positions. The Company adopted this standard on January 1, 2014; however, the implementation of the standard did not have a significant impact on its financial results or in the presentation and disclosure of its financial statements.
In February 2013, the FASB issued an update on the reporting of amounts reclassified from accumulated other comprehensive income. An entity is required to present either parenthetically on the face of the financial statements or in the notes, significant amounts reclassified from each component of accumulated other comprehensive income and the income statement line items affected by the reclassification. However, an entity is not required to show the income statement line item affected for certain components that are not required to be reclassified in their entirety to net income, such as amounts amortized into net periodic pension cost. The standard was effective prospectively for public entities for fiscal years, and interim periods within those years, beginning after December 15, 2012. The Company adopted this standard on January 1, 2013; however, the implementation of the amendments did not have a significant impact on its financial results or in the presentation and disclosure of its financial statements.
No other new accounting standards have been adopted during the year ended December 31, 2014.
(c) Recent accounting standards issued and not yet adopted are summarized below:
In August 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The ASU applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. Adoption of the standard is not expected to have a significant impact on the Company's financial results or in the presentation and disclosure of its financial statements.
In June 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-12, Accounting for Share-Based Payments, when the terms of an award provide that a performance target could be achieved after the requisite service period. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the performance target shall not be reflected in estimating the fair value of the award at the grant date. The amendments in this update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015 for all entities, however earlier adoption is permitted. Adoption of the standard is not expected to have a significant impact on the Company's financial results or in the presentation and disclosure of its financial statements.
On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
On April 10, 2014, the FASB issued (ASU) No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, which changes the criteria for determining which disposals can be presented as discontinued operations and modifies related disclosure requirements. The guidance applies prospectively to new disposals and new classifications of disposal groups as held for sale after the effective date. The standard is required to be adopted by the Company in annual periods beginning on or after December 15, 2014, and interim periods within those annual periods. However, all entities may early adopt the guidance for new disposals (or new classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. Adoption of the standard is not expected to have a significant impact on the Company's financial results or in the presentation and disclosure of its financial statements.
No other new standards have been issued during the year ended December 31, 2014 that the Company assessed to have a significant impact on its financial results or in the presentation and disclosure of its financial statements.

Stock_Split

Stock Split	12 Months Ended
	Dec. 31, 2014
Stock Split [Abstract]
Stock Split	Stock Split
	On September 6, 2012, the Company announced that its board of directors had declared a nominal dividend on the issued and outstanding common shares of the Company to effect a two-for-one stock split. Shareholders of record at the close of business on September 20, 2012 were issued one additional common share for each share owned as of that date. The additional common shares were distributed on October 1, 2012.
	All share and per share data presented in these consolidated financial statements have been adjusted to reflect the stock split noted above.

Business_Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Business Combinations	Business Combinations
	Restat Acquisition
	On October 1, 2013, the Company completed the acquisition of all of outstanding equity interests of Restat, LLC ("Restat"), a privately held pharmacy benefit manager based in Milwaukee, Wisconsin, for a purchase price of $409.5 million in cash subject to certain customary post-closing adjustments. The purchase price was funded from Catamaran’s existing cash balance and $350.0 million in borrowings under a five-year senior secured revolving credit facility (the “Revolving Facility”). The acquisition provides the Company the opportunity to bring Catamaran's full-suite of technology and clinical services to Restat's clients, including mail and specialty pharmacy services. The results of Restat have been included in the Company's results since October 1, 2013. The consolidated statement of operations for the year ended December 31, 2013 includes Restat's total revenues of $209.2 million following the acquisition.
	The acquisition was accounted for under the acquisition method of accounting with the Company treated as the acquiring entity. Accordingly, the consideration paid by the Company to complete the acquisition has been recorded to the assets acquired and liabilities assumed based upon their estimated fair values as of the date of acquisition. The carrying values for current assets and liabilities were deemed to approximate their fair values due to the short-term nature of their maturities. Fair values for acquired amortizable intangible assets were determined as follows: customer relationships were valued using an excess earnings model based on expected future revenues derived from the customers acquired, non-compete agreements were valued using discounted cash flow models based on expected future results of Restat, trademarks/tradenames were valued using a royalty savings model based on future projected revenues of Restat and applicable market royalty rates and licenses utilized a replacement cost approach. The excess of the purchase price over the estimated fair values of the net assets acquired was recorded as goodwill.
	All of the assets and liabilities recorded for the acquisition are included within the Company's PBM segment. The residual amount of the purchase price after allocation to identifiable net assets represents goodwill. Goodwill is non-amortizing for financial statement purposes. Goodwill of $227.8 million related to the Restat acquisition is tax deductible. The goodwill recognized by the Company represents many of the synergies and business growth opportunities that the Company anticipates may be realized from the acquisition of Restat. The synergies include improved pricing from the Company's suppliers due to the increased volume of prescription drug purchases, pull through opportunities of the Company's mail and specialty service offerings, and a more efficient leveraging of resources to achieve operating profits.
	The following summarizes the fair values assigned to the assets acquired and liabilities assumed at the acquisition date (in thousands):
		Initial Amounts Recognized at Acquisition Date (a)				Measurement Period Adjustments (b)			Final Amounts Recognized at Acquisition Date
	Accounts receivable	$	13,842			$	—		$	13,842
	Rebates receivable	6,635				(254		)	6,381
	Other current assets	383				—			383
	Total current assets	20,860				(254		)	20,606
	Property and equipment	1,263				—			1,263
	Intangible assets	182,720				—			182,720
	Goodwill	223,474				4,364			227,838
	Total assets acquired	428,317				4,110			432,427
	Accounts payable	22,370				—			22,370
	Rebates payable	16,106				—			16,106
	Accrued liabilities	7,231				—			7,231
	Other long-term liabilities	—				2,084			2,084
	Total liabilities assumed	45,707				2,084			47,791
	Net assets acquired	$	382,610			$	2,026		$	384,636
	(a) As previously reported in the Company's Form 10-K for the period ended December 31, 2013.
	(b) These measurement period adjustments were recorded from January 1, 2014 through June 30, 2014 to reflect an additional $2.0 million paid to former Restat owners in connection with post-closing working capital adjustment as well as changes in the estimated fair values of the associated assets acquired and liabilities assumed based on factors existing as of the acquisition date.
	During the years ended December 31, 2014 and 2013 the Company recognized $33.7 million and $8.7 million of amortization expense from intangible assets acquired in the Restat acquisition, respectively.
	The estimated fair values and useful lives of intangible assets acquired are as follows (dollars in thousands):
		Fair Value				Useful Life
	Customer relationships - PBM	$	143,200			10 years
	Customer relationships - cash card	35,500				3 years
	Trademarks/Trade names	1,000				1 year
	Non-compete agreements	3,020				5 years
	Total	$	182,720
	None of the acquired intangible assets will have any residual value at the end of the amortization periods. There were no in-process research and development assets acquired.
	Catalyst Merger
	On July 2, 2012, the Company completed its merger with Catalyst, a full-service PBM. Each share of Catalyst common stock outstanding immediately prior to the effective time of the Merger (other than shares owned by the Company or Catalyst or any of their respective wholly-owned subsidiaries) was converted in the Merger into the right to receive 1.3212 (0.6606 prior to split adjustment) of a Company common share and $28.00 in cash. This resulted in the Company issuing approximately 66.8 million common shares, issuing 0.5 million warrants, and paying $1.4 billion in cash to Catalyst stockholders to complete the Merger. The results of Catalyst have been included in the Company's results since July 2, 2012.
	The Merger was accounted for under the acquisition method of accounting with the Company treated as the acquiring entity. Accordingly, the consideration paid by the Company to complete the acquisition has been allocated to the assets acquired and liabilities assumed based upon their estimated fair values as of the date of acquisition. The carrying values for current assets and liabilities were deemed to approximate their fair values due to the short-term nature of their maturities. The fair value for the acquired customer relationships intangible asset was valued using an excess earnings model based on expected future revenues derived from the customers acquired. The excess of the purchase price over the estimated fair values of the net assets acquired was recorded as goodwill.
	All of the assets and liabilities recorded for the Merger are included within the Company's PBM segment. Goodwill of $525 million related to the Catalyst Merger is tax deductible. The goodwill recognized by the Company represents many of the synergies and business growth opportunities that the Company expected to be realized from the Merger. The synergies included improved pricing from the Company's suppliers due to the increased volume of prescription drug purchases, pull through opportunities of the combined companies' mail and specialty service offerings, and a more efficient leveraging of resources to achieve operating profits.
	The purchase price of the acquired Catalyst operations was comprised of the following (in thousands):
					Amount
	Cash paid to Catalyst shareholders				$	1,415,276
	Fair value of common shares issued (a)				3,238,141
	Fair value of warrants and stock options issued (b)				19,824
	Total purchase price				$	4,673,241
	(a)	Valued based on the number of outstanding shares issued in the Merger multiplied by the closing market price of Catamaran shares on July 2, 2012.
	(b)	The Black-Scholes option pricing model was used to calculate the fair value of the replacement warrants and stock options issued.
	The following summarizes the fair values assigned to the assets acquired and liabilities assumed at the acquisition date (in thousands):
		Initial Amounts Recognized at Acquisition Date (a)				2012 Measurement Period Adjustments (b)			2013 Measurement Period Adjustments (c)			Final Amounts Recognized at Acquisition Date
	Cash and cash equivalents	$	93,775			$	(315	)	$	—		$	93,460
	Other current assets	695,888				5,202			2,411			703,501
	Total current assets	789,663				4,887			2,411			796,961
	Goodwill	4,010,235				8,492			16,141			4,034,868
	Customer relationships intangible	1,184,800				—			—			1,184,800
	Other long-term assets	87,174				1,547			8			88,729
	Total assets acquired	6,071,872				14,926			18,560			6,105,358
	Accounts payable	338,819				—			5			338,824
	Pharmacy benefit management rebates payable	176,202				2,935			(1,522		)	177,615
	Accrued expenses and other current liabilities	187,851				1,348			5,473			194,672
	Long-term debt	311,994				—			—			311,994
	Other long-term liabilities	385,375				10,643			14,604			410,622
	Total liabilities assumed	1,400,241				14,926			18,560			1,433,727
	Non-controlling interest	(1,610		)		—			—			(1,610		)
	Net assets acquired	$	4,673,241			$	—		$	—		$	4,673,241
	(a) As previously reported in the Company's Form 10-Q for the period ended September 30, 2012.
	(b) These measurement period adjustments from the acquisition date through December 31, 2012 were recorded to reflect changes in the estimated fair values of the associated assets acquired and liabilities assumed based on factors existing as of the acquisition date.
	(c) These represent measurement period adjustments during 2013 through the end of the measurement period and were recorded to reflect changes in the estimated fair values of the associated assets acquired and liabilities assumed based on factors existing as of the acquisition date.
During the years ended December 31, 2014 and 2013 the Company recognized $154.7 million and $166.1 million of amortization expense from intangible assets acquired in the Merger, respectively. The estimated fair value of the customer relationship intangible asset was $1.2 billion at the date of acquisition with a useful life of 9 years. The intangible asset acquired will not have any residual value at the end of the amortization period. There were no in-process research and development assets acquired.
Separate Transactions and Preexisting Relationships
During the year ended December 31, 2012, the Company incurred transaction and integration expenses related to the Merger, exclusive of debt financing costs, totaling $27.2 million which includes transaction expenses of $22.8 million. These costs are included in selling, general and administrative ("SG&A") expenses. Additionally, during the year ended December 31, 2012, the Company recorded $17.0 million in charges to SG&A expenses due to transactions related to the Merger, recognized separately from the acquisition of assets and assumptions of liabilities from the Merger. The charges recorded related to $3.5 million in contract settlements and terminations made by Catalyst prior to the acquisition that had future benefit to the Company, $3.1 million for payments made to Catalyst employees based on contractual arrangements which had future benefit to the Company, and $10.4 million in severance charges incurred subsequent to the close of the Merger.
Due to the previous contractual relationship between the Company and Catalyst, there were pre-existing transactions between the entities which resulted in approximately $4.1 million in accounts receivable due to the Company from Catalyst at the time of the Merger, mainly for HCIT transaction processing services provided. No gain or loss was generated from the subsequent settlement of these pre-existing balances.
HealthTran LLC Acquisition
In January 2012, the Company completed the acquisition of all of the outstanding equity interests of HealthTran LLC (“HealthTran”), a full-service PBM, in exchange for $250.0 million in cash, subject to certain customary post-closing adjustments, in each case upon the terms and subject to the conditions contained in the HealthTran purchase agreement. HealthTran was an existing HCIT client and utilized a Company platform for its claims adjudication services. The acquisition provided the opportunity to create new revenues from HealthTran's customer base and generate cost savings through purchasing and SG&A synergies. The results of HealthTran have been included in the Company's results since January 1, 2012. Costs related to the HealthTran acquisition of $0.9 million were included in SG&A expenses for the year ended December 31, 2011.
The HealthTran acquisition was accounted for under the acquisition method of accounting with the Company treated as the acquiring entity. Accordingly, the consideration paid by the Company to complete the acquisition has been recorded to the assets acquired and liabilities assumed based upon their estimated fair values as of the date of acquisition. The carrying values for current assets and liabilities were deemed to approximate their fair values due to the short-term nature of their maturities. Fair values for acquired amortized intangible assets were determined as follows: customer relationships were valued using an excess earnings model based on expected future revenues derived from the customers acquired, non-compete agreements were valued using discounted cash flow models based on expected future results of HealthTran, trademarks/tradenames were valued using a royalty savings model based on future projected revenues of HealthTran and applicable market royalty rates and licenses utilized a replacement cost approach. The excess of the purchase price over the estimated fair values of the net assets acquired was recorded as goodwill. All of the assets and liabilities recorded for the HealthTran acquisition are included within the Company's PBM segment. Goodwill is non-amortizing for financial statement purposes and the entire goodwill balance generated from the HealthTran acquisition is tax deductible. The goodwill recognized by the Company represents many of the synergies and business growth opportunities that may be realized from this acquisition. The synergies include the expansion of the Company's product offerings and improved pricing from the Company's suppliers due to the increased volume of prescription drug purchases.
The following summarizes the fair values assigned to the assets acquired and liabilities assumed at the acquisition date and related measurement period adjustments (in thousands):
	Initial Amounts Recognized at Acquisition Date (a)				Measurement Period Adjustments (b)			Final Amounts Recognized at Acquisition Date
Current assets	$	30,654			$	245		$	30,899
Property and equipment	2,787				—			2,787
Goodwill	173,642				833			174,475
Intangible assets	77,130				(2,600		)	74,530
Total assets acquired	284,213				(1,522		)	282,691
Current liabilities	36,784				(496		)	36,288
Total liabilities assumed	36,784				(496		)	36,288
Net assets acquired	$	247,429			$	(1,026	)	$	246,403
(a) As previously reported in the Company's Form 10-Q for the period ended March 31, 2012.
(b) These measurement period adjustments were recorded to reflect an additional $1.0 million paid to the former HealthTran owners for the working capital reconciliation and changes in the estimated fair values of the associated assets acquired and liabilities assumed based on factors existing as of the acquisition date.
The estimated fair values and useful lives of intangible assets acquired are as follows (dollars in thousands):
	Fair Value				Useful Life
Trademarks/Trade names	$	1,750			6 months
Customer relationships	69,800				4-9 years
Non-compete agreements	2,600				5 years
License	380				3 years
Total	$	74,530
During the years ended December 31, 2014 and 2013 the Company recognized $12.6 million and $14.6 million of amortization expense from intangible assets acquired in the HealthTran acquisition, respectively. None of the acquired intangible assets will have any residual value at the end of the amortization periods. There were no in-process research and development assets acquired.
Unaudited Pro Forma Financial Information
The following unaudited pro forma financial information presents the combined historical results of operations of the Company and its acquisition of Restat as if the acquisition had occurred on the first day of the fiscal year prior to the fiscal year the acquisition was completed. The unaudited pro forma financial information includes certain adjustments related to the acquisition, such as increased amortization from the fair value of intangible assets acquired recorded as part of the purchase accounting, the elimination of transactions between the Company and the acquired entity, and related income tax effects.
Unaudited pro forma results of operations are as follows (dollars in thousands, except share and per share amounts):
	Year Ended December 31, 2013
Revenue	$	15,344,028
Gross profit	$	1,187,714
Net income	$	270,024
Earnings per share:
Basic	$	1.31
Diluted	$	1.31
Weighted average shares outstanding:
Basic	206,013,876
Diluted	206,719,526
This unaudited pro forma financial information is not intended to represent or be indicative of what would have occurred if the transactions had taken place on the dates presented and is not indicative of what the Company’s actual results of operations would have been had the acquisitions been completed at the beginning of the periods indicated above. Further, the pro forma combined results do not reflect one-time costs to fully merge and operate the combined organization more efficiently, or anticipated synergies expected to result from the combination and should not be relied upon as being indicative of the future results that the Company will experience.
Salveo Specialty Pharmacy Acquisition
Subsequent to the end of the Company's current reporting period, on January 2, 2015, the Company completed the acquisition of Salveo Specialty Pharmacy, Inc. ("Salveo"), an independent specialty pharmacy platform with pharmacy locations in New York and California, for a purchase price of $260.0 million in cash, subject to certain customary post-closing adjustments. The purchase price was funded from Catamaran's existing cash balance. The initial accounting for this acquisition was incomplete at the time these financial statements were available for issuance. The Company expects to finalize its accounting for this acquisition as soon as practicable, but no later than one year from the acquisition date.
Healthcare Solutions Inc. Acquisition
Subsequent to the end of the Company's current reporting period, on February 26, 2015, the Company announced it has entered into a definitive agreement to acquire Healthcare Solutions, Inc., a current PBM client that serves the workers' compensation market, for $405 million in cash, subject to certain customary post-closing adjustments. The acquisition is expected to be completed in the second quarter of 2015, subject to certain customary closing conditions.

Variable_Interest_Entity

Variable Interest Entity	12 Months Ended
	Dec. 31, 2014
Variable Interest Entity [Abstract]
Variable Interest Entity	Variable Interest Entity
	The Company holds an ownership interest in excess of 40%, but not a controlling interest, in Script Relief LLC ("Script Relief"), a Delaware limited liability company. Script Relief operates a direct to consumer pharmacy benefit business, including discount card offerings and associated activities. The Company evaluated its investment in Script Relief and determined that Script Relief is a variable interest entity with Catamaran being the primary beneficiary, as the Company's underlying PBM and pharmacy contracts represent Script Relief's key business operations and the Company has the power to direct these activities. As a result, Script Relief is consolidated in the Company's consolidated financial statements with the amounts attributable to the non-controlling interests disclosed. Through April 2016, the Company has the right to purchase all of the outstanding interests owned by the other equity member of Script Relief. The purchase of the outstanding interests is at the Company's sole discretion and is subject to a contractually-defined purchase price.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment
	Net property and equipment was made up of the following at December 31, 2014 and 2013 (in thousands):
	December 31, 2014	Cost		Accumulated			Net Book Value
				Depreciation
	Furniture and equipment	$	39,690	$	(13,577	)	$	26,113
	Computer equipment and software	208,628		(107,565		)	101,063
	Leasehold improvements	96,784		(23,078		)	73,706
	Construction in progress	9,145		—			9,145
		$	354,247	$	(144,220	)	$	210,027
	December 31, 2013	Cost		Accumulated			Net Book Value
				Depreciation
	Furniture and equipment	$	30,374	$	(10,815	)	$	19,559
	Computer equipment and software	168,463		(77,880		)	90,583
	Leasehold improvements	91,294		(15,163		)	76,131
	Construction in progress	10,734		—			10,734
		$	300,865	$	(103,858	)	$	197,007
	Depreciation expense, including property and equipment acquired under capital leases, totaled $63.5 million, $42.2 million, and $20.2 million for the years ended December 31, 2014, 2013, and 2012, respectively. Of the total depreciation expense, $4.0 million, $4.3 million, and $3.5 million was related to the data center operations and allocated to cost of revenue for the years ended December 31, 2014, 2013 and 2012, respectively.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets
	The changes in the carrying amounts of goodwill by reportable segment for the years ended December 31, 2014 and 2013 are as follows (in thousands):
		PBM		HCIT		Total
	Balance at December 31, 2012	$	4,458,373	$	19,665	$	4,478,038
	Acquisitions (1)	225,761		—		225,761
	Measurement period adjustments (2)	16,476		—		16,476
	Balance at December 31, 2013	4,700,610		19,665		4,720,275
	Acquisitions (3)	2,026		—		2,026
	Measurement period adjustments (4)	2,338		—		2,338
	Balance at December 31, 2014	$	4,704,974	$	19,665	$	4,724,639
	-1	Initial goodwill recorded in connection with the acquisition of Restat in October 2013 and another insignificant acquisition in 2013.
	-2	Adjustments to the fair value of assets acquired and liabilities assumed for recent acquisitions during the measurement period. The measurement period adjustments were not recast to the 2012 consolidated financial statements as they were not deemed material.
	-3	Represents adjustments to purchase price for the Restat acquisition, including settlement of working capital adjustment.
	-4	Represents adjustments in connection with the post-closing working capital adjustment as well as changes in the estimated fair values of the associated assets acquired and liabilities assumed for Restat acquisition during the measurement period. The measurement period adjustments were not recast to the 2013 consolidated financial statements as they were not deemed material.
	Definite-lived intangible assets are amortized over the useful lives of the related assets. The components of intangible assets were as follows (in thousands):
		December 31, 2014						December 31, 2013
		Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
	Customer relationships	$	1,527,722	$	564,623	$	963,099	$	1,528,475	$	355,737	$	1,172,738
	Non-compete agreements	11,920		7,435		4,485		13,430		6,463		6,967
	Other intangible assets	3,060		2,445		615		3,060		1,346		1,714
	Total	$	1,542,702	$	574,503	$	968,199	$	1,544,965	$	363,546	$	1,181,419
	Future amortization associated with intangible assets recorded as of December 31, 2014 is estimated to be $194.0 million in 2015, $166.7 million in 2016, $147.5 million in 2017, $137.2 million in 2018, $126.8 million in 2019, and $196.0 million for years after 2019.

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities
	The Company's accrued expenses and other current liabilities are comprised of the following (in thousands):
		December 31,
		2014		2013
	Customer deposits	$	13,619	$	12,148
	Salaries and wages payable	65,481		54,761
	Deferred revenue	31,630		10,053
	Income taxes payable	—		7,456
	Other accrued expenses	216,460		169,682
	Total accrued expenses and other current liabilities	$	327,190	$	254,100

LongTerm_Liabilities

Long-Term Liabilities	12 Months Ended
	Dec. 31, 2014
Long-term Liabilities [Abstract]
Long-Term Liabilities	Long-Term Liabilities
	Long- term debt
	The following table sets forth the components of long-term debt (in thousands), net of unamortized debt discounts as of December 31, 2014 and December 31, 2013.
		Year Ended December 31,
		2014			2013
	Senior secured term loan facility due June 1, 2018 with an interest rate of 1.81% at December 31, 2014 and 2013	$	932,875		$	965,363
	Senior secured revolving credit facility due June 1, 2018 with an interest rate of 1.81% at December 31, 2014 and 2013	—			300,000
	4.75% Senior Notes due 2021	493,348			—
	Less current maturities	(81,250		)	(50,000		)
	Long-term debt	$	1,344,973		$	1,215,363
	Senior Notes
	In March 2014, the Company issued $500.0 million aggregate principal amount of 4.75% Senior Notes due 2021 (the “Senior Notes”). The Senior Notes mature on March 15, 2021 and bear interest at 4.75% per year. The Company pays interest semi-annually on the Senior Notes on March 15 and September 15 of each year, or the first business day thereafter if such date is not a business day. The Company made an initial interest payment of $12.1 million in September 2014 on the Senior Notes. The Company received approximately $492.5 million in net proceeds from the Senior Note offering, after deducting $7.5 million in underwriting discounts. Additionally the Company incurred approximately $2.0 million in offering expenses. The Company used part of the net proceeds from this offering to repay $300.0 million of the Company's outstanding borrowings under the Revolving Facility and the remainder of the net proceeds from this offering for general corporate purposes.
	As discussed, in connection with the Senior Notes, the Company incurred approximately $7.5 million in underwriting debt discount and approximately $2.0 million in debt issuance costs. The $7.5 million debt discount incurred in connection with the Senior Notes is presented on the consolidated balance sheet as a reduction to long-term debt. The debt discount amounts are being amortized to interest expense over the life of the Senior Notes. The Company uses the straight-line method to amortize the debt discount amounts as it does not result in a materially different amount of interest expense than the effective interest rate method. The $2.0 million in offering expenses incurred in connection with the issuance of the Senior Notes are presented on the consolidated balance sheet as other assets. The offering expenses are being amortized to interest expense over the life of the Senior Notes using the straight-line method. The amortization related to financing costs and debt discounts totaled $1.1 million for the year ended December 31, 2014.
	Guarantees
	The Senior Notes are jointly and severally and fully and unconditionally guaranteed by each of the Company’s existing and future wholly-owned subsidiaries that guarantees obligations under (i) the Credit Agreement or (ii) certain other future indebtedness in aggregate principal amount in excess of $175.0 million.
	A subsidiary guarantor will be released from its obligations under its respective guarantee of the Senior Notes upon the release or discharge of such subsidiary guarantor from its guarantee of obligations under the Credit Agreement or certain other future indebtedness in an aggregate principal amount in excess of $175.0 million, or upon the earlier occurrence of certain other customary circumstances as set forth in the indenture governing the Senior Notes. The Senior Notes and the guarantees by the subsidiary guarantors are the general senior unsecured obligations of the Company and the subsidiary guarantors, respectively and rank equally in right of payment with the existing and future senior unsecured indebtedness of the Company and the subsidiary guarantors, respectively.
	Prepayments and Repayments
	Prior to the scheduled maturity of the Senior Notes, the Company may at any time redeem all or a part of the Senior Notes, upon not less than 30 nor more than 60 days’ prior written notice at a redemption price equal to the greater of: (i) 100% of the principal amount of the Senior Notes to be redeemed, and (ii) the sum of the present values of the remaining scheduled payments of principal of and interest on the Senior Notes to be redeemed (exclusive of interest accrued to the applicable redemption date) discounted to such redemption date on a semi-annual basis, assuming a 360-day year consisting of twelve 30-day months, at the then current treasury rate plus 50 basis points, plus, in each case, accrued and unpaid interest thereon to, but not including, the applicable redemption date.
	If the Company experiences a change of control triggering event (as defined in the supplemental indenture governing the Senior Notes), holders of the Senior Notes may require the Company to purchase the Senior Notes at a purchase price equal to 101% of the aggregate principal amount, plus accrued and unpaid interest, if any, to the date of purchase.
	The Company is not required to make mandatory redemption payments or sinking fund payments with respect to the Senior Notes.
	Certain Covenants and Events of Default
	The indenture governing the Senior Notes includes certain restrictive covenants, including covenants that limit the Company's ability and the ability of our subsidiaries to, among other things, incur secured debt; enter into sale and leaseback transactions; and amalgamate, consolidate, merge or transfer substantially all of the Company's assets to another entity. The covenants are subject to a number of important exceptions and qualifications set forth in the indenture.
	The indenture governing the Senior Notes provides for customary events of default (subject in certain cases to customary grace and cure periods), which include nonpayment, breach of covenants in the indenture and certain events of bankruptcy and insolvency. Generally, if an event of default occurs, the trustee or holders of at least 25% in aggregate principal amount of and accrued but unpaid interest on the then outstanding Senior Notes may declare the principal amount of all the Senior Notes to be due and payable immediately. As of December 31, 2014, the Company was in compliance with the covenants under the Senior Notes.
	Senior secured credit facility
	Concurrent with the consummation of the Merger on July 2, 2012, the Company executed a credit agreement (the "Credit Agreement") with JPMorgan Chase Bank, N.A. ("JPMCB"), as administrative agent, and a syndicate of lenders. The Credit Agreement initially provided for a senior secured credit facility in an aggregate amount of $1.8 billion consisting of (i) a five-year senior secured term loan facility in the amount of $1.1 billion (the “Term Loan Facility”) and (ii) the Revolving Facility in the amount of $700.0 million. In July 2012, the Company borrowed $1.4 billion under the Credit Agreement consisting of $1.1 billion under the Term Loan Facility and $300.0 million under the Revolving Facility to fund in part the aggregate cash consideration payable to Catalyst stockholders in the Merger, repay and discharge existing indebtedness of the Company and Catalyst and pay related transaction fees and expenses. Net proceeds received under the Term Loan Facility were $1.1 billion less $29.6 million in debt discount. Additionally, the Company paid $18.8 million in debt issuance costs related to the Revolving Facility.
	On June 3, 2013, the Company entered into an Amendment (the “Amendment”) to the Credit Agreement. Pursuant to the Amendment, the following key terms of the Credit Agreement were modified:
	•	an extension of the maturity date for the Term Loan Facility and the Revolving Facility from July 2, 2017 to June 1, 2018;
	•	an increase in the commitments under the Revolving Facility from $700.0 million to $800.0 million;
	•	a decrease in the commitments under the Term Loan Facility from $1.1 billion to $1.0 billion;
	•	additional flexibility for the Company and its subsidiaries to (i) make certain permitted acquisitions, (ii) create liens, (iii) make
	investments, loans, advances or guarantees, and (iv) pay dividends and distributions or repurchase its own capital stock; and
	•	modifications to the interest rates and financial covenants applicable to the Company and its subsidiaries as described further below.
	After giving effect to the Amendment, the interest rates applicable to the Term Loan Facility and the Revolving Facility will continue to be based on a fluctuating rate of interest measured by reference to either, at the Company's option, (i) a base rate, plus an applicable margin, or (ii) an adjusted London interbank offered rate (adjusted for maximum reserves) (“LIBOR”), plus an applicable margin. The applicable margin, in each case, will continue to be adjusted from time to time based on the Company's consolidated leverage ratio for the previous fiscal quarter. The Amendment provides for a reduction in the applicable margins that would be in effect at any time when the Company's consolidated leverage ratio is greater than 1.50 to 1 and less than 2.50 to 1. After giving effect to the Amendment, the initial applicable margin for all borrowings was 0.625% per annum with respect to base rate borrowings and 1.625% per annum with respect to LIBOR borrowings. The Company intends to continue to elect the LIBOR rate as it has previously done during the term of the loan. This resulted in the applicable interest rate decreasing to 1.81% at December 31, 2014 from 2.25% prior to the Amendment. See Note 18 — Financial Instruments for information on the Company's interest rate swap agreements.
	In connection with the Amendment, the Company made a $100.0 million prepayment on the Term Loan Facility to reduce its outstanding balance to $1.0 billion from $1.1 billion. In addition, the Company made scheduled principal repayments of $12.5 million in 2013 on the Term Loan Facility leaving the Company with $987.5 million outstanding as of December 31, 2013. The Company made scheduled principal repayments of $37.5 million on the Term Loan Facility in 2014 leaving the Company with $950.0 million outstanding as of December 31, 2014.
	The Company utilized funds from the Revolving Facility to make the prepayment in connection with the Amendment, leaving the Company with $700.0 million of remaining available borrowing capacity under the Revolving Facility at the time of the Amendment execution. On October 1, 2013, the Company utilized $350.0 million under the Revolving Facility to partially fund the acquisition of Restat. In 2013, the Company repaid $150.0 million, of the amount borrowed under the Revolving Facility, leaving the Company with approximately $500.0 million of borrowing capacity under the Revolving Facility as of December 31, 2013. In March 2014 the Company used the proceeds from the offering of the Senior Notes (refer above for a detailed discussion) to repay $300.0 million of the outstanding borrowings under the Revolving Facility. As of December 31, 2014, the Company had approximately $800.0 million of available borrowing capacity under the Revolving Facility.
	In connection with executing the Amendment, the Company paid $2.3 million in direct lender fees to the syndication of banks providing credit to the Company. The fees consisted of a $1.3 million debt discount related to the Term Loan Facility and $1.0 million of debt issuance costs related to the Revolving Facility. The $1.3 million debt discount incurred in connection with the Amendment is presented on the consolidated balance sheet as a reduction to long-term debt, along with the $24.1 million of unamortized debt discount incurred in connection with the execution of the Credit Agreement. The debt discount amounts are being amortized to interest expense over the amended life of the Term Loan Facility. The Company uses the straight-line method to amortize the debt discount as it does not result in a materially different amount of interest expense than the effective interest rate method. The additional $1.0 million debt issue cost incurred in connection with the execution of the Amendment related to the Revolving Facility, along with $16.6 million of unamortized debt issuance costs incurred in connection with the execution of the Credit Agreement are presented on the consolidated balance sheet as other assets. The debt issuance costs are being amortized to interest expense over the amended life of the Revolving Facility using the straight-line method.
	The amortization related to financing costs and debt discounts totaled $8.5 million, $9.1 million, and $5.0 million for the years ended December 31, 2014, December 31, 2013, and December 31, 2012, respectively.
	As a result of executing the Amendment, the Company assessed whether the modifications to the Credit Agreement were substantial and should be accounted for using extinguishment accounting. The Company made its assessment both on a total basis of all lenders and on an individual basis for each member of the syndicate. The Company performed separate assessments for the Term Loan Facility and the Revolving Facility. As a result of the assessments, the Company recorded an additional interest expense charge of $0.4 million from unamortized debt discount and debt issuance costs during the year ended December 31, 2013.
	The Credit Agreement, as amended by the Amendment, requires the Company to maintain a consolidated leverage ratio at all times less than or equal to 4.00 to 1 and a consolidated senior secured leverage ratio at all times less than or equal to 3.25 to 1. The Company's consolidated leverage ratio is defined as the ratio of (1) consolidated total debt to (2) consolidated EBITDA (with add-backs permitted to consolidated EBITDA for (a) fees and expenses related to the Merger, the closing of the Credit Agreement, a specified historic acquisition and future permitted acquisitions, (b) synergies projected by the Company in good faith to be realized as a result of the Merger in an aggregate amount not to exceed a specified threshold and (c) fees and expenses and integration costs related to historical acquisitions by Catalyst in an aggregate amount not to exceed a specified threshold). The Company's new consolidated senior secured leverage ratio is defined as the ratio of (1) (a) consolidated total debt minus (b) any portion of consolidated total debt that is subordinated or not secured by a lien upon the assets of the Company or its subsidiaries to (2) consolidated EBITDA (subject to the permitted add-backs noted above). The Amendment continues to require the Company to maintain an interest coverage ratio greater than or equal to 4.00 to 1. The interest coverage ratio is defined as the ratio of (1) consolidated EBIT (subject to the permitted add-backs noted above) to (2) consolidated interest expense, tested at the end of each fiscal quarter for the rolling four fiscal quarter period then most recently ended. As of December 31, 2014, the Company was in compliance with the covenants of the Credit Agreement, as amended by the Amendment.
	Principal amounts outstanding under the Revolving Facility are due and payable in full on June 1, 2018. Principal repayments on the Term Loan Facility will be due as follows (in thousands):
	Year	Amount due
	2015	81,250
	2016	93,750
	2017	118,750
	2018	656,250
	Total	$	950,000
	The Credit Agreement also contains a number of covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its subsidiaries to: incur additional indebtedness; create liens; make investments, loans, advances or guarantees; sell or transfer assets; pay dividends and distributions or repurchase its own capital stock; prepay certain indebtedness; engage in mergers, acquisitions or consolidations (subject to exceptions for certain permitted acquisitions); change its lines of business or enter into new lines of business; engage in certain transactions with affiliates; enter into agreements restricting the ability to grant liens in favor of the collateral agent for the benefit of the secured parties; engage in sale and leaseback transactions; or enter into swap, forward, future or derivative transaction or option or similar agreements. In addition, the Credit Agreement includes various (i) customary affirmative covenants and other reporting requirements and (ii) customary events of default, including, without limitation, payment defaults, violation of covenants, material inaccuracy of representations or warranties, cross-defaults to other material agreements evidencing indebtedness, bankruptcy events, certain ERISA events, material judgments, invalidity of guarantees or security documents and change of control. Drawings under the Revolving Facility are subject to certain conditions precedent, including material accuracy of representations and warranties and absence of default.
	The Company’s obligations under the Credit Agreement are guaranteed by all existing and future, direct and indirect, material subsidiaries of the Company (collectively, the “Subsidiary Guarantors”).  In addition, the Company and each Subsidiary Guarantor have pledged substantially all of their assets, subject to certain exceptions, to secure the Company’s obligations under the Credit Agreement.
	The carrying value of the Company's debt at December 31, 2014 approximates its fair value.

Shareholders_Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Shareholders' Equity
	(a)	Common shares:
	(i) Authorized:  Unlimited no par value voting common shares
	(ii) Issuance of common shares:
	On May 16, 2012, the Company completed a public offering of 12.0 million of its common shares at a price to the public of $45.30 per share. The net proceeds to the Company from the offering were approximately $519.1 million, after deducting the underwriting discounts and commissions and offering expenses. The Company used part of the net proceeds from the offering to pay a portion of the cash component of the Merger consideration and other related fees and expenses in connection with the Merger and the balance was used for general corporate purposes.
	On July 2, 2012, the Company issued 66.8 million common shares and 0.5 million warrants in connection with the Catalyst Merger. See Note 4 — Business Combinations for further information related to the Merger.
	(b)	Equity incentive plans:
	Effective on March 11, 2009, the Board of Directors of the Company adopted the Catamaran Corporation Long-Term Incentive Plan (“LTIP”), which was approved by the shareholders of the Company at the Annual and Special Meeting of Shareholders on May 13, 2009. The LTIP provides for the grant of stock option awards, stock appreciation rights, restricted stock awards, restricted stock unit ("RSU") awards, performance awards and other stock-based awards to eligible persons, including executive officers and directors of the Company. The purpose of the LTIP is to advance the interests of the Company by attracting and retaining high caliber employees and other key individuals who perform services for the Company, a subsidiary or an affiliate; align the interests of the Company’s shareholders and recipients of awards under the LTIP by increasing the proprietary interest of such recipients in the Company’s growth and success; and motivate award recipients to act in the best long-term interest of the Company and its shareholders. The LTIP replaced the previous stock option plan, and no further grants or awards will be issued under the previous stock option plan. The maximum common shares of the Company allowed to be issued under the LTIP was increased by 3.6 million on May 11, 2011, after the Company’s shareholders approved an amendment to the LTIP at the Annual and Special Meeting of Shareholders of the Company. In July 2012, the maximum common shares of the Company allowed to be issued under the LTIP was increased by 5.0 million. Any full-value awards (i.e., any awards other than stock options or stock appreciation rights) granted under the LTIP are counted against this share limit as 1.79 shares for every one share granted. There were 4,815,112 stock-based awards available for grant under the LTIP as of December 31, 2014.
	In connection with the closing of the Merger with Catalyst on July 2, 2012, the Company assumed two stock incentive plans (together the "Assumed Plans"), each as amended and adjusted for the purpose of granting awards to certain employees of the Company subsequent to the close of the Merger or to newly hired employees of the Company who were not employed with the Company as of the close of the Merger. The Assumed Plans provide for the grant of stock option awards, RSU awards, performance awards and other stock-based awards to eligible persons. The maximum common shares of the Company allowed to be issued under the Assumed Plans is 1,480,936. Any full-value awards (i.e., any awards other than stock options or SARs) granted under the Assumed Plans are counted against this share limit as 1.45 shares for every one share granted. There were 730,056 stock-based awards available for grant under the Assumed Plans as of December 31, 2014.
	(c)	Stock Options
	The following table summarizes activity related to stock options for the year ended
	December 31, 2014:
		Number of Options		Weighted Average Exercise Price
	Outstanding, beginning of period	1,396,144		$	31.6
	Granted	432,586		$	44.72
	Exercised	(298,108	)	$	18.92
	Forfeited	(82,090	)	$	47.54
	Outstanding, end of period	1,448,532		$	37.22
	Options granted during 2014, were primarily subject to a graded vesting schedule of four years. Options granted expire seven years from the grant date.
	The following table summarizes certain information about the options outstanding at December 31, 2014:
	Range of Exercise Price	Options Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price				Options Exercisable			Weighted Average Exercise Price
	$6.39- $24.92	233,300		2.16		$	14.05			230,038			$	13.88
	$24.93 - $32.45	233,294		3.25		$	25.51			140,764			$	25.57
	$32.46 - $44.15	279,524		4.29		$	35.78			110,540			$	35.25
	$44.16 - $44.90	347,132		6.18		$	44.7			—			$	—
	$44.91 - $56.25	355,282		5.26		$	53.99			86,773			$	54.22
	$6.39 - $56.25	1,448,532		4.47		$	37.22			568,115			$	27.1
	The aggregate intrinsic value and remaining contractual term of exercisable stock options at December 31, 2014 was $14.0 million and 3.26 years, respectively. The aggregate intrinsic value and remaining contractual term of all vested options and options that are expected to vest are $21.0 million and 4.47 years, respectively. The total fair value of stock options which vested during the years ended December 31, 2014, 2013 and 2012 was approximately $4.6 million, $3.5 million, and $2.8 million, respectively.
	As of December 31, 2014, there were $8.2 million and $1.7 million of unrecognized compensation costs related to stock options for LTIP and Assumed Plans, respectively, which are expected to be recognized over a weighted-average period of 2.39 years and 3.01 years, respectively.
	The total intrinsic value of stock options exercised during the years ended December 31, 2014, 2013, and 2012 was $8.2 million, $14.9 million, and $50.3 million, respectively.
	(d)	Employee Stock Purchase Plan:
	On May 16, 2007, shareholders of the Company approved the creation of the Employee Stock Purchase Plan (“ESPP”) which allows eligible employees to withhold annually up to a maximum of 15% of their base salary, or $25,000, subject to U.S. Internal Revenue Service limitations, for the purchase of the Company’s common shares. Common shares will be purchased on the last day of each offering period at a discount of 5% of the fair market value of the common shares on such date. The aggregate number of common shares that may be awarded under the ESPP may not exceed 400,000 common shares. Common shares available for purchase under the ESPP are drawn from reacquired common shares purchased on behalf of the Company in the open market. During 2014, 2013, and 2012, the Company delivered 40,156, 33,728, and 14,697 common shares, respectively, under the ESPP.
	The ESPP is not considered compensatory as the plan terms are no more favorable than to all other shareholders, and the purchase discount does not exceed the per-share costs that would be incurred through a public offering. Since the plan is not considered compensatory, no portion of the costs related to ESPP purchases is included in the Company’s stock-based compensation expense.
	(e)	Restricted Stock Units:
	During 2014, the Company granted both time-based RSUs and performance based RSUs to its employees and non-employee directors under both the LTIP and the Assumed Plans. Time-based RSUs vest on a straight-line basis over a range of three to four years. During 2012 and 2013, the Company also granted time-based RSUs that cliff vest after a three to four year period. Performance-based RSUs cliff vest based upon reaching agreed upon three-year performance conditions. The number of outstanding performance-based RSUs as of December 31, 2014 stated below assumes the associated performance targets will be met at the maximum level. The table below summarizes the number of time-based and performance-based RSUs that were granted and outstanding under both plans for the year ended December 31, 2014:
		LTIP Plan									Assumed Plans
		Number of Restricted Stock Units									Number of Restricted Stock Units
		Time-Based		Performance - Based			Weighted Average Grant Date Fair Value Per Unit				Time-Based			Performance - Based	Weighted Average Grant Date Fair Value Per Unit
	Granted	302,257		392,388			$	44.84			155,615			91,516	$	44.41
	Outstanding	714,810		830,880			—				243,925			86,948	—
	The total fair value of RSUs that vested during 2014, 2013, and 2012 was $20.8 million, $27.3 million, and $18.0 million, respectively. The weighted average grant date fair value of awards granted during 2014, 2013, and 2012 was $44.72, $55.99, and $38.49, respectively.
	The following table summarizes the information about RSUs for the year ended December 31, 2014 under the Company's equity incentive plans:
		LTIP Plan						Assumed Plans
		Number of Restricted Stock Units		Weighted Average Grant Date Fair Value Per Unit				Number of Restricted Stock Units			Weighted Average Grant Date Fair Value Per Unit
	Nonvested balance as of the beginning of the period	1,334,694		$	40.14			213,656			$	50.98
	Granted	694,645		$	44.84			247,131			$	44.41
	Vested	(411,817	)	$	30.23			(53,386	)		$	50.38
	Forfeited	(71,832	)	$	44.57			(76,528	)		$	49.06
	Nonvested balance as of the end of the period	1,545,690		$	44.69			330,873			$	46.62
	(f)	Warrants:
	On July 2, 2012, the Company issued 66.8 million common shares and 0.5 million warrants in connection with the Company's merger with Catalyst Health Solutions, Inc. As of December 31, 2013, 425,160 of the warrants issued were outstanding. In June 2014, all of the outstanding warrants were exercised carrying a weighted average exercise price of $8.12. As of December 31, 2014, there were no warrants outstanding.
	(g)	Stock-based Compensation:
	For the years ended December 31, 2014, 2013, and 2012, the Company recorded stock-based compensation expense of $33.6 million, $25.6 million, and $17.7 million, respectively. At December 31, 2014, there was $34.6 million and $12.0 million unrecognized compensation cost related to RSUs under the LTIP and Assumed Plans, respectively, which is expected to be recognized over a weighted-average period of 2.02  and 2.49 years, respectively.
	The Company allocated stock-based compensation costs to the same statement of operations line item as the cash compensation to those employees. Accordingly, the allocation of the compensation costs is as follows for the years ended December 31, 2014, 2013, and 2012 (in thousands):
		2014			2013				2012
	Cost of revenue	$	2,284		$	1,404			$	687
	Selling, general and administrative	31,270			24,158				16,980
	Total stock-based compensation	$	33,554		$	25,562			$	17,667
	The total income tax benefit, using the Company’s statutory tax rates, recognized in the statements of operations for stock-based compensation arrangements for years ended December 31, 2014, 2013, and 2012 was $12.7 million, $9.5 million, and $6.5 million, respectively.
	The Black-Scholes-Merton option-pricing model was used to estimate the fair value of the options at grant date for the years ended December 31, 2014, 2013, and 2012, based on the following assumptions:
		2014			2013				2012
	Volatility	37.7-39.2%			41.4-45.4%				47.2-49.2%
	Risk-free interest rate	1.54 - 1.73%			0.81-1.74%				0.65-0.83%
	Expected life	4.5 years			4.5 years				4.5 years
Dividend yield	—			—				—
Weighted average grant date fair value	$	15.47		$	21.33			$	14.7
The volatility assumption is based on historical volatility at the date of grant for the period equal to the expected life of the option.
The expected life assumption is based on historical exercise patterns. The options issued to employees typically have a longer expected life of 4.5 to 5 years due to the vesting schedules, whereas options issued to directors have a shorter expected life of 1 to 2.5 years due to the shorter vesting period of some director options.
The Company does not expect to pay dividends and, therefore, no dividend yield assumption is used in calculating the fair value of stock options.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	The income tax effects of temporary differences that give rise to significant portions of deferred income tax assets and liabilities are as follows.
		December 31,
		2014				2013
		(In thousands)
	Deferred income tax assets:
	Non-capital loss carryforwards (“NOL”)	$	28,906			$	18,229
	Lease inducements and deferred financing	15,826				12,528
	Reserves and accruals	62,487				45,974
	Stock-based compensation	17,889				12,763
	Other	12,318				9,408
	Total	137,426				98,902
	Less valuation allowance - current	804				875
	Less valuation allowance - long term	28,915				17,486
	Total valuation allowance	29,719				18,361
	Total deferred tax assets	$	107,707			$	80,541
	Deferred tax assets — current	$	58,631			$	44,029
	Deferred tax assets — long term	49,076				36,512
	Total	$	107,707			$	80,541
	Deferred income tax liabilities:
	Property and equipment and intangible assets	$	297,978			$	329,842
	Dividend withholding tax	5,675				5,675
	Other	5,156				3,146
	Total	$	308,809			$	338,663
	At December 31, 2014, the Company had gross deferred tax assets (“DTAs”) totaling $137.4 million compared to $98.9 million at December 31, 2013. Of the $137.4 million, $30.8 million of DTAs related to its Canadian operations compared to $18.1 million at December 31, 2013. The Company also had deferred tax liabilities which decreased to $308.8 million at December 31, 2014 from $338.7 million at December 31, 2013.
	The balance of the valuation allowance was $29.7 million at December 31, 2014 compared to $18.4 million at December 31, 2013. The valuation allowance arising from the Canadian operations was $28.4 million at December 31, 2014 and $17.1 million at December 31, 2013. The Canadian valuation allowance increased during the year as a result of a loss from operations. The amount of this valuation allowance is subject to adjustment by the Company in future periods based upon its assessment of evidence supporting the degree of probability that DTAs will be realized.
	At December 31, 2014, the Company had a DTA of $28.9 million related to Canadian, US Federal and state NOLs. The NOLs are available to reduce future years’ taxable income and expire beginning in 2031. A valuation allowance of $26.7 million has been established against a portion of the NOLs not anticipated to be utilized.
	The differences between the effective tax rate reflected in the provision for income taxes and the U.S. statutory income tax rate are as follows (dollars in thousands):
		Years Ended December 31,
		2014				2013				2012
	Corporate statutory rate	35		%		35		%		35		%
	Income tax expense on income before income taxes	$	177,768			$	140,751			$	66,618
	Tax effect of:
	State and local income taxes, net of federal benefit	13,527				10,726				4,281
	Transaction costs and transaction related expenses	453				938				5,252
	Dividend withholding tax	—				(65		)		13,074
	Impact of foreign tax rates	(3,191		)		(3,693		)		(1,582		)
	Non-controlling interest	(22,452		)		(13,670		)		(1,645		)
	Cross-jurisdictional financing	(48,252		)		(44,659		)		(23,937		)
	Other	3,662				4,479				3,763
	Valuation allowance	12,671				8,596				3,492
		$	134,186			$	103,403			$	69,316
	Income from U.S. operations before income taxes was $428.7 million, $319.8 million, and $158.7 million for the years ended December 31, 2014, 2013 and 2012, respectively. Income from outside the U.S. before income taxes, including taxable income attributable to intercompany debt, was $79.2 million, $82.3 million, and $31.6 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	The components of the provision for income taxes are as follows (in thousands):
		Years Ended December 31,
		2014				2013				2012
	Current tax expense
	United States	$	192,021			$	146,484			$	94,834
	Foreign	212				1,255				12,407
	Total current tax expense	192,233				147,739				107,241
	Deferred tax expense (benefit)
	United States	(57,889		)		(44,180		)		(38,441		)
	Foreign	(158		)		(156		)		516
	Total deferred tax expense	(58,047		)		(44,336		)		(37,925		)
	Total tax expense	$	134,186			$	103,403			$	69,316
	Uncertain Tax Positions
	Accounting guidance for uncertain tax positions prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As of December 31, 2014, the Company has an accrued liability in the consolidated balance sheet of $35.4 million. As of December 31, 2013 and 2012, the Company had an accrued liability of $28.9 million and $18.8 million, respectively. This liability related to various uncertain federal and state income tax matters, the resolution of all of which would not have a material impact on the Company’s effective tax rate.
	A reconciliation of the beginning and ending amount of unrecognized tax benefits, including interest and penalties, for 2014, 2013 and 2012 , respectively are as follows (in millions):
			2014				2013				2012
	Balance at January 1		$	28.9			$	18.8			$	0.6
	Additions for tax positions related to prior years		9				26.5				10.3
	Reductions for tax positions related to prior years		(0.9		)		(13.9		)		—
	Additions based on tax positions related to the current year		3.8				0.4				7.9
	Reductions due to lapse of the applicable statute of limitations		(4.7		)		—				—
Decrease related to settlements with taxing authorities		(0.7		)		(2.9		)		—
Balance at December 31		$	35.4			$	28.9			$	18.8
The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. Accrued interest and penalties at December 31, 2014, 2013, and 2012 was $5.9 million, $4.7 million, and $0.5 million, respectively. It is reasonably possible that the total amount of unrecognized tax benefits will increase or decrease within twelve months of December 31, 2014. The Company currently estimates that such increases or decreases will not be material.
The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions, including Canada. With few exceptions, the Company is no longer subject to tax examinations by tax authorities for years prior to 2010.

Lease_Exit_Costs

Lease Exit Costs	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Lease Exit Costs	Lease Exit Costs
	Bannockburn Lease
	In September 2014, the Company executed a plan to exit the space it had leased in Bannockburn, IL. As a result of this exit, the Company recorded a charge and corresponding lease loss accrual equal to the present value of the amount by which the net future lease obligations exceed the remaining rent-related deferred balances. As a result of this exit, the Company recorded approximately $5.7 million of lease loss expense during 2014 in SG&A expense in the consolidated statements of operations. As of December 31, 2014, the Company had an accrual for the present value of future amounts due through the end of the lease term of approximately $6.9 million, which is included in accrued expenses and other current liabilities in the consolidated balance sheets. Based on the Company's current assumptions as of December 31, 2014, we expect that cash outflows totaling $7.0 million will occur through July 2015. The exit from the space in Bannockburn, IL did not involve any employee termination costs.
	Maryland Lease
	In August 2013, the Company executed a plan to exit a portion of space it had leased in Maryland and entered into a sub-lease agreement with a third-party tenant that was coterminous with the Company's remaining lease term. As a result of this exit, the Company recorded an approximately $5.6 million charge in SG&A expense and corresponding lease loss accrual equal to the present value of the amount by which the net future lease obligations exceed the remaining rent-related deferred balances. The net future lease obligations were calculated by taking the remaining contractual rent obligation less the amount the Company will receive from the sub-lease agreement and recorded at its present value based on the Company's credit adjusted risk-free interest rate. As of December 31, 2014, the Company had an accrual of approximately $5.2 million related to lease exit costs included in accrued expenses and other current liabilities in the consolidated balance sheets. A roll forward of the lease exit cost accrual is presented below (in thousands):
		Amount
	Liability at 12/31/2013	$	5,774
	Net payments	(819		)
	Change in Present Value	260
	Liability at 12/31/2014	$	5,215
	Based on the Company's current assumptions as of December 31, 2014, we expect that cash outflows totaling $6.1 million will occur through June 2022.

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share
	The following table sets forth the computation of basic and diluted EPS for the years ended December 31, 2014, 2013, and 2012 (in thousands, except share and per share data):
		2014			2013			2012
	Numerator:
	Net income available to common shareholders	$	317,293		$	262,170		$	116,658
	Denominator for basic EPS — weighted average common shares outstanding	207,103,603			206,013,876			166,765,682
	Effect of dilutive securities:
	Restricted stock units	402,992			321,587			329,975
	Stock options	245,550			384,063			734,963
	Denominator for diluted EPS	207,752,145			206,719,526			167,830,620
	Earnings per share:
	Basic	$	1.53		$	1.27		$	0.7
	Diluted	$	1.53		$	1.27		$	0.7
	The Company calculated the number of options and RSUs included in the diluted EPS calculation following the treasury stock method as outlined in earnings per-share accounting guidance. The following represents the stock options and RSUs that are not included in the calculation of diluted EPS due to their anti-dilutive impact:
		December 31,
		2014		2013			2012
	Anti-dilutive RSUs	746,999		615,608			773,509
	Anti-dilutive stock options	669,144		30,381			288,532
		1,416,143		645,989			1,062,041

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2014
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information	Supplemental Cash Flow Information
	(a) Other non-cash activities (in thousands):
		Year Ended December 31, 2012
	Equity shares issued as a result of the NMHC acquisition	$	4
	Equity shares issued as a result of the Catalyst Merger	$	3,238,141
	(b) Cash paid / received for income taxes and interest was as follows for the years ended December 31, 2014, 2013, and 2012 (in thousands):
		Years Ended December 31,
		2014		2013		2012
	Income taxes paid	$	201,263	$	158,053	$	22,052
	Interest paid	$	38,880	$	30,322	$	18,711
	Interest received	$	837	$	735	$	473

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plans	Employee Benefit Plans
	The Company has a 401(k) savings plan that allows eligible employees to defer a percentage of their salary, not to exceed $17,500 in 2014 and 2013 and $17,000 in 2012. The Company matches an amount equal to 100% of the first 1% of eligible earnings and 50% of the next 2% through 6% eligible earnings. All participant contributions are 100% vested. Employer contributions become 20% vested after one year of service and 100% vested after completion of two years of service. For 2014, 2013 and 2012, the Company’s contributions to this plan were $9.0 million, $7.0 million, and $4.9 million, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	(a)	Lease Commitments:
	The Company maintains operating lease agreements for office space in its main operating locations. The Company also leases certain office equipment.
	Aggregate future minimum payments in respect of non-cancellable operating lease agreements as of December 31, 2014, which extend until 2025, are as follows (in thousands):
		Operating Leases
	2015	$	20,747
	2016	19,529
	2017	19,847
	2018	16,901
	2019	15,752
	After 2019	53,633
		$	146,409
	The total rental expense under operating leases for the years ended December 31, 2014, 2013, and 2012 was $36.0 million, $35.4 million, and $17.1 million, respectively. The lease renewal terms have not been factored into the commitments noted above as not renewing these leases would not have a detrimental impact on the Company.
	(b)	Contingencies:
	In July 2014, the Company received a subpoena from the United States Attorney's Office for the District of Rhode Island, requesting documents and information concerning bona fide service fees and rebates received from certain pharmaceutical manufacturers in connection with certain drugs utilized under Part D of the Medicare program. The Company has been cooperating with the government, collecting and producing documents in response to the subpoena.
	Beeman, et al. v. Anthem Prescription Management, Inc., et al.  A purported class action lawsuit was filed in February 2004 in the United States District Court for the Central District of California against a number of  pharmacy benefit managers, including current subsidiaries of the Company, by several California pharmacies. Plaintiffs allege that defendants failed to comply with statutory obligations under California Civil Code Section 2527 to conduct studies of pharmacy dispensing fees and provide the results to third-party payors in California, and seek money damages.  Because the lawsuit was stayed by appeals, including a challenge to the constitutionality of the statute, for nearly its entire history and was remanded back to the District Court in 2014, it is still in its early stages. As of December 31, 2014, based on currently available information, the Company cannot reasonably estimate a potential impact in this matter.
	From time to time in connection with its operations, the Company is named as a defendant in other actions for damages and costs allegedly sustained by third-party plaintiffs. The Company has considered these proceedings and disputes in determining the necessity of any accruals for losses that are probable and reasonably estimable. In addition, various aspects of the Company’s business may subject it to litigation and liability for damages arising from errors in processing the pricing of prescription drug claims, failure to meet performance measures within certain contracts relating to its services performed, its ability to obtain certain levels of discounts or rebates on prescription purchases from retail pharmacies and drug manufacturers or other actions or omissions. The Company’s recorded accruals are based on estimates developed with consideration given to the potential merits of claims or quantification of any performance obligations. The Company takes into account its history of claims, the limitations of any insurance coverage, advice from outside counsel, and management’s strategy with regard to the settlement or defense of such claims and obligations. While the ultimate outcome of those claims, lawsuits or performance obligations cannot be predicted with certainty, the Company believes, based on its understanding of the facts of these claims and performance obligations, that adequate provisions have been recorded in the accounts where required. As of December 31, 2014, the Company did not have any material contingencies accrual related to lawsuits or allegations brought against the Company.
	(c)	Guarantees:
	The Company provides routine indemnification to its customers against liability if the Company’s products infringe on a third-party’s intellectual property rights. The maximum amount of these indemnifications cannot be reasonably estimated due to their uncertain nature. Historically, the Company has not made payments related to these indemnifications.

Segment_Information

Segment Information	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Information	Segment Information
	(a) Reportable Segments
	The Company manages its business in two segments: PBM and HCIT. The Company evaluates segment performance and allocates resources based upon revenue and gross profit. Selling, general and administrative expenses, depreciation and amortization, interest and other income and interest expense are reported as corporate expenses as these are managed on a consolidated basis by the Company. The Merger with Catalyst or the acquisition of Restat did not change the Company's conclusion on its reporting segments.
	PBM Segment
	The Company provides comprehensive PBM services to customers, which include managed care organizations, local governments, unions, corporations, HMOs, employers, workers’ compensation plans, third-party health care plan administrators, and federal and state government programs through its network of licensed pharmacies throughout the United States. The PBM services include electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail and specialty pharmacy claims management, Medicare Part D services, benefit design consultation, preferred drug management programs, drug review and analysis, consulting services, data access and reporting and information analysis.
	Revenue primarily consists of sales of prescription drugs, together with any associated administrative fees, to customers and participants, through the Company’s nationwide network of participating pharmacies and the Company's own mail and specialty pharmacies. Revenue and costs related to the sales of prescription drugs are recognized when the claims are adjudicated and the prescription drugs are shipped. Claims are adjudicated at the point-of-sale using an on-line processing system. Revenue and cost primarily consists of sales of prescription drugs to customers and participants.
	HCIT Segment
	The Company also provides HCIT solutions and services to providers, payors and other participants in the pharmaceutical supply chain in North America. The Company’s product offerings include a wide range of software products for managing prescription drug programs and for drug prescribing and dispensing. The Company’s solutions are available on a license basis with on-going maintenance and support or on a transaction fee basis using an ASP model. The Company’s payor customers include managed care organizations, Blue Cross Blue Shield organizations, government agencies, employers and intermediaries such as pharmacy benefit managers. The Company’s provider customers include independent, regional chain, institutional, and mail-order pharmacies. The solutions offered by the Company’s services assist both payors and providers in managing the complexity and reducing the cost of their prescription drug programs and dispensing activities. The Company’s profitability from HCIT depends primarily on revenue derived from transaction processing services, software license sales, hardware sales, maintenance, and professional services.
	Financial information by segment (in thousands):
	Year Ended December 31, 2014	PBM		HCIT		Corporate		Total
	Revenue	$	21,429,983	$	151,907	$	—	$	21,581,890
	Cost of revenue	20,155,768		66,069		—		20,221,837
	Gross profit	1,274,215		85,838		—		1,360,053
	Corporate expenses	—		—		852,145		852,145
	Income before income taxes	—		—		—		507,908
	Income tax expense	—		—		—		134,186
	Net income	—		—		—		373,722
	Less net income attributable to non-controlling interest	—		—		—		56,429
	Net income attributable to the Company	—		—		—		317,293
	Goodwill	4,704,974		19,665		—		4,724,639
	Total assets	$	9,103,603	$	220,582	$	—	$	9,324,185
	Year Ended December 31, 2013	PBM		HCIT		Corporate		Total
	Revenue	$	14,632,104	$	147,990	$	—	$	14,780,094
	Cost of revenue	13,583,941		70,508		—		13,654,449
	Gross profit	1,048,163		77,482		—		1,125,645
	Corporate expenses	—		—		723,503		723,503
	Income before income taxes	—		—		—		402,142
	Income tax expense	—		—		—		103,403
	Net income	—		—		—		298,739
	Less net income attributable to non-controlling interest	—		—		—		36,569
	Net income attributable to the Company	—		—		—		262,170
	Goodwill	4,700,610		19,665		—		4,720,275
	Total assets	$	7,634,033	$	361,730	$	—	$	7,995,763
	Year Ended December 31, 2012	PBM		HCIT		Corporate		Total
	Revenue	$	9,785,084	$	155,036	$	—	$	9,940,120
	Cost of revenue	9,141,029		65,715		—		9,206,744
	Gross profit	644,055		89,321		—		733,376
	Corporate expenses	—		—		543,039		543,039
	Income before income taxes	—		—		—		190,337
	Income tax expense	—		—		—		69,316
	Net income	—		—		—		121,021
	Less net income attributable to non-controlling interest	—		—		—		4,363
	Net income attributable to the Company	—		—		—		116,658
	Goodwill	4,458,373		19,665		—		4,478,038
	Total assets	$	7,159,098	$	226,029			$	7,385,127
	(b) Geographic Information
	Revenues of the Company are primarily earned in the United States. The Company’s Canadian operations represented less than 0.2% of the Company’s consolidated revenue for the years ended December 31, 2014, 2013 and 2012.
	(c) Major Customers
	During the year ended December 31, 2014, one customer accounted for 34% of total revenue. During the year ended December 31, 2013, one customer accounted for 23% of total revenue. During the year ended December 31, 2012, one customer accounted for 31% of total revenue. In 2014, 2013 and 2012, this major customer was included in the PBM segment.
	At December 31, 2014, one customer accounted for 17% of the total accounts receivable balance. At December 31, 2013, one customer accounted for 15% of the total accounts receivable balance.

Financial_Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial Instruments
	(a)	Credit risk:
	The Company is subject to concentrations of credit risk through cash and cash equivalents and accounts receivable. The Company monitors the credit risk and credit standing of counterparties on a regular basis.
	(b)	Interest rate risk:
	To manage credit risks, the Company selects counterparties based on credit assessments, limits overall exposure to any single counterparty, and monitors the market position with each counterparty. The Company assesses interest rate cash flow risk by continually identifying and monitoring changes in interest rate exposures that may adversely impact expected future cash flows and by evaluating hedging opportunities.
	The Company used variable rate debt to assist in financing its Merger with Catalyst and acquisition of Restat. The Company is subject to interest rate risk related to the variable rate debt. When interest rates increase, interest expense could increase. Conversely, when interest rates decrease, interest expense could also decrease.
	In order to manage fluctuations in cash flows resulting from interest rate risk attributable to changes in the benchmark interest rates, the Company entered into 3-year interest rate swap agreements with a total notional amount of $500 million to fix the variable LIBOR rate on the Company's term loan to 0.52%, resulting in an effective rate of 2.14% after adding the 1.63% margin per the Credit Agreement. Under the interest rate swap, the Company receives LIBOR-based variable interest rate payments and makes fixed interest rate payments, thereby creating the equivalent to fixed-rate debt with respect to the notional amount of such swap agreements. The interest rate contract derivative instrument was designated as a cash flow hedge upon its inception in August 2012 and it expires in August 2015. Hedge effectiveness is assessed by the Company on a quarterly basis. Based on the Company's assessment as of December 31, 2014, the Company concluded that the hedge is highly effective and thus hedge accounting is appropriate.
	The Company assesses interest rate cash flow risk by continually identifying and monitoring changes in interest rate exposures that may adversely impact expected future cash flows and by evaluating hedging opportunities. The Company does not enter into derivative instruments for any purpose other than hedging identified exposures. That is, the Company does not speculate using derivative instruments and has not designated any instruments as fair value hedges or hedges of the foreign currency exposure of a net investment in foreign operations.
	(c)	Fair value:
	The fair value of the interest rate swap liability as of December 31, 2014 was $1.1 million, and is included in other long-term liabilities on the consolidated balance sheet. Interest expense for the year ended December 31, 2014 includes $1.7 million of interest expense reclassified from other comprehensive income into current earnings. As of December 31, 2014, approximately $1.1 million of deferred expenses related to the derivative instruments accumulated in other comprehensive income is expected to be reclassified as interest expense during the next twelve months. This expectation is based on the expected timing of the occurrence of the hedged forecasted transactions.
	The estimated fair value of the Company’s financial instruments has been determined based on the Company’s assessment of available market information and appropriate valuation methodologies. However, these estimates may not necessarily be indicative of the amounts that the Company could realize in a current market exchange. See Note 19 for the Company’s disclosure on the fair value of derivative instruments.
	(d)	Foreign exchange risk:
	The Company is subject to foreign exchange risk related to its operations in Canada. The Company does not enter into derivative instruments to mitigate this risk. Exposure to fluctuations in Canadian-dollar denominated transactions is partially offset by Canadian dollar-denominated assets and liabilities.

Fair_Value

Fair Value	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value	Fair Value
	Fair value measurement guidance defines a hierarchy to prioritize the inputs to valuation techniques used to measure fair value into three broad levels, with Level 1 considered the most reliable. For assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheet, the table below categorizes fair value measurements across the three levels as of December 31, 2014 (in thousands):
	Year Ended December 31, 2014	Quoted Prices in Active Markets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
	Liabilities:
	Derivative	$	—	$	1,096	$	—	$	1,096
	Year Ended December 31, 2013	Quoted Prices in Active Markets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
	Liabilities
	Contingent purchase price consideration	$	—	$	—	$	19,954	$	19,954
	Derivatives	$	—	$	1,719	$	—	$	1,719
	Contingent purchase price consideration
	The contingent purchase price consideration liability as of December 31, 2013 reflects the fair values of potential future payments related to the acquisition of Walgreens Health Initiatives (acquired by Catalyst in 2011). The potential future payments were contingent upon the acquired entity meeting or exceeding certain revenue, gross profit or client retention targets. The contingent consideration criteria was met and during 2014 this liability was settled. Accordingly, there is no outstanding balance as of December 31, 2014. There was no impact on the consolidated statement of operations as a result of this settlement.
	As the fair value measurement for the contingent consideration was based on inputs not observed in the market, these measurements are classified as Level 3 measurements as defined by fair value measurements guidance.
	Derivatives
	Derivative liabilities relate to the interest rate swap (refer to Note 18 — Financial Instruments for further information), which had a fair value of $1.1 million as of December 31, 2014. As the fair value measurement for the derivative instrument is based on quoted prices from a financial institution, the measurement is classified as Level 2 measurement as defined by fair value measurements guidance.
	During 2014 and 2013, there were no movements of fair value measurements between levels 1, 2 and 3.

Supplemental_Information

Supplemental Information	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Supplemental Information	Supplemental Information
		Beginning Balance		Charged to Expense		Adjustments			Ending Balance
		(In thousands)
	Allowance for doubtful accounts
	Year Ended December 31, 2014	$	5,860	$	2,259	$	(3,252	)	$	4,867
	Year Ended December 31, 2013	$	7,899	$	1,187	$	(3,226	)	$	5,860
	Year Ended December 31, 2012	$	2,725	$	3,328	$	1,846		$	7,899
		Beginning Balance		Charged to Expense		Adjustments			Ending Balance
		(In thousands)
	Valuation allowance for deferred tax assets
	Year Ended December 31, 2014	$	18,361	$	12,671	$	(1,313	)	$	29,719
	Year Ended December 31, 2013	$	5,797	$	8,596	$	3,968		$	18,361
	Year Ended December 31, 2012	$	3,603	$	2,194	$	—		$	5,797

Condensed_Consolidating_Financ

Condensed Consolidating Financial Statements	12 Months Ended
	Dec. 31, 2014
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Condensed Consolidating Financial Information	Condensed Consolidating Financial Information
	The Senior Notes issued by the Company are fully and unconditionally (subject to certain customary release provisions), guaranteed by certain of our wholly-owned subsidiaries.
	The following condensed consolidating financial information has been prepared in accordance with the requirements for presentation of such information (statements of comprehensive income were omitted as all other comprehensive income is attributed to the issuer and was not material in any period presented). The condensed consolidating financial information presented below is not indicative of what the financial position, results of operations or cash flows would have been had each of the entities operated as an independent company during the period for various reasons, including, but not limited to, intercompany transactions and integration of systems.
	The condensed consolidating financial information is presented separately for:
	i.	Catamaran Corporation (the parent company), the issuer of the Senior Notes;
	ii.	Guarantor subsidiaries, on a combined basis
	iii.	Non-guarantor subsidiaries, on a combined basis;
	iv.	Consolidating entries and eliminations representing adjustments to (a) eliminate intercompany transactions between or among Catamaran Corporation, the guarantor subsidiaries and the non-guarantor subsidiaries, (b) eliminate the investments in our subsidiaries and (c) record consolidating entries; and
	v.	Catamaran Corporation and subsidiaries on a consolidated basis.
	CATAMARAN CORPORATION
	Condensed Consolidated Balance Sheets
	(in thousands)
		Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
	As of December 31, 2014
	ASSETS
	Current assets
	Cash and cash equivalents	$	333,469		$	648,903		$	29,580		$	—		$	1,011,952
	Accounts receivable, net	304			1,217,675			166,937			(130,580		)	1,254,336
	Rebates receivable	10,710			851,929			155,719			(154,534		)	863,824
	Other current assets	99			166,858			52,478			—			219,435
	Intercompany receivable	—			675,551			—			(675,551		)	—
	Total current assets	344,582			3,560,916			404,714			(960,665		)	3,349,547
	Property and equipment, net	110			154,413			55,504			—			210,027
	Goodwill	—			4,689,522			35,117			—			4,724,639
	Other intangible assets, net	—			963,096			5,103			—			968,199
	Investment in subsidiaries	6,375,214			266,096			71			(6,641,381		)	—
	Other long-term assets	13,874			42,876			22,084			(7,061		)	71,773
	Total assets	$	6,733,780		$	9,676,919		$	522,593		$	(7,609,107	)	$	9,324,185
	LIABILITIES AND EQUITY
	Current liabilities
	Accounts payable	$	4		$	1,079,598		$	3,150		$	(114,961	)	$	967,791
	Accrued expenses and other current liabilities	10,580			304,309			18,846			(6,545		)	327,190
	Rebates payable	—			967,733			42,932			(42,932		)	967,733
	Current portion - long-term debt	81,250			—			—			—			81,250
	Intercompany payable	23,898			—			626,434			(650,332		)	—
	Total current liabilities	115,732			2,351,640			691,362			(814,770		)	2,343,964
	Deferred income taxes	—			255,777			1,548			—			257,325
	Long-term debt	1,344,973			—			—			—			1,344,973
	Other long-term liabilities	1,096			71,475			26,245			—			98,816
	Total liabilities	1,461,801			2,678,892			719,155			(814,770		)	4,045,078
	Commitments and contingencies (Note 16)
	Shareholders’ equity
	Total shareholders' equity	5,271,979			6,998,027			(197,807		)	(6,800,220		)	5,271,979
	Non-controlling interest	—			—			1,245			5,883			7,128
	Total equity	5,271,979			6,998,027			(196,562		)	(6,794,337		)	5,279,107
	Total liabilities and equity	$	6,733,780		$	9,676,919		$	522,593		$	(7,609,107	)	$	9,324,185
	CATAMARAN CORPORATION
	Condensed Consolidated Balance Sheets
	(in thousands)
		Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
	As of December 31, 2013
	ASSETS
	Current assets
	Cash and cash equivalents	$	15,090		$	362,647		$	9,504		$	—		$	387,241
	Accounts receivable, net	294			889,267			120,869			(50,844		)	959,586
	Rebates receivable	35,776			270,179			80,030			(80,030		)	305,955
	Other current assets	107			149,233			35,553			—			184,893
	Intercompany receivable	—			—			130,377			(130,377		)	—
	Total current assets	51,267			1,671,326			376,333			(261,251		)	1,837,675
	Property and equipment, net	69			172,090			24,848			—			197,007
	Goodwill	—			4,685,158			35,117			—			4,720,275
	Other intangible assets, net	—			1,173,347			8,072			—			1,181,419
	Intercompany loans receivable	—			175,000			—			(175,000		)	—
	Investment in subsidiaries	6,137,281			202,292			71			(6,339,644		)	—
Other long-term assets	15,675			24,117			21,818			(2,223		)	59,387
Total assets	$	6,204,292		$	8,103,330		$	466,259		$	(6,778,118	)	$	7,995,763
LIABILITIES AND EQUITY
Current liabilities
Accounts payable	$	—		$	851,260		$	8,315		$	(41,770	)	$	817,805
Accrued expenses and other current liabilities	3,047			228,801			22,252			—			254,100
Rebates payable	—			356,266			31,332			(31,333		)	356,265
Current portion - long-term debt	50,000			—			—			—			50,000
Intercompany payable	25,673			3,885			—			(29,558		)	—
Total current liabilities	78,720			1,440,212			61,899			(102,661		)	1,478,170
Deferred income taxes	—			299,794			1,547			—			301,341
Long-term debt	1,215,363			—			—			—			1,215,363
Intercompany loans payable	—			—			175,000			(175,000		)	—
Other long-term liabilities	1,719			65,812			21,860			—			89,391
Total liabilities	1,295,802			1,805,818			260,306			(277,661		)	3,084,265
Commitments and contingencies (Note 16)
Shareholders’ equity
Total shareholders' equity	4,908,490			6,297,512			204,707			(6,502,219		)	4,908,490
Non-controlling interest	—			—			1,246			1,762			3,008
Total equity	4,908,490			6,297,512			205,953			(6,500,457		)	4,911,498
Total liabilities and equity	$	6,204,292		$	8,103,330		$	466,259		$	(6,778,118	)	$	7,995,763
CATAMARAN CORPORATION
Condensed Consolidated Statements of Operations
(in thousands)
	Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
For the year ended December 31, 2014
Revenue	$	40,141		$	20,849,801		$	3,028,412		$	(2,336,464	)	$	21,581,890
Cost of revenue	33,917			19,764,270			2,760,114			(2,336,464		)	20,221,837
Gross profit	6,224			1,085,531			268,298			—			1,360,053
Expenses:
Selling, general and administrative	2,931			418,400			97,020			—			518,351
Depreciation of property and equipment	30			53,932			5,524			—			59,486
Amortization of intangible assets	—			210,251			2,969			—			213,220
Total Expenses	2,961			682,583			105,513			—			791,057
Operating income	3,263			402,948			162,785			—			568,996
Interest and other expense, net	51,904			3,007			6,177			—			61,088
Equity in (income) of subsidiaries	(365,934		)	(58,804		)	—			424,738			—
Income before income taxes	317,293			458,745			156,608			(424,738		)	507,908
Income tax expense	—			92,811			41,375			—			134,186
Net income	317,293			365,934			115,233			(424,738		)	373,722
Less net income attributable to non-controlling interest	—			—			—			56,429			56,429
Net income attributable to the Company	$	317,293		$	365,934		$	115,233		$	(481,167	)	$	317,293
CATAMARAN CORPORATION
Condensed Consolidated Statements of Operations
(in thousands)
	Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
For the year ended December 31, 2013
Revenue	$	34,875		$	13,682,194		$	1,750,509		$	(687,484	)	$	14,780,094
Cost of revenue	30,217			12,756,828			1,554,888			(687,484		)	13,654,449
Gross profit	4,658			925,366			195,621			—			1,125,645
Expenses:
Selling, general and administrative	1,094			374,435			65,230			—			440,759
Depreciation of property and equipment	29			35,005			2,892			—			37,926
Amortization of intangible assets	—			200,065			3,127			—			203,192
Total Expenses	1,123			609,505			71,249			—			681,877
Operating income	3,535			315,861			124,372			—			443,768
Interest and other (income) expense, net	36,700			(344		)	5,270			—			41,626
Equity in (income) of subsidiaries	(295,335		)	(51,924		)	—			347,259			—
Income before income taxes	262,170			368,129			119,102			(347,259		)	402,142
Income tax expense	—			72,794			30,609			—			103,403
Net income	262,170			295,335			88,493			(347,259		)	298,739
Less net income attributable to non-controlling interest	—			—			—			36,569			36,569
Net income attributable to the Company	$	262,170		$	295,335		$	88,493		$	(383,828	)	$	262,170
CATAMARAN CORPORATION
Condensed Consolidated Statements of Operations
(in thousands)
	Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
For the year ended December 31, 2012
Revenue	$	15,343		$	9,578,406		$	911,107		$	(564,736	)	$	9,940,120
Cost of revenue	12,306			8,926,325			832,849			(564,736		)	9,206,744
Gross profit	3,037			652,081			78,258			—			733,376
Expenses:
Selling, general and administrative	4,688			322,843			41,961			—			369,492
Depreciation of property and equipment	50			14,784			1,915			—			16,749
Amortization of intangible assets	—			126,847			3,269			—			130,116
Total Expenses	4,738			464,474			47,145			—			516,357
Operating income	(1,701		)	187,607			31,113			—			217,019
Interest and other expense, net	11,731			13,577			1,374			—			26,682
Equity in (income) of subsidiaries	(130,090		)	(14,551		)	—			144,641			—
Income before income taxes	116,658			188,581			29,739			(144,641		)	190,337
Income tax expense	—			58,491			10,825			—			69,316
Net income	116,658			130,090			18,914			(144,641		)	121,021
Less net income attributable to non-controlling interest	—			—			—			4,363			4,363
Net income attributable to the Company	$	116,658		$	130,090		$	18,914		$	(149,004	)	$	116,658
CATAMARAN CORPORATION
Condensed Consolidated Statements of Cash Flows
(in thousands)
	Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
For the year ended December 31, 2014
Cash flows from operating activities:
Net cash provided (used) by operating activities	$	341,698		$	612,430		$	(6,952	)	$	(356,995	)	$	590,181
Cash flows from investing activities:
Acquisitions, net of cash acquired	—			(2,026		)	—			—			(2,026		)
Purchases of property and equipment	(71		)	(41,664		)	(36,343		)	—			(78,078		)
Proceeds from restricted cash	—			20,006			—			—			20,006
Net cash used in investing activities	(71		)	(23,684		)	(36,343		)	—			(60,098		)
Cash flows from financing activities:
Proceeds from issuance of debt	492,500			—			—			—			492,500
Repayment of long-term debt	(337,500		)	—			—			—			(337,500		)
Payment of financing costs	(1,963		)	—			—			—			(1,963		)
Proceeds from exercise of options	8,011			(2,355		)	(17		)	—			5,639
Tax benefit on option exercises	—			3,455			37			—			3,492
Proceeds from warrants exercised	3,452			—			—			—			3,452
Payments of contingent consideration	—			(18,338		)	—			—			(18,338		)
Distributions to non-controlling interest	—			—			—			(52,309		)	(52,309		)
Net transactions with parent and affiliates	(208,486		)	(264,620		)	63,802			409,304			—
Proceeds from restricted stock	20,700			(20,249		)	(451		)	—			—
Other	—			(383		)	—			—			(383		)
Net cash provided (used) by financing activities	(23,286		)	(302,490		)	63,371			356,995			94,590
Effect of foreign exchange on cash balances	38			—			—			—			38
Change in cash and cash equivalents	318,379			286,256			20,076			—			624,711
Cash and cash equivalents, beginning of period	15,090			362,647			9,504			—			387,241
Cash and cash equivalents, end of period	$	333,469		$	648,903		$	29,580		$	—		$	1,011,952
CATAMARAN CORPORATION
Condensed Consolidated Statements of Cash Flows
(in thousands)
	Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
For the year ended December 31, 2013
Cash flows from operating activities:
Net cash provided (used) by operating activities	$	186,985		$	616,168		$	(30,476	)	$	(297,256	)	$	475,421
Cash flows from investing activities:
Acquisitions, net of cash acquired	—			(388,866		)	—			—			(388,866		)
Purchases of property and equipment	(11		)	(117,799		)	(11,032		)	—			(128,842		)
Proceeds from restricted cash	—			20,004			—			—			20,004
Net cash used by investing activities	(11		)	(486,661		)	(11,032		)	—			(497,704		)
Cash flows from financing activities:
Proceeds from issuance of debt	450,000			—			—			—			450,000
Repayment of long-term debt	(362,500		)	—			—			—			(362,500		)
Payment of financing costs	(2,347		)	—			—			—			(2,347		)
Proceeds from exercise of options and warrants	4,729			(1,248		)	(2		)	—			3,479
Tax benefit on option exercises	—			9,704			28			—			9,732
Payments of contingent consideration	—			(18,338		)	(4,865		)	—			(23,203		)
Distributions to non-controlling interest	—			—			—			(36,314		)	(36,314		)
Net transactions with parent and affiliates	(322,377		)	(49,103		)	37,910			333,570			—
Proceeds from restricted stock	27,107			(26,645		)	(462		)	—			—
Other	—			—			—			—			—
Net cash (used) provided by financing activities	(205,388		)	(85,630		)	32,609			297,256			38,847
Effect of foreign exchange on cash balances	(99		)	—			—			—			(99		)
Change in cash and cash equivalents	(18,513		)	43,877			(8,899		)	—			16,465
Cash and cash equivalents, beginning of period	33,603			318,770			18,403			—			370,776
Cash and cash equivalents, end of period	$	15,090		$	362,647		$	9,504		$	—		$	387,241
CATAMARAN CORPORATION
Condensed Consolidated Statements of Cash Flows
(in thousands)
	Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
For the year ended December 31, 2012
Cash flows from operating activities:
Net cash provided (used) by operating activities	$	(27,257	)	$	430,091		$	(18,449	)	$	(134,652	)	$	249,733
Cash flows from investing activities:
Acquisitions, net of cash acquired	3,644,364			(5,210,069		)	—			—			(1,565,705		)
Purchases of property and equipment	(66		)	(30,549		)	(9,621		)				(40,236		)
Net cash provided by (used in) investing activities	3,644,298			(5,240,618		)	(9,621		)	—			(1,605,941		)
Cash flows from financing activities:
Proceeds from issuance of debt	1,475,448			—			—			—			1,475,448
Repayment of long-term debt	(616,993		)	—			—			—			(616,993		)
Proceeds from public offering, net of issuance costs	519,075			—			—			—			519,075
Payment of financing costs	(18,806		)	—			—			—			(18,806		)
Proceeds from exercise of options	11,016			(3,253		)	—			—			7,763
Tax benefit on option exercises	—			19,206			191			—			19,397
Net transactions with parent and affiliates	(5,093,214		)	4,913,963			44,599			134,652			—
Proceeds from restricted stock	17,903			(17,651		)	(252		)	—			—
Other	(268		)	—			—			—			(268		)
Net cash (used) provided by financing activities	(3,705,839		)	4,912,265			44,538			134,652			1,385,616
Effect of foreign exchange on cash balances	(14		)	—			—			—			(14		)
Change in cash and cash equivalents	(88,812		)	101,738			16,468			—			29,394
Cash and cash equivalents, beginning of period	122,415			217,032			1,935			—			341,382
Cash and cash equivalents, end of period	$	33,603		$	318,770		$	18,403		$	—		$	370,776

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation:
	The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and include its wholly-owned subsidiaries as well as non-controlled entities. Amounts in the consolidated financial statements are expressed in U.S. dollars, except where otherwise indicated. Within the financial statements and tables presented, the totals of certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages presented are calculated from the underlying whole-dollar amounts. Certain reclassifications have been made to conform the prior years’ consolidated financial statements to the current year’s presentation.
Principles of consolidation	Principles of Consolidation:
	The consolidated financial statements include the accounts of the Company and its controlled subsidiaries, which are generally wholly owned. All significant inter-company transactions and balances have been eliminated in consolidation. Any non-controlling interest in the equity of a subsidiary is reported in equity in the Consolidated Statements of Shareholders' Equity. Net income attributable to the non-controlling interest is subtracted from Net Income to arrive at Net Income Attributable to the Company in the Consolidated Statements of Operations.
Use of estimates	Use of estimates:
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant items subject to such estimates and assumptions include revenue recognition, purchase price allocation and contingent consideration in connection with acquisitions, valuation of property and equipment, valuation of intangible assets acquired and related amortization periods, impairment of goodwill, contingencies, valuation allowances for receivables and income taxes. Actual results could differ from those estimates.
Revenue recognition	Revenue recognition:
	The Company's revenue is primarily derived from prescription drug sales. The Company has a small portion of its revenue that is derived from transaction processing and other services related to its HCIT products.
	The Company recognizes revenue when all of the following conditions are satisfied: (i) there is persuasive evidence of an arrangement; (ii) the service or product has been provided to the customer and no uncertainties exist surrounding product acceptance; (iii) the amount of fees to be paid by the customer is fixed or determinable; and (iv) the collection of fees is reasonably assured.
	When the Company enters into arrangements with multiple deliverables, exclusive of arrangements with software deliverables, it applies the Financial Accounting Standards Board's guidance for revenue arrangements with multiple deliverables and evaluates each deliverable to determine whether it represents a separate unit of accounting based on the following criteria: (i) whether the delivered item has value to the customer on a stand-alone basis, and (ii) if the contract includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Revenue is allocated to each unit of accounting or element based on relative selling prices. The Company determines relative selling prices by using either (i) vendor specific objective evidence (“VSOE”) if it exists; or (ii) third-party evidence of selling price ("TPE"). When neither VSOE nor TPE of selling price exists for a deliverable, the Company uses its best estimate of the selling price for that deliverable.
	After determining which deliverables represent a separate unit of accounting, each unit is then accounted for under the applicable revenue recognition guidance. In cases where elements cannot be treated as separate units of accounting, the elements are combined into a single unit of accounting for revenue recognition purposes.
	When the Company enters into arrangements with multiple deliverables involving software, the Company applies the accounting guidance for software. The entire arrangement fee is allocated to each element in the arrangement based on the respective VSOE of fair value of each element.
	When an arrangement includes software and non-software deliverables, the Company allocates the arrangement consideration to the non-software deliverables, and to the software deliverables as a group, based on the relative selling prices of all deliverables in the arrangement. When a tangible product contains software that is not essential to the product’s functionality, that nonessential software and any other deliverables within the arrangement that relate to that nonessential software are accounted for under accounting guidance for software. The non-software deliverables sold by the Company typically do not include software deliverables that are considered essential to the functionality of a tangible product.
	Revenue is recognized for specific types of transactions as follows:
	PBM revenue:  The Company’s PBM revenue is primarily derived from sales of prescription drugs, together with any associated administrative fees, to customers and participants through the Company’s nationwide network of pharmacies. Revenue related to the sales of prescription drugs by the Company’s nationwide network of pharmacies is recognized when the claims are adjudicated. Claims are adjudicated at the point-of-sale using the Company’s on-line processing system. The Company records an offsetting reduction to revenue for any rebates earned from pharmaceutical manufacturers and third-party administrators that are payable to the Company’s customers.
	For transactions at the Company's participating pharmacies, under the terms of the customer contracts, the pharmacy is solely obligated to collect the co-payments from the participants. The Company does not assume liability for participant co-payments in non-Company owned pharmacy transactions, and therefore does not include participant co-payments in revenue or cost of revenue. If these amounts were included in the Company’s operating results, its operating income and net income would not have been affected.
	The Company evaluates customer contracts to determine whether the Company acts as a principal or as an agent in the fulfillment of prescriptions through its participating pharmacy network. The Company acts as a principal in certain of its transactions with customers and, in these cases, revenues are recognized at the prescription price (ingredient cost plus dispensing fee) negotiated with customers, plus the Company’s administrative fees (“gross reporting”). Gross reporting is appropriate when the Company (i) has separate contractual relationships with customers and with pharmacies, (ii) is responsible to validate and manage a claim through its claims adjudication process, (iii) commits to set prescription prices for the pharmacy, (iv) manages the overall prescription drug plan relationship with the patients, who are members of customers’ plans, and (v) has credit risk for the amount due from the customer.
	Revenue for the sale of prescription drugs dispensed at the Company's mail and specialty pharmacies, including amounts due from third-party payors and member co-payments, is recorded when the prescription drugs are shipped.
	HCIT revenue: HCIT revenues are generated primarily from transaction processing and related services. The Company recognizes revenue for its HCIT products and services at the time the transaction is processed, or at the time the service is provided. If multiple elements are required to be delivered under a customer contract, the Company follows the guidance described above in relation to multiple elements.
Cost of revenue	Cost of revenue:
	The Company’s cost of revenue includes the cost of pharmaceuticals dispensed, either directly dispensed at its mail and specialty pharmacy locations, or indirectly through its nationwide network of participating pharmacies. Cost of revenue is reduced for rebates earned from pharmaceutical manufacturers and third-party administrators. Cost of revenue also includes the cost of personnel to support the Company’s transaction processing services, system sales, maintenance, and professional services. In addition, the Company includes in cost of revenue an amount of depreciation expense that is related to property and equipment used to provide services to customers.
Cash and cash equivalents	Cash and cash equivalents:
	The Company considers cash on hand, deposits in banks, money market funds, and bank term deposits with original maturities of ninety days or less as cash and cash equivalents. The amounts presented in the consolidated balance sheets approximate fair value of cash and cash equivalents. These assets are deemed Level 1 securities in the fair value hierarchy.
Fair value measurements	Fair value measurements:
	The Company applies the fair value accounting guidance for measuring its financial and non-financial assets and liabilities. Currently, none of the Company’s non-financial assets are required to be carried at fair value. The Company would apply the fair value accounting guidance to non-financial assets and liabilities in the event that a non-financial asset or liability was impaired, or, if non-financial assets and liabilities were purchased in a business acquisition.
	The fair value of contingent consideration is based upon probability-weighted discounted cash flow models, utilizing the Company's expectation of the amounts to be paid in the future to settle the contingent purchase price. The inputs utilized in calculating the fair value of the contingent purchase price liabilities are not observable in the marketplace. The fair value of the Company’s interest rate contracts is based upon observable market-based inputs that reflect the current value of the difference between the fixed rate payments the Company will make to the counter party, and the future variable rate receipts from the counterparty.
	Other assets and liabilities held by the Company deemed as financial instruments and required to be carried at fair value include cash and cash equivalents, accounts receivable, rebates receivable, accounts payable, accrued liabilities (current portion), pharmacy benefit management rebates payable and pharmacy benefit claim payments payable. The estimated fair values of these financial instruments approximate their carrying amounts due to the short-term nature of their maturities.
Inventory	Inventory:
	Inventory consists primarily of prescription drugs held for resale and is carried at the lower of cost or net realizable value. Inventory costs are calculated using the first-in, first-out method and the weighted-average method.
Property and equipment	Property and equipment:
	Property and equipment (“P&E”) are stated at cost less accumulated depreciation. Depreciation is generally calculated over the expected estimated useful lives of the assets. Assets are depreciated in the following manner: 1) Furniture and equipment is depreciated using the straight- line method based on a useful life of five years, 2) Computer equipment and software assets are depreciated using a straight-line method and a useful life of three to five years, and 3) Leasehold improvements are depreciated on a straight-line basis over the shorter of the asset’s life or the lease term.
Accounts receivable and allowance for doubtful accounts	Accounts receivable and allowance for doubtful accounts:
	Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Amounts collected on trade accounts receivable are included in net cash provided by operating activities in the consolidated statements of cash flows. In assessing the valuation of the allowance for doubtful accounts, management reviews the collectability of accounts receivable in aggregate and on an individual account-basis. Individual customer events such as subsequent collections, discussions with management of the debtor companies, or other activities are used by management as factors in concluding whether to increase or decrease the calculated allowance. Any increase or decrease to the allowance is recognized in the statements of operations as bad debt expense within selling, general and administrative expense.
Impairment of long-lived assets	Impairment of long-lived assets:
	Long-lived assets or asset groups held and used, including P&E and purchased intangibles subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances that could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; the accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and a current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its previously estimated useful life. Recoverability is assessed based on the carrying amount of the asset and the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset or asset group. An impairment loss is recognized when the carrying amount is not recoverable and exceeds the fair value of the asset or asset group. The impairment loss is measured as the amount by which the carrying amount of undiscounted cash flows exceeds fair value. During each of the years ended December 31, 2014, 2013 and 2012, no events or circumstances occurred that indicated that the carrying amounts of the long-lived assets may not be recoverable.
	While no asset was deemed impaired during 2012, the Company assessed whether one of its assets was recoverable due to a triggering event. In October 2012, the Company launched its new specialty brand BriovaRx. The Company previously acquired MedfusionRx, a specialty pharmacy, and recorded a trade name intangible asset related to the acquisition. As a result of the re-branding of the specialty business, the Company concluded that a triggering event had occurred that could impair the value of the trade name. While the asset was not deemed impaired, the Company concluded that the useful life of the trade name intangible asset should be reduced since the name would no longer be used by the Company, which was the asset's highest and best use. Before adjusting the useful life of the asset, the Company considered whether the asset had any value as a defensible asset which would extend its useful life. The Company determined that the MedfusionRx trade name had an insignificant value as a defensible asset, and the asset's useful life should be shortened due to the name change of the business.
Goodwill	Goodwill:
	Goodwill is the residual amount that results when the purchase price of an acquired business exceeds the sum of the amounts allocated to the identifiable assets acquired, less liabilities assumed, based on their fair values. Goodwill is allocated to the Company’s reporting unit that is expected to benefit from the business combination as of the date of the business combination. As of December 31, 2014, the amount of goodwill carried at the PBM and HCIT segments was $4.7 billion and $19.7 million, respectively.
	Goodwill is not amortized, but rather, is tested for impairment annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired. The Company completes its goodwill impairment test annually as of October 31. Circumstances that could trigger an interim impairment test include: a significant adverse change in the business climate or legal factors; an adverse action or assessment by a regulator; unanticipated competition; the loss of key personnel; a change in reporting units; the likelihood that a reporting unit or significant portion of a reporting unit will be sold or otherwise disposed of; the results of testing for recoverability of a significant asset group within a reporting unit; and the recognition of a goodwill impairment loss in the financial statements of a subsidiary that is a component of a reporting unit.
	The Company performed its goodwill impairment assessment in 2014 and there was no indication of an impairment to the Company's goodwill balances. In addition, an impairment in the near future is not considered reasonably likely. The Company previously completed impairment tests in 2013 and 2012 and concluded no impairments existed.
	The qualitative assessment performed by the Company considered the current operating results of the Company's reporting units, future expectations of each reporting unit, industry and competitor performance and other recent events that may impact each reporting unit. The Company then assessed whether, in light of the evidence gathered, it was more likely than not that a reporting unit's fair value was less than its carrying amount. As noted above, the Company concluded that it was not more likely than not that a reporting unit's fair value was less than its carrying value. If in the future the Company's qualitative assessment indicates that a reporting unit's fair value may be below its carrying value, the Company would prepare a quantitative test to determine whether an impairment existed, and the amount of such impairment.
	The quantitative impairment test is carried out in two steps for each of the Company's reporting units. In the first step, the carrying amount of the reporting unit is compared with its fair value. When the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not to be impaired and the second step of the impairment test is unnecessary. The second step is carried out when the carrying amount of a reporting unit exceeds its fair value, in which case the implied fair value of the reporting unit’s goodwill is compared with its carrying amount to measure the amount of the impairment loss, if any. The implied fair value of goodwill is determined in the same manner as the value of goodwill is determined in a business combination using the fair value of the reporting unit as if it was the purchase price. When the carrying amount of reporting unit goodwill exceeds the implied fair value of the goodwill, an impairment loss is recognized in an amount equal to the excess and is presented as a separate line item in the consolidated statements of operations.
Intangible assets	Intangible assets:
	The cost of a group of intangible assets acquired in a transaction, including those acquired in a business combination that meet the specified criteria for recognition apart from goodwill, is recorded to the individual assets acquired based on their fair values. Intangible assets acquired individually or as part of a group of other assets are initially recognized and measured at cost.
	Intangible assets with finite useful lives are amortized over their estimated useful lives on either a straight-line basis or in proportion to the economic benefits expected to be consumed. Customer relationships acquired with the acquisitions are amortized based on projected cash flows associated with existing customers at the acquisition date and typically have a life of three to ten years. The Company's remaining intangible assets are amortized on a straight-line basis over one to fifteen years.
Rebates	Rebates:
	The Company administers a rebate program through which it receives rebates and administrative fees from pharmaceutical manufacturers and third-party administrators that are shared with a majority of the Company’s customers. The rebates earned for the administration of the program are recorded as a reduction of cost of revenue and the portion of the rebate payable to customers, if applicable, is treated as a reduction of revenue. Rebates receivable include billed and unbilled PBM receivables from pharmaceutical manufacturers and third-party administrators. The Company records the gross rebate receivable and the related payable to the customers based on estimates, which are subject to final settlement due to the required validation of claims data submitted to the pharmaceutical manufacturers and third-party administrators, as well as contingent items contained in the total calculation for rebates earned. The estimates are based upon claims submitted and the Company’s rebate contracts, and are adjusted as additional information becomes available. Upon billing the pharmaceutical manufacturer or third-party administrator, any difference between the Company’s estimate and the actual amount of the rebate receivable is recorded to cost of revenue, net of the estimated impact to the Company’s customers. The Company generally pays rebates to its customers on a quarterly basis, or as agreed upon with its customers. There are certain instances where the Company pays rebates to its customers on a more accelerated basis.
Stock-based compensation	Stock-based compensation:
	For stock-based awards issued to employees and directors, compensation cost related to those awards is measured based on the fair value of the awards on the date of the grant. For stock options, the fair value is determined by using the Black-Scholes-Merton option-pricing model. The compensation cost of the awards expected to vest is recognized on a straight-line basis over the service period as compensation expense and additional paid-in capital. In addition, the Company estimates forfeitures as part of the initial measure of the grant date fair value of the award.
	The cumulative compensation cost is treated as a temporary difference for stock-based awards that are deductible for tax purposes. If a deduction reported on a tax return exceeds the cumulative compensation cost for those awards, any resulting realized tax benefit that exceeds the previously recognized deferred tax asset for those awards (the excess tax benefit) is recognized as additional paid-in capital. If the amount deductible is less than the cumulative compensation cost recognized for financial reporting purposes, the write-off of a deferred tax asset related to that deficiency, net of the related valuation allowance, if any, is first offset to the extent of any remaining additional paid-in capital from excess tax benefits from previous awards with the remainder recognized in the statement of operations.
Derivatives	Derivatives:
	The Company accounts for derivative instruments pursuant to derivative and hedge accounting guidance. The guidance requires that all derivative instruments are recorded on the balance sheet at their respective fair values. The Company records the change in the fair value of its derivative instruments deemed as cash flow hedges through other comprehensive income in each reporting period.
Foreign currency	Foreign currency:
	The Company’s functional currency and reporting currency is the U.S. dollar. Monetary items denominated in foreign currency are translated to U.S. dollars at exchange rates in effect at the balance sheet date and non-monetary items are translated at rates in effect when the assets were acquired or obligations incurred. Revenue and expenses are translated at rates in effect at the time of the transactions. Foreign exchange gains and losses are included in the consolidated statements of operations as "Interest and other expense, net."
Earnings per share	Earnings per share:
	Basic earnings per share (“EPS”) is computed by dividing net income by the weighted-average number of common shares outstanding for the period. Diluted EPS is computed by dividing net income by the weighted-average number of common shares adjusted for the dilutive effect of outstanding stock-based awards. The dilutive effect is calculated by assuming that the proceeds from the exercise of in-the-money stock options were used to acquire shares of common stock at the average market price for the period.
Income taxes	Income taxes:
	The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the deferred tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment.
	Future tax benefits resulting from historical net operating losses (“NOLs”) and deductible temporary differences are recognized in accordance with tax accounting guidance. In assessing the realizability of the related deferred income tax assets (“DTAs”), management considers whether it is more likely than not that some portion or all of the DTAs will be realized. The ultimate realization of DTAs is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible, in addition to management’s tax planning strategies. Management considers projected future taxable income, uncertainties related to the industry in which the Company operates, tax planning strategies, historical taxable income, and a comparison of actual levels of taxable income with pre-tax book income in making this assessment. Valuation allowances are established for DTAs that are not considered more likely than not to be realized. The amount of this valuation allowance is subject to adjustment by the Company in future periods based upon its assessment of evidence supporting the degree of probability that DTAs will be realized.
	The Company recognizes liabilities for uncertain tax positions, although the Company believes its tax position is supportable, when the Company believes that the tax positions may not be fully sustained upon review by tax authorities. Benefits from uncertain tax positions are recognized in the consolidated financial statements only when it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority having full knowledge of all relevant information. A tax position that meets the more-likely-than-not recognition threshold is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon settlement. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense.
	Non-refundable investment tax credits for Scientific Research and Experimental Development (“SRED”) activities are recorded when the Company has reasonable assurance that the credit will be realized. Management has made a number of estimates and assumptions in determining the expenditures eligible for the investment tax credit claim. It is possible that the allowable amount of the investment tax credit claim could be materially different from the recorded amount upon assessment by the Canada Revenue Agency. Non-refundable investment tax credits are recorded as a reduction of income tax expense on the consolidated statements of operations.
Recent accounting pronouncements	Recent accounting standards implemented are summarized below:
	In July 2013, the FASB issued authoritative guidance containing changes to the presentation of an unrecognized tax benefit when a loss or credit carryforward exists. The new standard requires the netting of unrecognized tax benefits against a deferred tax asset for a loss or other carryforward that would apply in the settlement of the uncertain tax positions. The Company adopted this standard on January 1, 2014; however, the implementation of the standard did not have a significant impact on its financial results or in the presentation and disclosure of its financial statements.
	In February 2013, the FASB issued an update on the reporting of amounts reclassified from accumulated other comprehensive income. An entity is required to present either parenthetically on the face of the financial statements or in the notes, significant amounts reclassified from each component of accumulated other comprehensive income and the income statement line items affected by the reclassification. However, an entity is not required to show the income statement line item affected for certain components that are not required to be reclassified in their entirety to net income, such as amounts amortized into net periodic pension cost. The standard was effective prospectively for public entities for fiscal years, and interim periods within those years, beginning after December 15, 2012. The Company adopted this standard on January 1, 2013; however, the implementation of the amendments did not have a significant impact on its financial results or in the presentation and disclosure of its financial statements.
	No other new accounting standards have been adopted during the year ended December 31, 2014.
	(c) Recent accounting standards issued and not yet adopted are summarized below:
	In August 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The ASU applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. Adoption of the standard is not expected to have a significant impact on the Company's financial results or in the presentation and disclosure of its financial statements.
	In June 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-12, Accounting for Share-Based Payments, when the terms of an award provide that a performance target could be achieved after the requisite service period. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the performance target shall not be reflected in estimating the fair value of the award at the grant date. The amendments in this update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015 for all entities, however earlier adoption is permitted. Adoption of the standard is not expected to have a significant impact on the Company's financial results or in the presentation and disclosure of its financial statements.
	On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
	On April 10, 2014, the FASB issued (ASU) No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, which changes the criteria for determining which disposals can be presented as discontinued operations and modifies related disclosure requirements. The guidance applies prospectively to new disposals and new classifications of disposal groups as held for sale after the effective date. The standard is required to be adopted by the Company in annual periods beginning on or after December 15, 2014, and interim periods within those annual periods. However, all entities may early adopt the guidance for new disposals (or new classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. Adoption of the standard is not expected to have a significant impact on the Company's financial results or in the presentation and disclosure of its financial statements.
	No other new standards have been issued during the year ended December 31, 2014 that the Company assessed to have a significant impact on its financial results or in the presentation and disclosure of its financial statements.

Business_Combinations_Tables

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2014
Restat
Business Acquisition [Line Items]
Schedule of fair values assigned to assets acquired and liabilities assumed at the acquisition date	The following summarizes the fair values assigned to the assets acquired and liabilities assumed at the acquisition date (in thousands):
		Initial Amounts Recognized at Acquisition Date (a)				Measurement Period Adjustments (b)			Final Amounts Recognized at Acquisition Date
	Accounts receivable	$	13,842			$	—		$	13,842
	Rebates receivable	6,635				(254		)	6,381
	Other current assets	383				—			383
	Total current assets	20,860				(254		)	20,606
	Property and equipment	1,263				—			1,263
	Intangible assets	182,720				—			182,720
	Goodwill	223,474				4,364			227,838
	Total assets acquired	428,317				4,110			432,427
	Accounts payable	22,370				—			22,370
	Rebates payable	16,106				—			16,106
	Accrued liabilities	7,231				—			7,231
	Other long-term liabilities	—				2,084			2,084
	Total liabilities assumed	45,707				2,084			47,791
	Net assets acquired	$	382,610			$	2,026		$	384,636
	(a) As previously reported in the Company's Form 10-K for the period ended December 31, 2013.
	(b) These measurement period adjustments were recorded from January 1, 2014 through June 30, 2014 to reflect an additional $2.0 million paid to former Restat owners in connection with post-closing working capital adjustment as well as changes in the estimated fair values of the associated assets acquired and liabilities assumed based on factors existing as of the acquisition date.
Schedule of estimated fair values and useful lives of intangible assets acquired	The estimated fair values and useful lives of intangible assets acquired are as follows (dollars in thousands):
		Fair Value				Useful Life
	Customer relationships - PBM	$	143,200			10 years
	Customer relationships - cash card	35,500				3 years
	Trademarks/Trade names	1,000				1 year
	Non-compete agreements	3,020				5 years
	Total	$	182,720
Unaudited pro forma results of operations	Unaudited pro forma results of operations are as follows (dollars in thousands, except share and per share amounts):
		Year Ended December 31, 2013
	Revenue	$	15,344,028
	Gross profit	$	1,187,714
	Net income	$	270,024
	Earnings per share:
	Basic	$	1.31
	Diluted	$	1.31
	Weighted average shares outstanding:
	Basic	206,013,876
	Diluted	206,719,526
Catalyst
Business Acquisition [Line Items]
Schedule of fair values assigned to assets acquired and liabilities assumed at the acquisition date	The following summarizes the fair values assigned to the assets acquired and liabilities assumed at the acquisition date (in thousands):
		Initial Amounts Recognized at Acquisition Date (a)				2012 Measurement Period Adjustments (b)			2013 Measurement Period Adjustments (c)			Final Amounts Recognized at Acquisition Date
	Cash and cash equivalents	$	93,775			$	(315	)	$	—		$	93,460
	Other current assets	695,888				5,202			2,411			703,501
	Total current assets	789,663				4,887			2,411			796,961
	Goodwill	4,010,235				8,492			16,141			4,034,868
	Customer relationships intangible	1,184,800				—			—			1,184,800
	Other long-term assets	87,174				1,547			8			88,729
	Total assets acquired	6,071,872				14,926			18,560			6,105,358
	Accounts payable	338,819				—			5			338,824
	Pharmacy benefit management rebates payable	176,202				2,935			(1,522		)	177,615
	Accrued expenses and other current liabilities	187,851				1,348			5,473			194,672
	Long-term debt	311,994				—			—			311,994
	Other long-term liabilities	385,375				10,643			14,604			410,622
	Total liabilities assumed	1,400,241				14,926			18,560			1,433,727
	Non-controlling interest	(1,610		)		—			—			(1,610		)
	Net assets acquired	$	4,673,241			$	—		$	—		$	4,673,241
	(a) As previously reported in the Company's Form 10-Q for the period ended September 30, 2012.
	(b) These measurement period adjustments from the acquisition date through December 31, 2012 were recorded to reflect changes in the estimated fair values of the associated assets acquired and liabilities assumed based on factors existing as of the acquisition date.
	(c) These represent measurement period adjustments during 2013 through the end of the measurement period and were recorded to reflect changes in the estimated fair values of the associated assets acquired and liabilities assumed based on factors existing as of the acquisition date.
Schedule of total purchase price	The purchase price of the acquired Catalyst operations was comprised of the following (in thousands):
					Amount
	Cash paid to Catalyst shareholders				$	1,415,276
	Fair value of common shares issued (a)				3,238,141
	Fair value of warrants and stock options issued (b)				19,824
	Total purchase price				$	4,673,241
	(a)	Valued based on the number of outstanding shares issued in the Merger multiplied by the closing market price of Catamaran shares on July 2, 2012.
	(b)	The Black-Scholes option pricing model was used to calculate the fair value of the replacement warrants and stock options issued.
HealthTran
Business Acquisition [Line Items]
Schedule of fair values assigned to assets acquired and liabilities assumed at the acquisition date	The following summarizes the fair values assigned to the assets acquired and liabilities assumed at the acquisition date and related measurement period adjustments (in thousands):
		Initial Amounts Recognized at Acquisition Date (a)				Measurement Period Adjustments (b)			Final Amounts Recognized at Acquisition Date
	Current assets	$	30,654			$	245		$	30,899
	Property and equipment	2,787				—			2,787
	Goodwill	173,642				833			174,475
	Intangible assets	77,130				(2,600		)	74,530
	Total assets acquired	284,213				(1,522		)	282,691
	Current liabilities	36,784				(496		)	36,288
	Total liabilities assumed	36,784				(496		)	36,288
	Net assets acquired	$	247,429			$	(1,026	)	$	246,403
	(a) As previously reported in the Company's Form 10-Q for the period ended March 31, 2012.
	(b) These measurement period adjustments were recorded to reflect an additional $1.0 million paid to the former HealthTran owners for the working capital reconciliation and changes in the estimated fair values of the associated assets acquired and liabilities assumed based on factors existing as of the acquisition date.
Schedule of estimated fair values and useful lives of intangible assets acquired	The estimated fair values and useful lives of intangible assets acquired are as follows (dollars in thousands):
		Fair Value				Useful Life
	Trademarks/Trade names	$	1,750			6 months
	Customer relationships	69,800				4-9 years
	Non-compete agreements	2,600				5 years
	License	380				3 years
	Total	$	74,530

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of net property and equipment	Net property and equipment was made up of the following at December 31, 2014 and 2013 (in thousands):
	December 31, 2014	Cost		Accumulated			Net Book Value
				Depreciation
	Furniture and equipment	$	39,690	$	(13,577	)	$	26,113
	Computer equipment and software	208,628		(107,565		)	101,063
	Leasehold improvements	96,784		(23,078		)	73,706
	Construction in progress	9,145		—			9,145
		$	354,247	$	(144,220	)	$	210,027
	December 31, 2013	Cost		Accumulated			Net Book Value
				Depreciation
	Furniture and equipment	$	30,374	$	(10,815	)	$	19,559
	Computer equipment and software	168,463		(77,880		)	90,583
	Leasehold improvements	91,294		(15,163		)	76,131
	Construction in progress	10,734		—			10,734
		$	300,865	$	(103,858	)	$	197,007

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in carrying amounts of goodwill by reportable segments	The changes in the carrying amounts of goodwill by reportable segment for the years ended December 31, 2014 and 2013 are as follows (in thousands):
		PBM		HCIT		Total
	Balance at December 31, 2012	$	4,458,373	$	19,665	$	4,478,038
	Acquisitions (1)	225,761		—		225,761
	Measurement period adjustments (2)	16,476		—		16,476
	Balance at December 31, 2013	4,700,610		19,665		4,720,275
	Acquisitions (3)	2,026		—		2,026
	Measurement period adjustments (4)	2,338		—		2,338
	Balance at December 31, 2014	$	4,704,974	$	19,665	$	4,724,639
	-1	Initial goodwill recorded in connection with the acquisition of Restat in October 2013 and another insignificant acquisition in 2013.
	-2	Adjustments to the fair value of assets acquired and liabilities assumed for recent acquisitions during the measurement period. The measurement period adjustments were not recast to the 2012 consolidated financial statements as they were not deemed material.
	-3	Represents adjustments to purchase price for the Restat acquisition, including settlement of working capital adjustment.
	-4	Represents adjustments in connection with the post-closing working capital adjustment as well as changes in the estimated fair values of the associated assets acquired and liabilities assumed for Restat acquisition during the measurement period. The measurement period adjustments were not recast to the 2013 consolidated financial statements as they were not deemed material.
Components of intangible assets	Definite-lived intangible assets are amortized over the useful lives of the related assets. The components of intangible assets were as follows (in thousands):
		December 31, 2014						December 31, 2013
		Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
	Customer relationships	$	1,527,722	$	564,623	$	963,099	$	1,528,475	$	355,737	$	1,172,738
	Non-compete agreements	11,920		7,435		4,485		13,430		6,463		6,967
	Other intangible assets	3,060		2,445		615		3,060		1,346		1,714
	Total	$	1,542,702	$	574,503	$	968,199	$	1,544,965	$	363,546	$	1,181,419

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of accrued expenses and other current liabilities	The Company's accrued expenses and other current liabilities are comprised of the following (in thousands):
		December 31,
		2014		2013
	Customer deposits	$	13,619	$	12,148
	Salaries and wages payable	65,481		54,761
	Deferred revenue	31,630		10,053
	Income taxes payable	—		7,456
	Other accrued expenses	216,460		169,682
	Total accrued expenses and other current liabilities	$	327,190	$	254,100

LongTerm_Liabilities_Tables

Long-Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Long-term Liabilities [Abstract]
Components of long-term debt	The following table sets forth the components of long-term debt (in thousands), net of unamortized debt discounts as of December 31, 2014 and December 31, 2013.
		Year Ended December 31,
		2014			2013
	Senior secured term loan facility due June 1, 2018 with an interest rate of 1.81% at December 31, 2014 and 2013	$	932,875		$	965,363
	Senior secured revolving credit facility due June 1, 2018 with an interest rate of 1.81% at December 31, 2014 and 2013	—			300,000
	4.75% Senior Notes due 2021	493,348			—
	Less current maturities	(81,250		)	(50,000		)
	Long-term debt	$	1,344,973		$	1,215,363
Schedule of maturities of principal amounts outstanding under Revolving Facility	Principal amounts outstanding under the Revolving Facility are due and payable in full on June 1, 2018. Principal repayments on the Term Loan Facility will be due as follows (in thousands):
	Year	Amount due
	2015	81,250
	2016	93,750
	2017	118,750
	2018	656,250
	Total	$	950,000

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Schedule of stock options activity
	The following table summarizes activity related to stock options for the year ended
	December 31, 2014:
		Number of Options		Weighted Average Exercise Price
	Outstanding, beginning of period	1,396,144		$	31.6
	Granted	432,586		$	44.72
	Exercised	(298,108	)	$	18.92
	Forfeited	(82,090	)	$	47.54
	Outstanding, end of period	1,448,532		$	37.22
Summary of stock options outstanding by exercise price range	The following table summarizes certain information about the options outstanding at December 31, 2014:
	Range of Exercise Price	Options Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price				Options Exercisable			Weighted Average Exercise Price
	$6.39- $24.92	233,300		2.16		$	14.05			230,038			$	13.88
	$24.93 - $32.45	233,294		3.25		$	25.51			140,764			$	25.57
	$32.46 - $44.15	279,524		4.29		$	35.78			110,540			$	35.25
	$44.16 - $44.90	347,132		6.18		$	44.7			—			$	—
	$44.91 - $56.25	355,282		5.26		$	53.99			86,773			$	54.22
	$6.39 - $56.25	1,448,532		4.47		$	37.22			568,115			$	27.1
Schedule of restricted stock units activity	The following table summarizes the information about RSUs for the year ended December 31, 2014 under the Company's equity incentive plans:
		LTIP Plan						Assumed Plans
		Number of Restricted Stock Units		Weighted Average Grant Date Fair Value Per Unit				Number of Restricted Stock Units			Weighted Average Grant Date Fair Value Per Unit
	Nonvested balance as of the beginning of the period	1,334,694		$	40.14			213,656			$	50.98
	Granted	694,645		$	44.84			247,131			$	44.41
	Vested	(411,817	)	$	30.23			(53,386	)		$	50.38
	Forfeited	(71,832	)	$	44.57			(76,528	)		$	49.06
	Nonvested balance as of the end of the period	1,545,690		$	44.69			330,873			$	46.62
	The table below summarizes the number of time-based and performance-based RSUs that were granted and outstanding under both plans for the year ended December 31, 2014:
		LTIP Plan									Assumed Plans
		Number of Restricted Stock Units									Number of Restricted Stock Units
		Time-Based		Performance - Based			Weighted Average Grant Date Fair Value Per Unit				Time-Based			Performance - Based	Weighted Average Grant Date Fair Value Per Unit
	Granted	302,257		392,388			$	44.84			155,615			91,516	$	44.41
	Outstanding	714,810		830,880			—				243,925			86,948	—
Schedule of allocated stock-based compensation	The Company allocated stock-based compensation costs to the same statement of operations line item as the cash compensation to those employees. Accordingly, the allocation of the compensation costs is as follows for the years ended December 31, 2014, 2013, and 2012 (in thousands):
		2014			2013				2012
	Cost of revenue	$	2,284		$	1,404			$	687
	Selling, general and administrative	31,270			24,158				16,980
	Total stock-based compensation	$	33,554		$	25,562			$	17,667
Schedule of fair value assumptions	The Black-Scholes-Merton option-pricing model was used to estimate the fair value of the options at grant date for the years ended December 31, 2014, 2013, and 2012, based on the following assumptions:
		2014			2013				2012
	Volatility	37.7-39.2%			41.4-45.4%				47.2-49.2%
	Risk-free interest rate	1.54 - 1.73%			0.81-1.74%				0.65-0.83%
	Expected life	4.5 years			4.5 years				4.5 years
	Dividend yield	—			—				—
	Weighted average grant date fair value	$	15.47		$	21.33			$	14.7

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of deferred income tax assets and liabilities	The income tax effects of temporary differences that give rise to significant portions of deferred income tax assets and liabilities are as follows.
		December 31,
		2014				2013
		(In thousands)
	Deferred income tax assets:
	Non-capital loss carryforwards (“NOL”)	$	28,906			$	18,229
	Lease inducements and deferred financing	15,826				12,528
	Reserves and accruals	62,487				45,974
	Stock-based compensation	17,889				12,763
	Other	12,318				9,408
	Total	137,426				98,902
	Less valuation allowance - current	804				875
	Less valuation allowance - long term	28,915				17,486
	Total valuation allowance	29,719				18,361
	Total deferred tax assets	$	107,707			$	80,541
	Deferred tax assets — current	$	58,631			$	44,029
	Deferred tax assets — long term	49,076				36,512
	Total	$	107,707			$	80,541
	Deferred income tax liabilities:
	Property and equipment and intangible assets	$	297,978			$	329,842
	Dividend withholding tax	5,675				5,675
	Other	5,156				3,146
	Total	$	308,809			$	338,663
Schedule of effective income tax rate reconciliation	The differences between the effective tax rate reflected in the provision for income taxes and the U.S. statutory income tax rate are as follows (dollars in thousands):
		Years Ended December 31,
		2014				2013				2012
	Corporate statutory rate	35		%		35		%		35		%
	Income tax expense on income before income taxes	$	177,768			$	140,751			$	66,618
	Tax effect of:
	State and local income taxes, net of federal benefit	13,527				10,726				4,281
	Transaction costs and transaction related expenses	453				938				5,252
	Dividend withholding tax	—				(65		)		13,074
	Impact of foreign tax rates	(3,191		)		(3,693		)		(1,582		)
	Non-controlling interest	(22,452		)		(13,670		)		(1,645		)
	Cross-jurisdictional financing	(48,252		)		(44,659		)		(23,937		)
	Other	3,662				4,479				3,763
	Valuation allowance	12,671				8,596				3,492
		$	134,186			$	103,403			$	69,316
Components of income tax expense (benefit)	The components of the provision for income taxes are as follows (in thousands):
		Years Ended December 31,
		2014				2013				2012
	Current tax expense
	United States	$	192,021			$	146,484			$	94,834
	Foreign	212				1,255				12,407
	Total current tax expense	192,233				147,739				107,241
	Deferred tax expense (benefit)
	United States	(57,889		)		(44,180		)		(38,441		)
	Foreign	(158		)		(156		)		516
	Total deferred tax expense	(58,047		)		(44,336		)		(37,925		)
	Total tax expense	$	134,186			$	103,403			$	69,316
Reconciliation of unrecognized tax benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits, including interest and penalties, for 2014, 2013 and 2012 , respectively are as follows (in millions):
			2014				2013				2012
	Balance at January 1		$	28.9			$	18.8			$	0.6
	Additions for tax positions related to prior years		9				26.5				10.3
	Reductions for tax positions related to prior years		(0.9		)		(13.9		)		—
	Additions based on tax positions related to the current year		3.8				0.4				7.9
	Reductions due to lapse of the applicable statute of limitations		(4.7		)		—				—
	Decrease related to settlements with taxing authorities		(0.7		)		(2.9		)		—
	Balance at December 31		$	35.4			$	28.9			$	18.8

Lease_Exit_Costs_Tables

Lease Exit Costs (Tables)	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Lease Loss Accrual	A roll forward of the lease exit cost accrual is presented below (in thousands):
		Amount
	Liability at 12/31/2013	$	5,774
	Net payments	(819		)
	Change in Present Value	260
	Liability at 12/31/2014	$	5,215

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Schedule of computation of basic and diluted earnings per share	The following table sets forth the computation of basic and diluted EPS for the years ended December 31, 2014, 2013, and 2012 (in thousands, except share and per share data):
		2014			2013			2012
	Numerator:
	Net income available to common shareholders	$	317,293		$	262,170		$	116,658
	Denominator for basic EPS — weighted average common shares outstanding	207,103,603			206,013,876			166,765,682
	Effect of dilutive securities:
	Restricted stock units	402,992			321,587			329,975
	Stock options	245,550			384,063			734,963
	Denominator for diluted EPS	207,752,145			206,719,526			167,830,620
	Earnings per share:
	Basic	$	1.53		$	1.27		$	0.7
	Diluted	$	1.53		$	1.27		$	0.7
Schedule of stock options and RSUs not included in calculation of diluted earnings per share due to their anti-dilutive impact	The following represents the stock options and RSUs that are not included in the calculation of diluted EPS due to their anti-dilutive impact:
		December 31,
		2014		2013			2012
	Anti-dilutive RSUs	746,999		615,608			773,509
	Anti-dilutive stock options	669,144		30,381			288,532
		1,416,143		645,989			1,062,041

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2014
Supplemental Cash Flow Information [Abstract]
Schedule of other cash flow non-cash activities	Other non-cash activities (in thousands):
		Year Ended December 31, 2012
	Equity shares issued as a result of the NMHC acquisition	$	4
	Equity shares issued as a result of the Catalyst Merger	$	3,238,141
Schedule of cash paid (received) for income taxes and interest
	(b) Cash paid / received for income taxes and interest was as follows for the years ended December 31, 2014, 2013, and 2012 (in thousands):
		Years Ended December 31,
		2014		2013		2012
	Income taxes paid	$	201,263	$	158,053	$	22,052
	Interest paid	$	38,880	$	30,322	$	18,711
	Interest received	$	837	$	735	$	473

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum payments for non-cancellable operating lease agreements	Aggregate future minimum payments in respect of non-cancellable operating lease agreements as of December 31, 2014, which extend until 2025, are as follows (in thousands):
		Operating Leases
	2015	$	20,747
	2016	19,529
	2017	19,847
	2018	16,901
	2019	15,752
	After 2019	53,633
		$	146,409

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of financial information by segment	Financial information by segment (in thousands):
	Year Ended December 31, 2014	PBM		HCIT		Corporate		Total
	Revenue	$	21,429,983	$	151,907	$	—	$	21,581,890
	Cost of revenue	20,155,768		66,069		—		20,221,837
	Gross profit	1,274,215		85,838		—		1,360,053
	Corporate expenses	—		—		852,145		852,145
	Income before income taxes	—		—		—		507,908
	Income tax expense	—		—		—		134,186
	Net income	—		—		—		373,722
	Less net income attributable to non-controlling interest	—		—		—		56,429
	Net income attributable to the Company	—		—		—		317,293
	Goodwill	4,704,974		19,665		—		4,724,639
	Total assets	$	9,103,603	$	220,582	$	—	$	9,324,185
	Year Ended December 31, 2013	PBM		HCIT		Corporate		Total
	Revenue	$	14,632,104	$	147,990	$	—	$	14,780,094
	Cost of revenue	13,583,941		70,508		—		13,654,449
	Gross profit	1,048,163		77,482		—		1,125,645
	Corporate expenses	—		—		723,503		723,503
	Income before income taxes	—		—		—		402,142
	Income tax expense	—		—		—		103,403
	Net income	—		—		—		298,739
	Less net income attributable to non-controlling interest	—		—		—		36,569
	Net income attributable to the Company	—		—		—		262,170
	Goodwill	4,700,610		19,665		—		4,720,275
	Total assets	$	7,634,033	$	361,730	$	—	$	7,995,763
	Year Ended December 31, 2012	PBM		HCIT		Corporate		Total
	Revenue	$	9,785,084	$	155,036	$	—	$	9,940,120
	Cost of revenue	9,141,029		65,715		—		9,206,744
	Gross profit	644,055		89,321		—		733,376
	Corporate expenses	—		—		543,039		543,039
	Income before income taxes	—		—		—		190,337
	Income tax expense	—		—		—		69,316
	Net income	—		—		—		121,021
	Less net income attributable to non-controlling interest	—		—		—		4,363
	Net income attributable to the Company	—		—		—		116,658
	Goodwill	4,458,373		19,665		—		4,478,038
	Total assets	$	7,159,098	$	226,029			$	7,385,127

Fair_Value_Tables

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair value measurements on recurring basis	For assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheet, the table below categorizes fair value measurements across the three levels as of December 31, 2014 (in thousands):
	Year Ended December 31, 2014	Quoted Prices in Active Markets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
	Liabilities:
	Derivative	$	—	$	1,096	$	—	$	1,096
	Year Ended December 31, 2013	Quoted Prices in Active Markets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
	Liabilities
	Contingent purchase price consideration	$	—	$	—	$	19,954	$	19,954
	Derivatives	$	—	$	1,719	$	—	$	1,719

Supplemental_Information_Table

Supplemental Information (Tables)	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Schedule of allowance for doubtful accounts and valuation allowance for deferred tax assets
		Beginning Balance		Charged to Expense		Adjustments			Ending Balance
		(In thousands)
	Allowance for doubtful accounts
	Year Ended December 31, 2014	$	5,860	$	2,259	$	(3,252	)	$	4,867
	Year Ended December 31, 2013	$	7,899	$	1,187	$	(3,226	)	$	5,860
	Year Ended December 31, 2012	$	2,725	$	3,328	$	1,846		$	7,899
		Beginning Balance		Charged to Expense		Adjustments			Ending Balance
		(In thousands)
	Valuation allowance for deferred tax assets
	Year Ended December 31, 2014	$	18,361	$	12,671	$	(1,313	)	$	29,719
	Year Ended December 31, 2013	$	5,797	$	8,596	$	3,968		$	18,361
	Year Ended December 31, 2012	$	3,603	$	2,194	$	—		$	5,797

Condensed_Consolidating_Financ1

Condensed Consolidating Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2014
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Summary of condensed balance sheets	CATAMARAN CORPORATION
	Condensed Consolidated Balance Sheets
	(in thousands)
		Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
	As of December 31, 2014
	ASSETS
	Current assets
	Cash and cash equivalents	$	333,469		$	648,903		$	29,580		$	—		$	1,011,952
	Accounts receivable, net	304			1,217,675			166,937			(130,580		)	1,254,336
	Rebates receivable	10,710			851,929			155,719			(154,534		)	863,824
	Other current assets	99			166,858			52,478			—			219,435
	Intercompany receivable	—			675,551			—			(675,551		)	—
	Total current assets	344,582			3,560,916			404,714			(960,665		)	3,349,547
	Property and equipment, net	110			154,413			55,504			—			210,027
	Goodwill	—			4,689,522			35,117			—			4,724,639
	Other intangible assets, net	—			963,096			5,103			—			968,199
	Investment in subsidiaries	6,375,214			266,096			71			(6,641,381		)	—
	Other long-term assets	13,874			42,876			22,084			(7,061		)	71,773
	Total assets	$	6,733,780		$	9,676,919		$	522,593		$	(7,609,107	)	$	9,324,185
	LIABILITIES AND EQUITY
	Current liabilities
	Accounts payable	$	4		$	1,079,598		$	3,150		$	(114,961	)	$	967,791
	Accrued expenses and other current liabilities	10,580			304,309			18,846			(6,545		)	327,190
	Rebates payable	—			967,733			42,932			(42,932		)	967,733
	Current portion - long-term debt	81,250			—			—			—			81,250
	Intercompany payable	23,898			—			626,434			(650,332		)	—
	Total current liabilities	115,732			2,351,640			691,362			(814,770		)	2,343,964
	Deferred income taxes	—			255,777			1,548			—			257,325
	Long-term debt	1,344,973			—			—			—			1,344,973
	Other long-term liabilities	1,096			71,475			26,245			—			98,816
	Total liabilities	1,461,801			2,678,892			719,155			(814,770		)	4,045,078
	Commitments and contingencies (Note 16)
	Shareholders’ equity
	Total shareholders' equity	5,271,979			6,998,027			(197,807		)	(6,800,220		)	5,271,979
	Non-controlling interest	—			—			1,245			5,883			7,128
	Total equity	5,271,979			6,998,027			(196,562		)	(6,794,337		)	5,279,107
	Total liabilities and equity	$	6,733,780		$	9,676,919		$	522,593		$	(7,609,107	)	$	9,324,185
	CATAMARAN CORPORATION
	Condensed Consolidated Balance Sheets
	(in thousands)
		Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
	As of December 31, 2013
	ASSETS
	Current assets
	Cash and cash equivalents	$	15,090		$	362,647		$	9,504		$	—		$	387,241
	Accounts receivable, net	294			889,267			120,869			(50,844		)	959,586
	Rebates receivable	35,776			270,179			80,030			(80,030		)	305,955
	Other current assets	107			149,233			35,553			—			184,893
	Intercompany receivable	—			—			130,377			(130,377		)	—
	Total current assets	51,267			1,671,326			376,333			(261,251		)	1,837,675
	Property and equipment, net	69			172,090			24,848			—			197,007
	Goodwill	—			4,685,158			35,117			—			4,720,275
	Other intangible assets, net	—			1,173,347			8,072			—			1,181,419
	Intercompany loans receivable	—			175,000			—			(175,000		)	—
	Investment in subsidiaries	6,137,281			202,292			71			(6,339,644		)	—
	Other long-term assets	15,675			24,117			21,818			(2,223		)	59,387
	Total assets	$	6,204,292		$	8,103,330		$	466,259		$	(6,778,118	)	$	7,995,763
	LIABILITIES AND EQUITY
	Current liabilities
	Accounts payable	$	—		$	851,260		$	8,315		$	(41,770	)	$	817,805
	Accrued expenses and other current liabilities	3,047			228,801			22,252			—			254,100
	Rebates payable	—			356,266			31,332			(31,333		)	356,265
	Current portion - long-term debt	50,000			—			—			—			50,000
	Intercompany payable	25,673			3,885			—			(29,558		)	—
Total current liabilities	78,720			1,440,212			61,899			(102,661		)	1,478,170
Deferred income taxes	—			299,794			1,547			—			301,341
Long-term debt	1,215,363			—			—			—			1,215,363
Intercompany loans payable	—			—			175,000			(175,000		)	—
Other long-term liabilities	1,719			65,812			21,860			—			89,391
Total liabilities	1,295,802			1,805,818			260,306			(277,661		)	3,084,265
Commitments and contingencies (Note 16)
Shareholders’ equity
Total shareholders' equity	4,908,490			6,297,512			204,707			(6,502,219		)	4,908,490
Non-controlling interest	—			—			1,246			1,762			3,008
Total equity	4,908,490			6,297,512			205,953			(6,500,457		)	4,911,498
Total liabilities and equity	$	6,204,292		$	8,103,330		$	466,259		$	(6,778,118	)	$	7,995,763
Summary of condensed income statements	CATAMARAN CORPORATION
	Condensed Consolidated Statements of Operations
	(in thousands)
		Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
	For the year ended December 31, 2014
	Revenue	$	40,141		$	20,849,801		$	3,028,412		$	(2,336,464	)	$	21,581,890
	Cost of revenue	33,917			19,764,270			2,760,114			(2,336,464		)	20,221,837
	Gross profit	6,224			1,085,531			268,298			—			1,360,053
	Expenses:
	Selling, general and administrative	2,931			418,400			97,020			—			518,351
	Depreciation of property and equipment	30			53,932			5,524			—			59,486
	Amortization of intangible assets	—			210,251			2,969			—			213,220
	Total Expenses	2,961			682,583			105,513			—			791,057
	Operating income	3,263			402,948			162,785			—			568,996
	Interest and other expense, net	51,904			3,007			6,177			—			61,088
	Equity in (income) of subsidiaries	(365,934		)	(58,804		)	—			424,738			—
	Income before income taxes	317,293			458,745			156,608			(424,738		)	507,908
	Income tax expense	—			92,811			41,375			—			134,186
	Net income	317,293			365,934			115,233			(424,738		)	373,722
	Less net income attributable to non-controlling interest	—			—			—			56,429			56,429
	Net income attributable to the Company	$	317,293		$	365,934		$	115,233		$	(481,167	)	$	317,293
	CATAMARAN CORPORATION
	Condensed Consolidated Statements of Operations
	(in thousands)
		Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
	For the year ended December 31, 2013
	Revenue	$	34,875		$	13,682,194		$	1,750,509		$	(687,484	)	$	14,780,094
	Cost of revenue	30,217			12,756,828			1,554,888			(687,484		)	13,654,449
	Gross profit	4,658			925,366			195,621			—			1,125,645
	Expenses:
	Selling, general and administrative	1,094			374,435			65,230			—			440,759
	Depreciation of property and equipment	29			35,005			2,892			—			37,926
	Amortization of intangible assets	—			200,065			3,127			—			203,192
	Total Expenses	1,123			609,505			71,249			—			681,877
	Operating income	3,535			315,861			124,372			—			443,768
	Interest and other (income) expense, net	36,700			(344		)	5,270			—			41,626
	Equity in (income) of subsidiaries	(295,335		)	(51,924		)	—			347,259			—
	Income before income taxes	262,170			368,129			119,102			(347,259		)	402,142
	Income tax expense	—			72,794			30,609			—			103,403
	Net income	262,170			295,335			88,493			(347,259		)	298,739
	Less net income attributable to non-controlling interest	—			—			—			36,569			36,569
	Net income attributable to the Company	$	262,170		$	295,335		$	88,493		$	(383,828	)	$	262,170
	CATAMARAN CORPORATION
	Condensed Consolidated Statements of Operations
	(in thousands)
		Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
	For the year ended December 31, 2012
	Revenue	$	15,343		$	9,578,406		$	911,107		$	(564,736	)	$	9,940,120
	Cost of revenue	12,306			8,926,325			832,849			(564,736		)	9,206,744
	Gross profit	3,037			652,081			78,258			—			733,376
	Expenses:
	Selling, general and administrative	4,688			322,843			41,961			—			369,492
	Depreciation of property and equipment	50			14,784			1,915			—			16,749
	Amortization of intangible assets	—			126,847			3,269			—			130,116
	Total Expenses	4,738			464,474			47,145			—			516,357
	Operating income	(1,701		)	187,607			31,113			—			217,019
	Interest and other expense, net	11,731			13,577			1,374			—			26,682
	Equity in (income) of subsidiaries	(130,090		)	(14,551		)	—			144,641			—
	Income before income taxes	116,658			188,581			29,739			(144,641		)	190,337
	Income tax expense	—			58,491			10,825			—			69,316
	Net income	116,658			130,090			18,914			(144,641		)	121,021
	Less net income attributable to non-controlling interest	—			—			—			4,363			4,363
	Net income attributable to the Company	$	116,658		$	130,090		$	18,914		$	(149,004	)	$	116,658
Summary of condensed cash flow statements	CATAMARAN CORPORATION
	Condensed Consolidated Statements of Cash Flows
	(in thousands)
		Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
	For the year ended December 31, 2014
	Cash flows from operating activities:
	Net cash provided (used) by operating activities	$	341,698		$	612,430		$	(6,952	)	$	(356,995	)	$	590,181
	Cash flows from investing activities:
	Acquisitions, net of cash acquired	—			(2,026		)	—			—			(2,026		)
	Purchases of property and equipment	(71		)	(41,664		)	(36,343		)	—			(78,078		)
	Proceeds from restricted cash	—			20,006			—			—			20,006
	Net cash used in investing activities	(71		)	(23,684		)	(36,343		)	—			(60,098		)
	Cash flows from financing activities:
	Proceeds from issuance of debt	492,500			—			—			—			492,500
	Repayment of long-term debt	(337,500		)	—			—			—			(337,500		)
	Payment of financing costs	(1,963		)	—			—			—			(1,963		)
	Proceeds from exercise of options	8,011			(2,355		)	(17		)	—			5,639
	Tax benefit on option exercises	—			3,455			37			—			3,492
	Proceeds from warrants exercised	3,452			—			—			—			3,452
	Payments of contingent consideration	—			(18,338		)	—			—			(18,338		)
	Distributions to non-controlling interest	—			—			—			(52,309		)	(52,309		)
	Net transactions with parent and affiliates	(208,486		)	(264,620		)	63,802			409,304			—
	Proceeds from restricted stock	20,700			(20,249		)	(451		)	—			—
	Other	—			(383		)	—			—			(383		)
	Net cash provided (used) by financing activities	(23,286		)	(302,490		)	63,371			356,995			94,590
	Effect of foreign exchange on cash balances	38			—			—			—			38
	Change in cash and cash equivalents	318,379			286,256			20,076			—			624,711
	Cash and cash equivalents, beginning of period	15,090			362,647			9,504			—			387,241
	Cash and cash equivalents, end of period	$	333,469		$	648,903		$	29,580		$	—		$	1,011,952
	CATAMARAN CORPORATION
	Condensed Consolidated Statements of Cash Flows
	(in thousands)
		Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
	For the year ended December 31, 2013
	Cash flows from operating activities:
	Net cash provided (used) by operating activities	$	186,985		$	616,168		$	(30,476	)	$	(297,256	)	$	475,421
	Cash flows from investing activities:
	Acquisitions, net of cash acquired	—			(388,866		)	—			—			(388,866		)
	Purchases of property and equipment	(11		)	(117,799		)	(11,032		)	—			(128,842		)
	Proceeds from restricted cash	—			20,004			—			—			20,004
	Net cash used by investing activities	(11		)	(486,661		)	(11,032		)	—			(497,704		)
	Cash flows from financing activities:
	Proceeds from issuance of debt	450,000			—			—			—			450,000
	Repayment of long-term debt	(362,500		)	—			—			—			(362,500		)
	Payment of financing costs	(2,347		)	—			—			—			(2,347		)
	Proceeds from exercise of options and warrants	4,729			(1,248		)	(2		)	—			3,479
	Tax benefit on option exercises	—			9,704			28			—			9,732
	Payments of contingent consideration	—			(18,338		)	(4,865		)	—			(23,203		)
	Distributions to non-controlling interest	—			—			—			(36,314		)	(36,314		)
	Net transactions with parent and affiliates	(322,377		)	(49,103		)	37,910			333,570			—
	Proceeds from restricted stock	27,107			(26,645		)	(462		)	—			—
	Other	—			—			—			—			—
	Net cash (used) provided by financing activities	(205,388		)	(85,630		)	32,609			297,256			38,847
	Effect of foreign exchange on cash balances	(99		)	—			—			—			(99		)
	Change in cash and cash equivalents	(18,513		)	43,877			(8,899		)	—			16,465
	Cash and cash equivalents, beginning of period	33,603			318,770			18,403			—			370,776
	Cash and cash equivalents, end of period	$	15,090		$	362,647		$	9,504		$	—		$	387,241
	CATAMARAN CORPORATION
	Condensed Consolidated Statements of Cash Flows
	(in thousands)
		Catamaran Corporation			Guarantors			Non-Guarantors			Consolidations			Consolidated
	For the year ended December 31, 2012
	Cash flows from operating activities:
	Net cash provided (used) by operating activities	$	(27,257	)	$	430,091		$	(18,449	)	$	(134,652	)	$	249,733
Cash flows from investing activities:
Acquisitions, net of cash acquired	3,644,364			(5,210,069		)	—			—			(1,565,705		)
Purchases of property and equipment	(66		)	(30,549		)	(9,621		)				(40,236		)
Net cash provided by (used in) investing activities	3,644,298			(5,240,618		)	(9,621		)	—			(1,605,941		)
Cash flows from financing activities:
Proceeds from issuance of debt	1,475,448			—			—			—			1,475,448
Repayment of long-term debt	(616,993		)	—			—			—			(616,993		)
Proceeds from public offering, net of issuance costs	519,075			—			—			—			519,075
Payment of financing costs	(18,806		)	—			—			—			(18,806		)
Proceeds from exercise of options	11,016			(3,253		)	—			—			7,763
Tax benefit on option exercises	—			19,206			191			—			19,397
Net transactions with parent and affiliates	(5,093,214		)	4,913,963			44,599			134,652			—
Proceeds from restricted stock	17,903			(17,651		)	(252		)	—			—
Other	(268		)	—			—			—			(268		)
Net cash (used) provided by financing activities	(3,705,839		)	4,912,265			44,538			134,652			1,385,616
Effect of foreign exchange on cash balances	(14		)	—			—			—			(14		)
Change in cash and cash equivalents	(88,812		)	101,738			16,468			—			29,394
Cash and cash equivalents, beginning of period	122,415			217,032			1,935			—			341,382
Cash and cash equivalents, end of period	$	33,603		$	318,770		$	18,403		$	—		$	370,776

Significant_Accounting_Policie2

Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013
Significant Accounting Policies [Line Items]
Amortization of intangible assets	$8,000,000
Goodwill	4,478,038,000	4,724,639,000	4,720,275,000
Unbilled rebates receivable		366,700,000	54,600,000
PBM
Significant Accounting Policies [Line Items]
Goodwill	4,458,373,000	4,704,974,000	4,700,610,000
HCIT
Significant Accounting Policies [Line Items]
Goodwill	$19,665,000	19,665,000	$19,665,000
Minimum
Significant Accounting Policies [Line Items]
Finite-lived intangibles, estimated useful life		1 year
Minimum | Customer Relationships
Significant Accounting Policies [Line Items]
Finite-lived intangibles, estimated useful life		3 years
Maximum
Significant Accounting Policies [Line Items]
Finite-lived intangibles, estimated useful life		15 years
Maximum | Customer Relationships
Significant Accounting Policies [Line Items]
Finite-lived intangibles, estimated useful life		10 years
Furniture and equipment
Significant Accounting Policies [Line Items]
Property and equipment, useful Life		5 years
Computer equipment and software | Minimum
Significant Accounting Policies [Line Items]
Property and equipment, useful Life		3 years
Computer equipment and software | Maximum
Significant Accounting Policies [Line Items]
Property and equipment, useful Life		5 years

Stock_Split_Details

Stock Split (Details)	0 Months Ended
	Sep. 06, 2012
Stock Split [Abstract]
Stock split ratio	2

Business_Combinations_Restat_D

Business Combinations - Restat (Details) (USD $)	12 Months Ended			0 Months Ended	6 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 01, 2013	Jun. 30, 2014
Business Acquisition [Line Items]
Amortization of intangible assets	$213,220,000	$203,192,000	$130,116,000
Future amortization expense, 2015	194,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Goodwill	4,724,639,000	4,720,275,000	4,478,038,000
Restat
Business Acquisition [Line Items]
Purchase price				409,500,000
Revenue of acquiree		209,200,000
Amortization of intangible assets	33,700,000	8,700,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Intangible assets				182,720,000
Goodwill expected to be tax deductible				227,800,000
Restat | Revolving credit facility
Business Acquisition [Line Items]
Debt amount				350,000,000
Term of long-term debt				5 years
Restat | Customer Relationship - PBM
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Intangible assets				143,200,000
Finite-lived intangibles, estimated useful life				10 years
Restat | Customer relationships - cash card
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Intangible assets				35,500,000
Finite-lived intangibles, estimated useful life				3 years
Restat | Trademarks/Trade names
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Intangible assets				1,000,000
Finite-lived intangibles, estimated useful life				1 year
Restat | Non-compete agreements
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Intangible assets				3,020,000
Finite-lived intangibles, estimated useful life				5 years
Initial Amounts Recognized at Acquisition Date | Restat
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Accounts receivable				13,842,000
Rebates receivable				6,635,000
Other current assets				383,000
Total current assets				20,860,000
Property and equipment				1,263,000
Intangible assets				182,720,000
Goodwill				223,474,000
Total assets acquired				428,317,000
Accounts payable				22,370,000
Rebates payable				16,106,000
Accrued liabilities				7,231,000
Other long-term liabilities				0
Total liabilities assumed				45,707,000
Net assets acquired				382,610,000
Measurement Period Adjustments | Restat
Business Acquisition [Line Items]
Business acquisition, consideration transferred					2,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Accounts receivable					0
Rebates receivable					-254,000
Other current assets					0
Total current assets					-254,000
Property and equipment					0
Intangible assets					0
Goodwill					4,364,000
Total assets acquired					4,110,000
Accounts payable					0
Rebates payable					0
Accrued liabilities					0
Other long-term liabilities					2,084,000
Total liabilities assumed					2,084,000
Net assets acquired					2,026,000
Final Amounts Recognized at Acquisition Date | Restat
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Accounts receivable				13,842,000
Rebates receivable				6,381,000
Other current assets				383,000
Total current assets				20,606,000
Property and equipment				1,263,000
Intangible assets				182,720,000
Goodwill				227,838,000
Total assets acquired				432,427,000
Accounts payable				22,370,000
Rebates payable				16,106,000
Accrued liabilities				7,231,000
Other long-term liabilities				2,084,000
Total liabilities assumed				47,791,000
Net assets acquired				$384,636,000

Business_Combinations_Catalyst

Business Combinations - Catalyst Merger (Details) (USD $)	0 Months Ended	12 Months Ended
	Jul. 02, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 02, 2012
Merger Agreement [Abstract]
Amortization of intangible assets		$213,220,000	$203,192,000	$130,116,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill		4,724,639,000	4,720,275,000	4,478,038,000
Common Shares
Merger Agreement [Abstract]
Public offering, shares of common stock				11,960,000
Catalyst
Merger Agreement [Abstract]
Goodwill expected to be tax deductible	525,000,000				525,000,000
Amortization of intangible assets		154,700,000	166,100,000
Fair value of intangible assets	1,200,000,000
Customer relationships, weighted average useful life		9 years
Business Combination, Consideration Transferred [Abstract]
Fair value of common shares issued	3,238,141,000
Fair value of warrants and stock options issued	19,824,000
Total purchase price	4,673,241,000
Separate Tranactions and Preexisting Relationships [Abstract]
Transaction and integration expense				27,200,000
Business Combination, Transaction Expense				22,800,000
Acquisition costs included in selling, general and administrative expenses				17,000,000
Contract settlements and termination charges recorded				3,500,000
Accounts receivable with acquired business				4,100,000
Catalyst | Common Shares
Merger Agreement [Abstract]
Stock conversion, share received per share converted	1.3212				1.3212
Stock conversion, cash received per share converted, prior to stock split	0.6606				0.6606
Stock conversion, cash received per share converted	$28				$28
Public offering, shares of common stock	66,800,000
Warrants, Issued	500,000
Business Combination, Consideration Transferred [Abstract]
Cash paid to shareholders	1,415,276,000
Catalyst | Initial Amounts Recognized at Acquisition Date
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Cash and cash equivalents	93,775,000				93,775,000
Other current assets	695,888,000				695,888,000
Total current assets	789,663,000				789,663,000
Goodwill	4,010,235,000				4,010,235,000
Customer relationships intangible	1,184,800,000				1,184,800,000
Other long-term assets	87,174,000				87,174,000
Total assets acquired	6,071,872,000				6,071,872,000
Accounts payable	338,819,000				338,819,000
Pharmacy benefit management rebates payable	176,202,000				176,202,000
Accrued expenses and other current liabilities	187,851,000				187,851,000
Long-term debt	311,994,000				311,994,000
Other long-term liabilities	385,375,000				385,375,000
Total liabilities assumed	1,400,241,000				1,400,241,000
Non-controlling interest	-1,610,000				-1,610,000
Net assets acquired	4,673,241,000				4,673,241,000
Catalyst | Measurement Period Adjustments
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Cash and cash equivalents			0	-315,000
Other current assets			2,411,000	5,202,000
Total current assets			2,411,000	4,887,000
Goodwill			16,141,000	8,492,000
Customer relationships intangible			0	0
Other long-term assets			8,000	1,547,000
Total assets acquired			18,560,000	14,926,000
Accounts payable			5,000	0
Pharmacy benefit management rebates payable			-1,522,000	2,935,000
Accrued expenses and other current liabilities			5,473,000	1,348,000
Long-term debt			0	0
Other long-term liabilities			14,604,000	10,643,000
Total liabilities assumed			18,560,000	14,926,000
Non-controlling interest			0	0
Net assets acquired			0	0
Catalyst | Final Amounts Recognized at Acquisition Date
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Cash and cash equivalents	93,460,000				93,460,000
Other current assets	703,501,000				703,501,000
Total current assets	796,961,000				796,961,000
Goodwill	4,034,868,000				4,034,868,000
Customer relationships intangible	1,184,800,000				1,184,800,000
Other long-term assets	88,729,000				88,729,000
Total assets acquired	6,105,358,000				6,105,358,000
Accounts payable	338,824,000				338,824,000
Pharmacy benefit management rebates payable	177,615,000				177,615,000
Accrued expenses and other current liabilities	194,672,000				194,672,000
Long-term debt	311,994,000				311,994,000
Other long-term liabilities	410,622,000				410,622,000
Total liabilities assumed	1,433,727,000				1,433,727,000
Non-controlling interest	-1,610,000				-1,610,000
Net assets acquired	4,673,241,000				4,673,241,000
Catalyst | Employees Settlements
Separate Tranactions and Preexisting Relationships [Abstract]
Expenses and losses recognized				3,100,000
Catalyst | Severence Cost
Separate Tranactions and Preexisting Relationships [Abstract]
Expenses and losses recognized				$10,400,000

Business_Combinations_HealthTr

Business Combinations - HealthTran (Details) (USD $)	12 Months Ended			1 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 31, 2012	Dec. 31, 2011
Business Acquisition [Line Items]
Amortization of acquired intangible assets	$213,220,000	$203,192,000	$130,116,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Goodwill	4,724,639,000	4,720,275,000	4,478,038,000
Minimum
Business Acquisition [Line Items]
Finite-lived intangibles, estimated useful life	1 year
Maximum
Business Acquisition [Line Items]
Finite-lived intangibles, estimated useful life	15 years
Customer Relationships | Minimum
Business Acquisition [Line Items]
Finite-lived intangibles, estimated useful life	3 years
Customer Relationships | Maximum
Business Acquisition [Line Items]
Finite-lived intangibles, estimated useful life	10 years
HealthTran
Business Acquisition [Line Items]
Cash paid to shareholders				250,000,000
Acquisition costs included in selling, general and administrative expenses					900,000
Amortization of acquired intangible assets	14,600,000	12,600,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Intangible assets				74,530,000
HealthTran | Trade Mark Trade Name
Business Acquisition [Line Items]
Finite-lived intangibles, estimated useful life				6 months
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Intangible assets				1,750,000
HealthTran | Customer Relationships
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Intangible assets				69,800,000
HealthTran | Customer Relationships | Minimum
Business Acquisition [Line Items]
Finite-lived intangibles, estimated useful life				4 years
HealthTran | Customer Relationships | Maximum
Business Acquisition [Line Items]
Finite-lived intangibles, estimated useful life				9 years
HealthTran | Non-compete agreements
Business Acquisition [Line Items]
Finite-lived intangibles, estimated useful life				5 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Intangible assets				2,600,000
HealthTran | Licensing Agreements
Business Acquisition [Line Items]
Finite-lived intangibles, estimated useful life				3 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Intangible assets				380,000
HealthTran | Initial Amounts Recognized at Acquisition Date
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Current assets				30,654,000
Property and equipment				2,787,000
Goodwill				173,642,000
Intangible assets				77,130,000
Total assets acquired				284,213,000
Current liabilities				36,784,000
Total liabilities assumed				36,784,000
Net assets acquired				247,429,000
HealthTran | Measurement Period Adjustments
Business Acquisition [Line Items]
Adjustment paid to former owners				1,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Current assets				245,000
Property and equipment				0
Goodwill				833,000
Intangible assets				-2,600,000
Total assets acquired				-1,522,000
Current liabilities				-496,000
Total liabilities assumed				-496,000
Net assets acquired				-1,026,000
HealthTran | Final Amounts Recognized at Acquisition Date
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Current assets				30,899,000
Property and equipment				2,787,000
Goodwill				174,475,000
Intangible assets				74,530,000
Total assets acquired				282,691,000
Current liabilities				36,288,000
Total liabilities assumed				36,288,000
Net assets acquired				$246,403,000

Business_Combinations_Pro_Form

Business Combinations - Pro Forma Information (Details) (Restat, USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013
Restat
Business Acquisition, Pro Forma Information [Abstract]
Revenue	$15,344,028
Gross profit	1,187,714
Net income	$270,024
Earnings per share attributable to the Company:
Basic (in dollars per share)	$1.31
Diluted (in dollars per share)	$1.31
Weighted average number of shares used in computing earnings per share:
Basic (in shares)	206,013,876
Diluted (in shares)	206,719,526

Business_Combinations_Salveo_S

Business Combinations - Salveo Specialty Pharmacy (Details) (Subsequent Event, Salveo Specialty Pharmacy, USD $)	0 Months Ended
In Thousands, unless otherwise specified	Jan. 02, 2015
Subsequent Event | Salveo Specialty Pharmacy
Business Acquisition [Line Items]
Purchase price	$260,000

Business_Combinations_Business

Business Combinations Business Combination - Healthcare Solutions Inc. (Details) (Subsequent Event, Healthcare Solutions Inc., USD $)	0 Months Ended
In Thousands, unless otherwise specified	Feb. 26, 2015
Subsequent Event | Healthcare Solutions Inc.
Business Acquisition [Line Items]
Purchase price	$405,000

Variable_Interest_Entity_Detai

Variable Interest Entity (Details) (Variable Interest Entity, Primary Beneficiary)	Dec. 31, 2014
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Ownership percentage (in excess of 40%)	40.00%

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Cost	$354,247,000	$300,865,000
Accumulated Depreciation	-144,220,000	-103,858,000
Net Book Value	210,027,000	197,007,000
Depreciation	63,468,000	42,232,000	20,234,000
Depreciation, cost of revenue	4,000,000	4,300,000	3,500,000
Furniture and equipment
Property, Plant and Equipment [Line Items]
Cost	39,690,000	30,374,000
Accumulated Depreciation	-13,577,000	-10,815,000
Net Book Value	26,113,000	19,559,000
Computer equipment and software
Property, Plant and Equipment [Line Items]
Cost	208,628,000	168,463,000
Accumulated Depreciation	-107,565,000	-77,880,000
Net Book Value	101,063,000	90,583,000
Leasehold improvements
Property, Plant and Equipment [Line Items]
Cost	96,784,000	91,294,000
Accumulated Depreciation	-23,078,000	-15,163,000
Net Book Value	73,706,000	76,131,000
Construction in progress
Property, Plant and Equipment [Line Items]
Cost	9,145,000	10,734,000
Accumulated Depreciation	0	0
Net Book Value	$9,145,000	$10,734,000

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Goodwill) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Roll Forward]
Goodwill, beginning of period	$4,720,275	$4,478,038
Acquisitions	2,026	225,761
Measurement periods adjustments	2,338	16,476
Goodwill, end of period	4,724,639	4,720,275
PBM
Goodwill [Roll Forward]
Goodwill, beginning of period	4,700,610	4,458,373
Acquisitions	2,026	225,761
Measurement periods adjustments	2,338	16,476
Goodwill, end of period	4,704,974	4,700,610
HCIT
Goodwill [Roll Forward]
Goodwill, beginning of period	19,665	19,665
Acquisitions	0	0
Measurement periods adjustments	0	0
Goodwill, end of period	$19,665	$19,665

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets (Intangible Assets) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$1,542,702,000	$1,544,965,000
Accumulated Amortization	574,503,000	363,546,000
Net	968,199,000	1,181,419,000
Definite-lived Intangible Assets, Future Amortization Expense [Abstract]
Future amortization expense, 2015	194,000,000
Future amortization expense, 2016	166,700,000
Future amortization expense, 2017	147,500,000
Future amortization expense, 2018	137,200,000
Future amortization expense, 2019	126,800,000
Future amortization expense, after 2019	196,000,000
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,527,722,000	1,528,475,000
Accumulated Amortization	564,623,000	355,737,000
Net	963,099,000	1,172,738,000
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	11,920,000	13,430,000
Accumulated Amortization	7,435,000	6,463,000
Net	4,485,000	6,967,000
Other Intangible Assets
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	3,060,000	3,060,000
Accumulated Amortization	2,445,000	1,346,000
Net	$615,000	$1,714,000

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Customer deposits	$13,619	$12,148
Salaries and wages payable	65,481	54,761
Deferred revenue	31,630	10,053
Income taxes payable	0	7,456
Other accrued expenses	216,460	169,682
Total accrued expenses and other current liabilities	$327,190	$254,100

LongTerm_Liabilities_Component

Long-Term Liabilities (Components of Long-term Debt) (Details) (USD $)	0 Months Ended	12 Months Ended			0 Months Ended	1 Months Ended		0 Months Ended
	Jun. 02, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 02, 2012	Sep. 30, 2014	Mar. 31, 2014	Jun. 03, 2013	Oct. 01, 2013
Debt Instrument [Line Items]
Interest rate		2.14%
Less current maturities		($81,250,000)	($50,000,000)
Long-term debt		1,344,973,000	1,215,363,000
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Debt amount					1,800,000,000
Interest rate		0.52%
Initial applicable margin for borrowings		1.63%
Interest rate during period	2.25%
Amortization of financing costs and discounts		8,500,000	9,100,000	5,000,000
Interest expense charge			400,000
Term A Facility
Debt Instrument [Line Items]
Interest rate		1.81%	1.81%
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Debt amount					1,100,000,000
Term of long-term debt					5 years
Secured Debt
Debt Instrument [Line Items]
Less current maturities		-81,250,000	-50,000,000
Secured Debt | Term A Facility
Debt Instrument [Line Items]
Long-term debt, current and noncurrent maturities		932,875,000	965,363,000
Senior Notes, 4.75% Due 2021
Debt Instrument [Line Items]
Long-term debt, current and noncurrent maturities		493,348,000	0
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Debt amount							500,000,000
Interest rate							4.75%
Periodic interest payment						12,100,000
Proceeds from issuance of long-term debt							492,500,000
Debt discount							7,500,000
Debt issuance cost							2,000,000
Amortization of financing costs and discounts		1,100,000
Catalyst
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Debt amount					1,400,000,000
Catalyst | Term A Facility
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Debt amount					1,100,000,000
Debt discount					29,600,000
Amended Credit Agreement
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Interest rate during period		1.81%
Maximum leverage ratio		4
Required maximum consolidated senior secured leverage ratio required		3.25
Maximum ratio of EBIT to interest expense		4
Amended Credit Agreement | Term A Facility
Debt Instrument [Line Items]
Long-term debt, current and noncurrent maturities		950,000,000	987,500,000
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Debt amount								1,000,000,000
Debt discount		24,100,000
Repayments of debt		37,500,000	12,500,000					100,000,000
Payment of debt discount		1,300,000
Amended Credit Agreement | Secured Debt
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Payments for fees		2,300,000
Revolving credit facility
Debt Instrument [Line Items]
Interest rate		1.81%	1.81%
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Debt amount					700,000,000
Revolving credit facility | Secured Debt
Debt Instrument [Line Items]
Long-term debt, current and noncurrent maturities		0	300,000,000
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Repayments of long-term lines of credit							300,000,000
Revolving credit facility | Catalyst
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Debt amount					300,000,000
Payments of debt issuance costs					18,800,000
Revolving credit facility | Restat
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Term of long-term debt									5 years
Proceeds from lines of credit									350,000,000
Revolving credit facility | Amended Credit Agreement
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Debt amount								800,000,000
Debt discount		16,600,000
Repayments of debt			150,000,000
Remaining borrowing capacity		800,000,000	500,000,000					700,000,000
Deferred finance costs		1,000,000
Base Rate Borrowings | Amended Credit Agreement
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Initial applicable margin for borrowings								0.63%
LIBOR Borrowings | Amended Credit Agreement
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Initial applicable margin for borrowings								1.63%
Minimum | LIBOR Borrowings | Amended Credit Agreement
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Leverage ratio allowed								1.5
Maximum | LIBOR Borrowings | Amended Credit Agreement
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Leverage ratio allowed								2.5
Debt Instrument, Redemption, Period One | Senior Notes, 4.75% Due 2021
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Percentage of principal amount redeemed		100.00%
Redemption price, percentage		101.00%
Percentage of aggregate amount of debt required to make note due and payable immediately		25.00%
Initial applicable margin for borrowings		0.50%
Debt Instrument, Redemption, Period One | Minimum | Senior Notes, 4.75% Due 2021
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Redemption period		30 days
Debt Instrument, Redemption, Period One | Maximum | Senior Notes, 4.75% Due 2021
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Redemption period		60 days
Financial Guarantee | Senior Notes, 4.75% Due 2021
Long-term Debt, by Category, Current and Noncurrent [Abstract]
Guarantor obligations, triggering amount		$175,000,000

LongTerm_Liabilities_Maturitie

Long-Term Liabilities (Maturities of Long-term Debt) (Details) (Term A Facility, Amended Credit Agreement, USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Term A Facility | Amended Credit Agreement
Maturities of Long-term Debt [Abstract]
2015	$81,250
2016	93,750
2017	118,750
2018	656,250
Total	$950,000	$987,500

Shareholders_Equity_Common_Sha

Shareholders' Equity (Common Shares) (Details) (USD $)	12 Months Ended			0 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 02, 2012	16-May-12
Class of Stock [Line Items]
Proceeds from public offering, net of issuance costs	$0	$0	$519,075
Common Shares
Class of Stock [Line Items]
Public offering, shares of common stock			11,960,000
Catalyst | Common Shares
Class of Stock [Line Items]
Public offering, shares of common stock				66,800,000
Warrants issued				500,000
Public Offering
Class of Stock [Line Items]
Proceeds from public offering, net of issuance costs					$519,100
Public Offering | Common Shares
Class of Stock [Line Items]
Public offering, shares of common stock					12,000,000
Public offering, price per share					$45.30

Shareholders_Equity_Equity_Inc

Shareholders' Equity (Equity Incentive Plans) (Details) (USD $)	12 Months Ended			0 Months Ended	1 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	11-May-11	Jul. 31, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Total intrinsic value of stock options exercised	$8.20	$14.90	$50.30
LTIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares counted against share limitations per share granted	1.79
Number of stock-based awards available for grant	4,815,112
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized				3,600,000	5,000,000
Compensation not yet recognized, stock options	8.2
Unrecognized compensation costs on nonvested awards, weighted average period of recognition (in years)	2 years 4 months 21 days
Assumed Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares counted against share limitations per share granted	1.45
Number of stock-based awards available for grant	730,056
Maximum common shares issued under plan	1,480,936
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Compensation not yet recognized, stock options	1.7
Unrecognized compensation costs on nonvested awards, weighted average period of recognition (in years)	3 years 0 months 4 days
US Dollars
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options expired, duration	7 years
Vesting period	4 years
Number of Options (in shares):
Beginning balance	1,396,144
Granted	432,586
Exercised	-298,108
Forfeited	-82,090
Ending balances	1,448,532	1,396,144
Weighted Average Exercise Price (in dollars per share):
Beginning balance	$31.60
Granted	$44.72
Exercised	$18.92
Forfeited	$47.54
Ending balance	$37.22	$31.60
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Range of Exercise Price, lower (in dollars per share	$6.39
Range of Exercise Price, upper (in dollars per share)	$56.25
Options Outstanding (in shares)	1,448,532
Options Outstanding, Weighted Average Contractual Life (in years)	4 years 5 months 21 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$37.22
Options Exercisable (in shares)	568,115
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$27.10
Aggregate intrinsic value, exercisable stock options	14
Options Exercisable, Weighted Average Remaining Contractual Life	3 years 3 months 4 days
Aggregate intrinsic value, vested and expected to vest stock options	21
Total fair value of vested stock options	$4.60	$3.50	$2.80
US Dollars | $6.39- $24.92
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Range of Exercise Price, lower (in dollars per share	$6.39
Range of Exercise Price, upper (in dollars per share)	$24.92
Options Outstanding (in shares)	233,300
Options Outstanding, Weighted Average Contractual Life (in years)	2 years 1 month 28 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$14.05
Options Exercisable (in shares)	230,038
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$13.88
US Dollars | $24.93 - $32.45
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Range of Exercise Price, lower (in dollars per share	$24.93
Range of Exercise Price, upper (in dollars per share)	$32.45
Options Outstanding (in shares)	233,294
Options Outstanding, Weighted Average Contractual Life (in years)	3 years 3 months 0 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$25.51
Options Exercisable (in shares)	140,764
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$25.57
US Dollars | $32.46 - $44.15
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Range of Exercise Price, lower (in dollars per share	$32.46
Range of Exercise Price, upper (in dollars per share)	$44.15
Options Outstanding (in shares)	279,524
Options Outstanding, Weighted Average Contractual Life (in years)	4 years 3 months 15 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$35.78
Options Exercisable (in shares)	110,540
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$35.25
US Dollars | $44.16 - $44.90
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Range of Exercise Price, lower (in dollars per share	$44.16
Range of Exercise Price, upper (in dollars per share)	$44.90
Options Outstanding (in shares)	347,132
Options Outstanding, Weighted Average Contractual Life (in years)	6 years 2 months 5 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$44.70
Options Exercisable (in shares)	0
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$0
US Dollars | $44.91 - $56.25
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Range of Exercise Price, lower (in dollars per share	$44.91
Range of Exercise Price, upper (in dollars per share)	$56.25
Options Outstanding (in shares)	355,282
Options Outstanding, Weighted Average Contractual Life (in years)	5 years 3 months 4 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$53.99
Options Exercisable (in shares)	86,773
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$54.22

Shareholders_Equity_Employee_S

Shareholders' Equity (Employee Stock Purchase Plan) (Details) (ESPP, USD $)	0 Months Ended	12 Months Ended
	16-May-07	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	16-May-07
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Base salary annual withholdings, maximum percentage	15.00%				15.00%
Base salary annual withholdings, maximum amount	$25,000				$25,000
Discount from market price	5.00%
Aggregate shares issuable under ESPP, maximum	400,000				400,000
Shares delivered (in shares)		40,156	33,728	14,697

Shareholders_Equity_Restricted

Shareholders' Equity (Restricted Stock Units) (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of vested stock options	$20.80	$27.30	$18
Weighted Average Grant Date Fair Value Per Unit (in dollars per share):
Vested	$44.72	$55.99	$38.49
Time-based RSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years	3 years	3 years
Time-based RSUs | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years	4 years	4 years
Performance-based RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
LTIP | Restricted Stock Units (RSUs)
Number of Restricted Stock Units (in shares):
Nonvested balance as of the beginning of the period	1,334,694
Granted	694,645
Vested	-411,817
Forfeited	-71,832
Nonvested balance as of the end of the period	1,545,690
Weighted Average Grant Date Fair Value Per Unit (in dollars per share):
Nonvested balance as of the beginning of the period	$40.14
Granted	$44.84
Vested	$30.23
Forfeited	$44.57
Nonvested balance as of the end of the period	$44.69
Catamaran Corporation Long-Term Incentive Plan | Restricted Stock Units (RSUs)
Weighted Average Grant Date Fair Value Per Unit (in dollars per share):
Granted	$44.84
Catamaran Corporation Long-Term Incentive Plan | Time-based RSUs
Number of Restricted Stock Units (in shares):
Granted	302,257
Nonvested balance as of the end of the period	714,810
Catamaran Corporation Long-Term Incentive Plan | Performance-based RSUs
Number of Restricted Stock Units (in shares):
Granted	392,388
Nonvested balance as of the end of the period	830,880
Assumed Plans | Restricted Stock Units (RSUs)
Number of Restricted Stock Units (in shares):
Nonvested balance as of the beginning of the period	213,656
Granted	247,131
Vested	-53,386
Forfeited	-76,528
Nonvested balance as of the end of the period	330,873
Weighted Average Grant Date Fair Value Per Unit (in dollars per share):
Nonvested balance as of the beginning of the period	$50.98
Granted	$44.41
Vested	$50.38
Forfeited	$49.06
Nonvested balance as of the end of the period	$46.62
Assumed Plans | Time-based RSUs
Number of Restricted Stock Units (in shares):
Granted	155,615
Nonvested balance as of the end of the period	243,925
Assumed Plans | Performance-based RSUs
Number of Restricted Stock Units (in shares):
Granted	91,516
Nonvested balance as of the end of the period	86,948

Shareholders_Equity_Warrants_D

Shareholders' Equity (Warrants) (Details) (Catalyst, USD $)	0 Months Ended
	Jul. 02, 2012	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Catalyst
Class of Stock [Line Items]
Issuance of common shares for acquisitions, shares	66,800,000
Warrants issued	500,000
Warrants outstanding		0		425,160
Weighted average exercise price			$8.12

Shareholders_Equity_StockBased

Shareholders' Equity (Stock-Based Compensation) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Equity Note [Abstract]
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	$12,700,000	$9,500,000	$6,500,000
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	33,554,000	25,562,000	17,667,000
Allocated stock-based compensation expense	33,554,000	25,562,000	17,667,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Volatility rate, minimum	37.70%	41.40%	47.20%
Volatility rate, maximum	39.20%	45.40%	49.20%
Risk free interest rate, minimum	1.54%	0.81%	0.65%
Risk free interest rate, maximum	1.73%	1.74%	0.83%
Expected life	4 years 6 months	4 years 6 months	4 years 6 months
Dividend yield	0.00%	0.00%	0.00%
Weighted-average grant date fair value (in dollars per share)	$15.47	$21.33	$14.70
Employee | Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected life	4 years 6 months
Employee | Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected life	5 years
Director | Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected life	1 year
Director | Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected life	2 years 6 months
Cost of Revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	2,284,000	1,404,000	687,000
Selling, General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	31,270,000	24,158,000	16,980,000
LTIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs on nonvested awards, weighted average period of recognition (in years)	2 years 4 months 21 days
Assumed Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs on nonvested awards, weighted average period of recognition (in years)	3 years 0 months 4 days
Restricted Stock Units (RSUs) | LTIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs on nonvested awards	34,600,000
Unrecognized compensation costs on nonvested awards, weighted average period of recognition (in years)	2 years 0 months 7 days
Restricted Stock Units (RSUs) | Assumed Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs on nonvested awards	$12,000,000
Unrecognized compensation costs on nonvested awards, weighted average period of recognition (in years)	2 years 5 months 27 days

Income_Taxes_Deferred_Income_T

Income Taxes (Deferred Income Tax Assets and Liabilities) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred income tax assets:
Non-capital loss carryforwards (“NOL”)	$28,906	$18,229
Lease inducements and deferred financing	15,826	12,528
Reserves and accruals	62,487	45,974
Stock-based compensation	17,889	12,763
Other	12,318	9,408
Total	137,426	98,902
Less valuation allowance - current	804	875
Less valuation allowance - long term	28,915	17,486
Total valuation allowance	29,719	18,361
Total deferred tax assets	107,707	80,541
Deferred tax assets — current	58,631	44,029
Deferred tax assets — long term	49,076	36,512
Deferred income tax liabilities:
Property and equipment and intangible assets	297,978	329,842
Dividend withholding tax	5,675	5,675
Other	5,156	3,146
Total	308,809	338,663
Foreign
Deferred income tax assets:
Total	30,800	18,100
Total valuation allowance	28,400	17,100
Canada, US Federal and state NOLs
Deferred income tax assets:
Total	28,900
Total valuation allowance	$26,700

Income_Taxes_Income_Tax_Reconc

Income Taxes (Income Tax Reconciliation) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Corporate statutory rate	35.00%	35.00%	35.00%
Income tax expense on income before income taxes	$177,768	$140,751	$66,618
Tax effect of:
State and local income taxes, net of federal benefit	13,527	10,726	4,281
Transaction costs and transaction related expenses	453	938	5,252
Dividend withholding tax	0	-65	13,074
Impact of foreign tax rates	-3,191	-3,693	-1,582
Non-controlling interest	-22,452	-13,670	-1,645
Cross-jurisdictional financing	-48,252	-44,659	-23,937
Other	3,662	4,479	3,763
Valuation allowance	12,671	8,596	3,492
Income tax expense	$134,186	$103,403	$69,316

Income_Taxes_Components_of_Inc

Income Taxes (Components of Income Tax) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current tax expense
Current tax expense	$192,233,000	$147,739,000	$107,241,000
Deferred tax expense (benefit)
Deferred tax expense	-58,047,000	-44,336,000	-37,925,000
Income tax expense	134,186,000	103,403,000	69,316,000
Income from U.S. operations before income taxes	428,700,000	319,800,000	158,700,000
United States
Current tax expense
Current tax expense	192,021,000	146,484,000	94,834,000
Deferred tax expense (benefit)
Deferred tax expense	-57,889,000	-44,180,000	-38,441,000
Foreign
Current tax expense
Current tax expense	212,000	1,255,000	12,407,000
Deferred tax expense (benefit)
Deferred tax expense	-158,000	-156,000	516,000
Income from Canadian operations before income taxes	$79,200,000	$82,300,000	$31,600,000

Income_Taxes_Uncertain_Tax_Pos

Income Taxes (Uncertain Tax Positions) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Unrecognized Tax Benefits, Excluding Interests and Penalties [Roll Forward]
Balance at January 1	$28.90	$18.80	$0.60
Additions for tax positions related to prior years	9	26.5	10.3
Reductions for tax positions related to prior years	-0.9	-13.9	0
Additions based on tax positions related to the current year	3.8	0.4	7.9
Reductions due to lapse of the applicable statute of limitations	-4.7	0	0
Decrease related to settlements with taxing authorities	-0.7	-2.9	0
Balance at December 31	35.4	28.9	18.8
Accrued interest for uncertain tax positions	$5.90	$4.70	$0.50

Lease_Exit_Costs_Details

Lease Exit Costs (Details) (USD $)	1 Months Ended
	Sep. 30, 2014	Aug. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Bannockburn
Operating Leased Assets [Line Items]
Lease loss accrual, cash outflow			$7,000,000
Bannockburn | Accrued expenses and other current liabilities
Operating Leased Assets [Line Items]
Lease loss accrual			6,900,000
Bannockburn | Selling, general and administrative expenses
Operating Leased Assets [Line Items]
Lease loss expense	5,700,000
Maryland
Operating Leased Assets [Line Items]
Lease loss accrual, cash outflow			6,100,000
Maryland | Accrued expenses and other current liabilities
Operating Leased Assets [Line Items]
Lease loss accrual			5,215,000	5,774,000
Maryland | Selling, general and administrative expenses
Operating Leased Assets [Line Items]
Lease loss expense		$5,600,000

Lease_Exit_Costs_Details_2

Lease Exit Costs (Details 2) (Accrued expenses and other current liabilities, Maryland, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Accrued expenses and other current liabilities | Maryland
Lease Exit Cost Accrual [Roll Forward]
Liability, beginning of period	$5,774
Net payments	819
Change in Present Value	260
Liability, end of period	$5,215

Earnings_Per_Share_Computation

Earnings Per Share (Computation of Basic and Diluted Earnings Per Share) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Line Items]
Net income available to common shareholders	$317,293	$262,170	$116,658
Denominator for basic EPS — weighted average common shares outstanding (in shares)	207,103,603	206,013,876	166,765,682
Effect of dilutive securities:
Denominator for diluted EPS (in shares)	207,752,145	206,719,526	167,830,620
Earnings per share:
Basic (in dollars per share)	$1.53	$1.27	$0.70
Diluted (in dollars per share)	$1.53	$1.27	$0.70
Restricted Stock Units (RSUs)
Effect of dilutive securities:
Stock-based compensation (in shares)	402,992	321,587	329,975
Stock Options
Effect of dilutive securities:
Stock-based compensation (in shares)	245,550	384,063	734,963

Earnings_Per_Share_Antidilutiv

Earnings Per Share (Anti-dilutive Securities) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares not included in the computation of diluted earnings per share	1,416,143	645,989	1,062,041
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares not included in the computation of diluted earnings per share	746,999	615,608	773,509
Anti-dilutive stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares not included in the computation of diluted earnings per share	669,144	30,381	288,532

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Supplemental Cash Flow Information [Line Items]
Income taxes paid	$201,263	$158,053	$22,052
Interest paid	38,880	30,322	18,711
Interest received	837	735	473
NMHC
Supplemental Cash Flow Information [Line Items]
Equity shares issued as a result of acquisition			4
Catalyst
Supplemental Cash Flow Information [Line Items]
Equity shares issued as a result of acquisition			$3,238,141

Employee_Benefit_Plans_Details

Employee Benefit Plans (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Defined Benefit Plan Disclosure [Line Items]
Maximum annual contributions	$17,500	$17,500	$17,000
Employer's matching contribution	100.00%
Percentage of employee eligible earnings matched	1.00%
Additional employer's matching contribution	50.00%
Participant contributions, vested percentage	100.00%
Company contributions	$9,000,000	$7,000,000	$4,900,000
Minimum
Defined Benefit Plan Disclosure [Line Items]
Additional percentage of employee eligible earnings matched	2.00%
Maximum
Defined Benefit Plan Disclosure [Line Items]
Additional percentage of employee eligible earnings matched	6.00%
One Year of Service
Defined Benefit Plan Disclosure [Line Items]
Employer contributions, vested percentage	20.00%
Employer contributions, requisite service period for vesting	1 year
Two Years of Service
Defined Benefit Plan Disclosure [Line Items]
Employer contributions, vested percentage	100.00%
Employer contributions, requisite service period for vesting	2 years

Commitments_and_Contingencies_1

Commitments and Contingencies (Lease Commitments) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2015	$20,747,000
2016	19,529,000
2017	19,847,000
2018	16,901,000
2019	15,752,000
After 2019	53,633,000
Total	146,409,000
Rent expense	$36,000,000	$35,400,000	$17,100,000

Segment_Information_Details

Segment Information (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	segment
Segment Reporting Information [Line Items]
Number of operating segments	2
Revenue	$21,581,890	$14,780,094	$9,940,120
Cost of revenue	20,221,837	13,654,449	9,206,744
Gross profit	1,360,053	1,125,645	733,376
Corporate expenses	852,145	723,503	543,039
Income before income taxes	507,908	402,142	190,337
Income tax expense	134,186	103,403	69,316
Net income	373,722	298,739	121,021
Less net income attributable to non-controlling interest	56,429	36,569	4,363
Net income attributable to the Company	317,293	262,170	116,658
Goodwill	4,724,639	4,720,275	4,478,038
Total assets	9,324,185	7,995,763	7,385,127
Customer Concentration Risk | Accounts Receivable
Segment Reporting Information [Line Items]
Number of customers accounting for greater than 10% of accounts receivable	1	1
Concentration risk, percentage (less than 0.2% for Canadian Operations)	17.00%	15.00%
PBM
Segment Reporting Information [Line Items]
Revenue	21,429,983	14,632,104	9,785,084
Cost of revenue	20,155,768	13,583,941	9,141,029
Gross profit	1,274,215	1,048,163	644,055
Corporate expenses	0	0	0
Income before income taxes	0	0	0
Income tax expense	0	0	0
Net income	0	0	0
Less net income attributable to non-controlling interest	0	0	0
Net income attributable to the Company	0	0	0
Goodwill	4,704,974	4,700,610	4,458,373
Total assets	9,103,603	7,634,033	7,159,098
PBM | Customer Concentration Risk | Sales
Segment Reporting Information [Line Items]
Number of customers accounting for greater than 10% of revenue	1	1	1
Concentration risk, percentage (less than 0.2% for Canadian Operations)	34.00%	23.00%	31.00%
HCIT
Segment Reporting Information [Line Items]
Revenue	151,907	147,990	155,036
Cost of revenue	66,069	70,508	65,715
Gross profit	85,838	77,482	89,321
Corporate expenses	0	0	0
Income before income taxes	0	0	0
Income tax expense	0	0	0
Net income	0	0	0
Less net income attributable to non-controlling interest	0	0	0
Net income attributable to the Company	0	0	0
Goodwill	19,665	19,665	19,665
Total assets	220,582	361,730	226,029
Corporate
Segment Reporting Information [Line Items]
Revenue	0	0	0
Cost of revenue	0	0	0
Gross profit	0	0	0
Corporate expenses	852,145	723,503	543,039
Income before income taxes	0	0	0
Income tax expense	0	0	0
Net income	0	0	0
Less net income attributable to non-controlling interest	0	0	0
Net income attributable to the Company	0	0	0
Goodwill	0	0	0
Total assets	$0	$0
CANADA | Geographic Concentration Risk [Member] | Sales
Segment Reporting Information [Line Items]
Concentration risk, percentage (less than 0.2% for Canadian Operations)	0.20%	0.20%	0.20%

Financial_Instruments_Details

Financial Instruments (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Derivative [Line Items]
Interest rate	0.52%
Debt instrument interest, effective percentage rate	2.14%
Interest rate margin for default	1.63%
Deferred expenses related to derivative instruments accumulated in other comprehensive income expected to reclassified in the next twelve months	$1,100,000
Recurring Basis
Derivative [Line Items]
Interest rate swap liability	1,096,000	1,719,000
Interest Rate Swap
Derivative [Line Items]
Derivative, Term	3 years
Notional amount of interest rate derivatives	500,000,000
Interest Rate Swap | Recurring Basis
Derivative [Line Items]
Interest expense reclassified from other comprehensive income into earnings	1,700,000
Interest Rate Swap | Significant Observable Inputs (Level 2) | Recurring Basis
Derivative [Line Items]
Interest rate swap liability	$1,096,000	$1,719,000

Fair_Value_Details

Fair Value (Details) (Recurring Basis, USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent purchase price		$19,954
Derivatives	1,096	1,719
Significant Unobservable Inputs (Level 3)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent purchase price		19,954
Interest Rate Swap | Significant Observable Inputs (Level 2)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivatives	$1,096	$1,719

Supplemental_Information_Detai

Supplemental Information (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for Doubtful Accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	$5,860	$7,899	$2,725
Charged to Expense	2,259	1,187	3,328
Adjustments	-3,252	-3,226	1,846
Ending Balance	4,867	5,860	7,899
Deferred Tax Assets
Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	18,361	5,797	3,603
Charged to Expense	12,671	8,596	2,194
Adjustments	-1,313	3,968	0
Ending Balance	$29,719	$18,361	$5,797

Condensed_Consolidating_Financ2

Condensed Consolidating Financial Statements Balance Sheet (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Current assets
Cash and cash equivalents	$1,011,952	$387,241	$370,776	$341,382
Accounts receivable, net	1,254,336	959,586
Rebates receivable	863,824	305,955
Other current assets	219,435	184,893
Intercompany receivable	0	0
Total current assets	3,349,547	1,837,675
Property and equipment, net	210,027	197,007
Goodwill	4,724,639	4,720,275	4,478,038
Other intangible assets, net	968,199	1,181,419
Intercompany loans receivable		0
Investment in subsidiaries	0	0
Other long-term assets	71,773	59,387
Total assets	9,324,185	7,995,763	7,385,127
Current liabilities
Accounts payable	967,791	817,805
Accrued expenses and other current liabilities	327,190	254,100
Rebates payable	967,733	356,265
Current portion - long-term debt	81,250	50,000
Intercompany payable	0	0
Total current liabilities	2,343,964	1,478,170
Deferred income taxes	257,325	301,341
Long-term debt	1,344,973	1,215,363
Intercompany loans payable		0
Other long-term liabilities	98,816	89,391
Total liabilities	4,045,078	3,084,265
Commitments and contingencies (Note 16)
Shareholders’ equity
Shareholders’ equity	5,271,979	4,908,490
Non-controlling interest	7,128	3,008
Total equity	5,279,107	4,911,498	4,609,861	671,038
Total liabilities and equity	9,324,185	7,995,763
Reportable Legal Entities | Catamaran Corporation
Current assets
Cash and cash equivalents	333,469	15,090	33,603	122,415
Accounts receivable, net	304	294
Rebates receivable	10,710	35,776
Other current assets	99	107
Intercompany receivable	0	0
Total current assets	344,582	51,267
Property and equipment, net	110	69
Goodwill	0	0
Other intangible assets, net	0	0
Intercompany loans receivable		0
Investment in subsidiaries	6,375,214	6,137,281
Other long-term assets	13,874	15,675
Total assets	6,733,780	6,204,292
Current liabilities
Accounts payable	4	0
Accrued expenses and other current liabilities	10,580	3,047
Rebates payable	0	0
Current portion - long-term debt	81,250	50,000
Intercompany payable	23,898	25,673
Total current liabilities	115,732	78,720
Deferred income taxes	0	0
Long-term debt	1,344,973	1,215,363
Intercompany loans payable		0
Other long-term liabilities	1,096	1,719
Total liabilities	1,461,801	1,295,802
Commitments and contingencies (Note 16)
Shareholders’ equity
Shareholders’ equity	5,271,979	4,908,490
Non-controlling interest	0	0
Total equity	5,271,979	4,908,490
Total liabilities and equity	6,733,780	6,204,292
Reportable Legal Entities | Guarantors
Current assets
Cash and cash equivalents	648,903	362,647	318,770	217,032
Accounts receivable, net	1,217,675	889,267
Rebates receivable	851,929	270,179
Other current assets	166,858	149,233
Intercompany receivable	675,551	0
Total current assets	3,560,916	1,671,326
Property and equipment, net	154,413	172,090
Goodwill	4,689,522	4,685,158
Other intangible assets, net	963,096	1,173,347
Intercompany loans receivable		175,000
Investment in subsidiaries	266,096	202,292
Other long-term assets	42,876	24,117
Total assets	9,676,919	8,103,330
Current liabilities
Accounts payable	1,079,598	851,260
Accrued expenses and other current liabilities	304,309	228,801
Rebates payable	967,733	356,266
Current portion - long-term debt	0	0
Intercompany payable	0	3,885
Total current liabilities	2,351,640	1,440,212
Deferred income taxes	255,777	299,794
Long-term debt	0	0
Intercompany loans payable		0
Other long-term liabilities	71,475	65,812
Total liabilities	2,678,892	1,805,818
Commitments and contingencies (Note 16)
Shareholders’ equity
Shareholders’ equity	6,998,027	6,297,512
Non-controlling interest	0	0
Total equity	6,998,027	6,297,512
Total liabilities and equity	9,676,919	8,103,330
Reportable Legal Entities | Non-Guarantors
Current assets
Cash and cash equivalents	29,580	9,504	18,403	1,935
Accounts receivable, net	166,937	120,869
Rebates receivable	155,719	80,030
Other current assets	52,478	35,553
Intercompany receivable	0	130,377
Total current assets	404,714	376,333
Property and equipment, net	55,504	24,848
Goodwill	35,117	35,117
Other intangible assets, net	5,103	8,072
Intercompany loans receivable		0
Investment in subsidiaries	71	71
Other long-term assets	22,084	21,818
Total assets	522,593	466,259
Current liabilities
Accounts payable	3,150	8,315
Accrued expenses and other current liabilities	18,846	22,252
Rebates payable	42,932	31,332
Current portion - long-term debt	0	0
Intercompany payable	626,434	0
Total current liabilities	691,362	61,899
Deferred income taxes	1,548	1,547
Long-term debt	0	0
Intercompany loans payable		175,000
Other long-term liabilities	26,245	21,860
Total liabilities	719,155	260,306
Commitments and contingencies (Note 16)
Shareholders’ equity
Shareholders’ equity	-197,807	204,707
Non-controlling interest	1,245	1,246
Total equity	-196,562	205,953
Total liabilities and equity	522,593	466,259
Consolidations
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	-130,580	-50,844
Rebates receivable	-154,534	-80,030
Other current assets	0	0
Intercompany receivable	-675,551	-130,377
Total current assets	-960,665	-261,251
Property and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Intercompany loans receivable		-175,000
Investment in subsidiaries	-6,641,381	-6,339,644
Other long-term assets	-7,061	-2,223
Total assets	-7,609,107	-6,778,118
Current liabilities
Accounts payable	-114,961	-41,770
Accrued expenses and other current liabilities	-6,545	0
Rebates payable	-42,932	-31,333
Current portion - long-term debt	0	0
Intercompany payable	-650,332	-29,558
Total current liabilities	-814,770	-102,661
Deferred income taxes	0	0
Long-term debt	0	0
Intercompany loans payable		-175,000
Other long-term liabilities	0	0
Total liabilities	-814,770	-277,661
Commitments and contingencies (Note 16)
Shareholders’ equity
Shareholders’ equity	-6,800,220	-6,502,219
Non-controlling interest	5,883	1,762
Total equity	-6,794,337	-6,500,457
Total liabilities and equity	($7,609,107)	($6,778,118)

Condensed_Consolidating_Financ3

Condensed Consolidating Financial Statements Income Statement (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Condensed Income Statements, Captions [Line Items]
Revenue	$21,581,890	$14,780,094	$9,940,120
Cost of revenue	20,221,837	13,654,449	9,206,744
Gross profit	1,360,053	1,125,645	733,376
Expenses:
Selling, general and administrative	518,351	440,759	369,492
Depreciation of property and equipment	59,486	37,926	16,749
Amortization of intangible assets	213,220	203,192	130,116
Total expenses	791,057	681,877	516,357
Operating income	568,996	443,768	217,019
Interest and other expense, net	61,088	41,626	26,682
Equity in (income) of subsidiaries	0	0	0
Income before income taxes	507,908	402,142	190,337
Income tax expense	134,186	103,403	69,316
Net income	373,722	298,739	121,021
Less net income attributable to non-controlling interest	56,429	36,569	4,363
Net income attributable to the Company	317,293	262,170	116,658
Reportable Legal Entities | Catamaran Corporation
Condensed Income Statements, Captions [Line Items]
Revenue	40,141	34,875	15,343
Cost of revenue	33,917	30,217	12,306
Gross profit	6,224	4,658	3,037
Expenses:
Selling, general and administrative	2,931	1,094	4,688
Depreciation of property and equipment	30	29	50
Amortization of intangible assets	0	0	0
Total expenses	2,961	1,123	4,738
Operating income	3,263	3,535	-1,701
Interest and other expense, net	51,904	36,700	11,731
Equity in (income) of subsidiaries	-365,934	-295,335	-130,090
Income before income taxes	317,293	262,170	116,658
Income tax expense	0	0	0
Net income	317,293	262,170	116,658
Less net income attributable to non-controlling interest	0	0	0
Net income attributable to the Company	317,293	262,170	116,658
Reportable Legal Entities | Guarantors
Condensed Income Statements, Captions [Line Items]
Revenue	20,849,801	13,682,194	9,578,406
Cost of revenue	19,764,270	12,756,828	8,926,325
Gross profit	1,085,531	925,366	652,081
Expenses:
Selling, general and administrative	418,400	374,435	322,843
Depreciation of property and equipment	53,932	35,005	14,784
Amortization of intangible assets	210,251	200,065	126,847
Total expenses	682,583	609,505	464,474
Operating income	402,948	315,861	187,607
Interest and other expense, net	3,007	-344	13,577
Equity in (income) of subsidiaries	-58,804	-51,924	-14,551
Income before income taxes	458,745	368,129	188,581
Income tax expense	92,811	72,794	58,491
Net income	365,934	295,335	130,090
Less net income attributable to non-controlling interest	0	0	0
Net income attributable to the Company	365,934	295,335	130,090
Reportable Legal Entities | Non-Guarantors
Condensed Income Statements, Captions [Line Items]
Revenue	3,028,412	1,750,509	911,107
Cost of revenue	2,760,114	1,554,888	832,849
Gross profit	268,298	195,621	78,258
Expenses:
Selling, general and administrative	97,020	65,230	41,961
Depreciation of property and equipment	5,524	2,892	1,915
Amortization of intangible assets	2,969	3,127	3,269
Total expenses	105,513	71,249	47,145
Operating income	162,785	124,372	31,113
Interest and other expense, net	6,177	5,270	1,374
Equity in (income) of subsidiaries	0	0	0
Income before income taxes	156,608	119,102	29,739
Income tax expense	41,375	30,609	10,825
Net income	115,233	88,493	18,914
Less net income attributable to non-controlling interest	0	0	0
Net income attributable to the Company	115,233	88,493	18,914
Consolidations
Condensed Income Statements, Captions [Line Items]
Revenue	-2,336,464	-687,484	-564,736
Cost of revenue	-2,336,464	-687,484	-564,736
Gross profit	0	0	0
Expenses:
Selling, general and administrative	0	0	0
Depreciation of property and equipment	0	0	0
Amortization of intangible assets	0	0	0
Total expenses	0	0	0
Operating income	0	0	0
Interest and other expense, net	0	0	0
Equity in (income) of subsidiaries	424,738	347,259	144,641
Income before income taxes	-424,738	-347,259	-144,641
Income tax expense	0	0	0
Net income	-424,738	-347,259	-144,641
Less net income attributable to non-controlling interest	56,429	36,569	4,363
Net income attributable to the Company	($481,167)	($383,828)	($149,004)

Condensed_Consolidating_Financ4

Condensed Consolidating Financial Statements Cash Flows (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net cash provided (used) by operating activities	$590,181	$475,421	$249,733
Cash flows from investing activities:
Acquisitions, net of cash acquired	-2,026	-388,866	-1,565,705
Purchases of property and equipment	-78,078	-128,842	-40,236
Proceeds from restricted cash	20,006	20,004	0
Net cash used in investing activities	-60,098	-497,704	-1,605,941
Cash flows from financing activities:
Proceeds from issuance of debt	492,500	450,000	1,475,448
Repayment of long-term debt	-337,500	-362,500	-616,993
Proceeds from public offering, net of issuance costs	0	0	519,075
Payment of financing costs	-1,963	-2,347	-18,806
Proceeds from exercise of options and warrants		3,479	7,763
Proceeds from exercise of options	5,639	2,992	7,763
Tax benefit on option exercises	3,492	9,732	19,397
Proceeds from warrants exercised	3,452	487	0
Payments of contingent consideration	-18,338	-23,203
Distribution to non-controlling interest	-52,309	-36,314	0
Net transactions with parent and affiliates	0	0	0
Proceeds from restricted stock	0	0	0
Other	-383	0	-268
Net cash provided by financing activities	94,590	38,847	1,385,616
Effect of foreign exchange on cash balances	38	-99	-14
Increase in cash and cash equivalents	624,711	16,465	29,394
Cash and cash equivalents, beginning of period	387,241	370,776	341,382
Cash and cash equivalents, end of period	1,011,952	387,241	370,776
Reportable Legal Entities | Catamaran Corporation
Cash flows from operating activities:
Net cash provided (used) by operating activities	341,698	186,985	-27,257
Cash flows from investing activities:
Acquisitions, net of cash acquired	0	0	3,644,364
Purchases of property and equipment	-71	-11	-66
Proceeds from restricted cash	0	0
Net cash used in investing activities	-71	-11	3,644,298
Cash flows from financing activities:
Proceeds from issuance of debt	492,500	450,000	1,475,448
Repayment of long-term debt	-337,500	-362,500	-616,993
Proceeds from public offering, net of issuance costs			519,075
Payment of financing costs	-1,963	-2,347	-18,806
Proceeds from exercise of options and warrants		4,729	11,016
Proceeds from exercise of options	8,011
Tax benefit on option exercises	0	0	0
Proceeds from warrants exercised	3,452
Payments of contingent consideration	0	0
Distribution to non-controlling interest	0	0
Net transactions with parent and affiliates	-208,486	-322,377	-5,093,214
Proceeds from restricted stock	20,700	27,107	17,903
Other	0	0	-268
Net cash provided by financing activities	-23,286	-205,388	-3,705,839
Effect of foreign exchange on cash balances	38	-99	-14
Increase in cash and cash equivalents	318,379	-18,513	-88,812
Cash and cash equivalents, beginning of period	15,090	33,603	122,415
Cash and cash equivalents, end of period	333,469	15,090	33,603
Reportable Legal Entities | Guarantors
Cash flows from operating activities:
Net cash provided (used) by operating activities	612,430	616,168	430,091
Cash flows from investing activities:
Acquisitions, net of cash acquired	-2,026	-388,866	-5,210,069
Purchases of property and equipment	-41,664	-117,799	-30,549
Proceeds from restricted cash	20,006	20,004
Net cash used in investing activities	-23,684	-486,661	-5,240,618
Cash flows from financing activities:
Proceeds from issuance of debt	0	0	0
Repayment of long-term debt	0	0	0
Proceeds from public offering, net of issuance costs			0
Payment of financing costs	0	0	0
Proceeds from exercise of options and warrants		-1,248	-3,253
Proceeds from exercise of options	-2,355
Tax benefit on option exercises	3,455	9,704	19,206
Proceeds from warrants exercised	0
Payments of contingent consideration	-18,338	-18,338
Distribution to non-controlling interest	0	0
Net transactions with parent and affiliates	-264,620	-49,103	4,913,963
Proceeds from restricted stock	-20,249	-26,645	-17,651
Other	-383	0	0
Net cash provided by financing activities	-302,490	-85,630	4,912,265
Effect of foreign exchange on cash balances	0	0	0
Increase in cash and cash equivalents	286,256	43,877	101,738
Cash and cash equivalents, beginning of period	362,647	318,770	217,032
Cash and cash equivalents, end of period	648,903	362,647	318,770
Reportable Legal Entities | Non-Guarantors
Cash flows from operating activities:
Net cash provided (used) by operating activities	-6,952	-30,476	-18,449
Cash flows from investing activities:
Acquisitions, net of cash acquired	0	0	0
Purchases of property and equipment	-36,343	-11,032	-9,621
Proceeds from restricted cash	0	0
Net cash used in investing activities	-36,343	-11,032	-9,621
Cash flows from financing activities:
Proceeds from issuance of debt	0	0	0
Repayment of long-term debt	0	0	0
Proceeds from public offering, net of issuance costs			0
Payment of financing costs	0	0	0
Proceeds from exercise of options and warrants		-2	0
Proceeds from exercise of options	-17
Tax benefit on option exercises	37	28	191
Proceeds from warrants exercised	0
Payments of contingent consideration	0	-4,865
Distribution to non-controlling interest	0	0
Net transactions with parent and affiliates	63,802	37,910	44,599
Proceeds from restricted stock	-451	-462	-252
Other	0	0	0
Net cash provided by financing activities	63,371	32,609	44,538
Effect of foreign exchange on cash balances	0	0	0
Increase in cash and cash equivalents	20,076	-8,899	16,468
Cash and cash equivalents, beginning of period	9,504	18,403	1,935
Cash and cash equivalents, end of period	29,580	9,504	18,403
Consolidations
Cash flows from operating activities:
Net cash provided (used) by operating activities	-356,995	-297,256	-134,652
Cash flows from investing activities:
Acquisitions, net of cash acquired	0	0	0
Purchases of property and equipment	0	0
Proceeds from restricted cash	0	0
Net cash used in investing activities	0	0	0
Cash flows from financing activities:
Proceeds from issuance of debt	0	0	0
Repayment of long-term debt	0	0	0
Proceeds from public offering, net of issuance costs			0
Payment of financing costs	0	0	0
Proceeds from exercise of options and warrants		0	0
Proceeds from exercise of options	0
Tax benefit on option exercises	0	0	0
Proceeds from warrants exercised	0
Payments of contingent consideration	0	0
Distribution to non-controlling interest	-52,309	-36,314
Net transactions with parent and affiliates	409,304	333,570	134,652
Proceeds from restricted stock	0	0	0
Other	0	0	0
Net cash provided by financing activities	356,995	297,256	134,652
Effect of foreign exchange on cash balances	0	0	0
Increase in cash and cash equivalents	0	0	0
Cash and cash equivalents, beginning of period	0	0	0
Cash and cash equivalents, end of period	$0	$0	$0